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1 0  •  In t roduct ion
I n t ro d u c t i o n
Aggression, and in its extreme form violence, is a complex trans-nosological behav-
iour frequently observed in psychiatric patients. The complexity of aggressive be-
haviour is also reflected in different definitions of aggression. The following com-
monly used definition for aggression measurement was introduced in 1990 by 
Moris son: “any verbal, non-verbal, or physical behaviour that is threatening (to self, 
others or property), or physical behaviour that actually does harm (to self, others, 
or prop erty)”(1). 
While there is no general agreement on the definition of aggression, both 
clinical and academical fields agree that aggression poses a problem in mental health 
care, which influences well-being of staff and patients and results in high costs (2). 
Aggressive behaviour does not only affect staff and other patients, but also has a 
negative impact on the patient, as some studies have shown that aggressive patients 
are admitted longer on psychiatric wards when compared to non-aggressive pa-
tients (3-5). 
In the Netherlands, for many years, seclusion has been a frequently used inter-
vention to manage (imminent) aggression. During the last years, the use of seclu-
sion has been heavily debated in response to reports and research indicating that 
seclusion rates are higher in the Netherlands than in surrounding countries (6). 
Nowadays, many mental health care institutes have large-scale programmes put 
in place that aim at reducing seclusion or even banning seclusion all together. An 
alternative for seclusion, fre quently used in surrounding countries, but also in the 
Netherlands, is (involuntarily administered) pharmacotherapy. In this introductory 
chapter, we will give a brief his torical overview of aggression management, before 
discussing the currently available knowledge about pharmacological management 
of aggression. 
D e a l i n g  w i t h  a g g r e s s i v e  b e h a v i o u r  t h r o u g h  t h e  a g e s
In the 1980s, some studies suggested that the incidence of aggression in psychiat-
ric wards was increasing, which seemed to parallel tendencies observed in society. 
Whether there is a real increase of aggressive behaviour, both in society as in men-
tal health care is not clear. Research by Wittebrood and Junger, showed that the 
observed increase of violence in society might be caused by improved registration 
(7). Further more, historical research shows that aggression has always been an im-
portant issue in mental health care and that ‘social intolerability’ was an important 
impetus to admis sion on psychiatric wards. Aggressive behaviour was an important 
component of such ‘social intolerability’ (8). Additionally, reforms in psychiatry of-
ten were triggered by discontentment with the amount and the way aggressive 
behaviour was managed. In the next paragraphs the means and measures used to 
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manage aggression in psychi atric wards through the years will be discussed, while 
giving special attention to the situation in the Netherlands (see also Figure 1).
Until the second half of the 18th century, mental problems were not viewed as dis-
eases, which eventually can be cured, but as an abnormality caused by possession (by 
the devil) or loosing reason thereby becoming animal-like. In institutions, there was 
hardly any treatment available, only efforts to manage difficult behaviour, including 
aggression. In the middle ages the “insane” posing danger to others or themselves 
were put in jail, often naked and in handcuffs. In the 15th century asylums arose in 
or der to give the “insane” a more dignified existence. Aim of these asylums was to 
shelter the “insane”, i.e. to withdraw “idle people” from the community (9). In the 
asy lums –also sheltering old people and orphans- aggressive behaviour of the ‘in-
sanes” was also controlled with restraints like handcuffs. Furthermore, small padded 
cells were in use for solitary confinement.
Then, at the end of the 18th century, in the time of Enlightenment, an optimis-
tic re form movement came. Under the influence of people like Conolly in England 
and Pinel in France, “insanity” was viewed as a disease, which can be influenced or 
cured. In these days, personality and behaviour of psychiatric patients were con-
sidered to be under total influence of the affected brain. Moral treatment was the 
way believed to achieve cure or alleviation of insanity. Moral treatment consisted 
of treating patients in a humane manner and by providing that the hospital was 
orderly, e.g. by organizing fixed daily schedules and giving timely and appetizing 
meals. It was during this movement that attempts were made to reduce the use of 
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Figure 1  Time table: Movements in psychiatry and used interventions.
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restraint. Conolly even thought that restraint would be of no longer use due to 
moral treatment, treatment considered as (almost) perfect. Besides a certain attitude 
of the caretakers as described in moral treatment, Conolly also thought the number 
of attendants to be important. Furthermore, Conolly thought it important to create 
different pavilions for quiet, semi-agitated and agitated patients. In the Netherlands, 
in Meerenberg (later on called Santpoort) mechanical restraints were successfully 
banned after adopting Conolly’s theory. Gradually in the rest of the Netherlands, use 
of physical restraint was reduced. Instead of being restrained, the “restless” patients 
underwent bed care but also were sent to labour. In those cases in which behaviour 
was not sufficiently manageable, seclusion and “wet packs” or hydrotherapies were 
used. Seclusion was not viewed as inhumane as the bodily freedom was hardly re-
stricted. Furthermore, a “single room” approach with an open door policy was tried 
first before secluding a patient (10).  Hy drotherapy, and bed care were inspired by 
the increasing interest for natural sciences and resulting in a more medical-somatic 
orientation such as in general hospitals. Hy drotherapy consisted of (forced) bathing 
with a length varying from hours to days. Administration of barbiturates, e.g. Veron-
al, was also mentioned in textbooks as a possible intervention in the acute situation. 
Furthermore, at the end of the 19th cen tury, the alkaloid hyoscine –better known as 
scopolamine- was introduced. Scopola mine, administered subcutaneously, appeared 
to better sedate than hyoscyamine which was already in use during the first half of 
the 19th century for mania (11). Hyoscine (in combination with morphine) was 
still in use in the 1950s for strong se dation of agitated psychiatric patients, despite 
the well-known side effects such as hallucinations and  depressed mood (11).
Around 1925, besides a medical-somatic orientation, attention was paid to 
environ mental and social factors influencing mental illness. It was also in this time 
that peo ple realized that bed care and hydrotherapies, originally meant as therapy, 
were dis guised forms of restraint to control disruptive behaviour. In this period, pa-
tients were no longer considered to be “under total control” of their mental illness; 
the opinion arose that only a part of the brain is affected. Agitated behaviour was 
not longer con sidered as a cause of illness, but caused by “environmental neglect”. 
In the Nether lands, van der Scheer, introduced active therapy, i.e. fitting labour, and 
making the patient (more) responsible for his own behaviour (12). This therapy 
from Germany, was partly a reaction on the very neurological oriented approach of 
mental illness(12). In order to stimulate own responsibility, nurses used “educational 
measures” to re ward or punish patients according to their behaviour. Seclusion and, 
after that, pre scribing sedative medication were considered last resort if other edu-
cational measures had no effect. Although textbooks promoted active therapy, chart 
review research from Vijselaar [2010] showed that bed therapy was still in use in the 
1940s, especially in an attempt to manage difficult behaviour (8). Furthermore, his 
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findings show that also the somatic therapies like somnifen sleeping therapy, cardia-
zol, insulin coma and electro shock therapy, arising in the 1920s and 1930s, were 
not only used for cure or care, but also to manage difficult behaviour. Wet packs in 
this time were replaced by “strait sheets” which gave patients more space to move 
and therefore considered more humane and recommended as possible “educational 
measure”. 
After the second world war, electro shock therapy was frequently used, not only 
for cure, but also for the management of agitation and aggressive behaviour(13).
In 1952 there was the introduction of chlorpromazine, an antipsychotic also 
known as Largactil (= large action). People witnessing the introduction of Largactil 
-initially used as co-medication for sleep therapy- were impressed by the sudden 
rest which came over the wards in the institutes, the “Largactil-peace on earth” (13). 
Schizo phrenic patients residing in long-stay wards for restless people became calm 
and started to participate in daily life in the institute, e.g. by attending therapies. 
Instead of being sedated, patients became calm and communication with patients 
was possible. At the same time, it should be stressed that in the Netherlands it took 
a while before the use of chlorpromazine was widespread. In the Netherlands some 
“hospital” psy chiatrists, for a long time, were sceptical about the effects of psycho-
tropics; they did not see the use of psychotropics as cure but as a way to manage 
symptoms (11). The lack of enthusiasm has been labelled as a possible reaction on 
previous therapies like insulin-coma and shock therapies with disappointing results 
(13) and as a reaction on observed side effects. Despite scepticism, psychotropics 
were used liberally due to a shortage of nursing staff and in order to maintain man-
age the agitation on the ward(13, 14). With the availability of parenteral psycho-
tropics, rapid tranquilization technique was developed, a strategy in which antipsy-
chotics or benzodiazepines are administered in a compressed time-frame, titrating 
dosage against symptoms to con trol assaultive, hyperactive, and hostile patients (15). 
Antipsychotics were not only registered for psychosis but also for agitation.  An 
advantage mentioned about the in troduction of the antipsychotics, is that people 
became calm and communication be came possible. In the 1960s anti-psychiatry 
movement appeared. The two principal opinions of this movement were that a) 
diagnoses were too vague thereby leaving too much room for opinions and inter-
pretations to meet basic scientific standards and b) prevailing psychiatric treatments 
were considered to be more damaging than helpful. 
Much resistance came against the use of restraint in general and the use of 
medication specifically. Although also in the Netherlands the antipsychiatry move-
ment greatly influenced daily practice, research shows that in the case of (severe) 
aggression, coer cion was still being used. Seclusion seemed to be given preference, 
although on acute psychiatric wards the use of chemical restraint was still in use 
(14).  
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C u r r e n t  p r a c t i c e
Previous paragraphs show that three kinds of interventions have been in use for a 
long time: interventions restricting freedom of movement (physical restraint and 
seclu sion), chemical restraint and a variety of more behavioural and interactional 
ap proaches. Furthermore, history shows that some therapies like prolonged bathing 
and insulin coma, initially deployed with the idea that they have healing properties, 
kept on being used even if they appeared to be ineffective. Reason for keeping on 
using them was to manage difficult behaviour like agitation and aggression. When 
not tak ing into account the historical background, it is difficult to understand how 
caretakers, could be convinced of the efficacy and rationality of such interven-
tions. Nowadays in medicine the importance of evidence-based treatment is highly 
emphasized.  From this perspective preference is given to evidence obtained from 
randomized controlled trials. The question is whether the current management 
of aggressive behaviour is more evidence based given the lack of proper studies 
into the effects of interventions on aggressive behaviour. For aggression in the 
acute situation, research shows that seclusion and chemical restraint is still in use, 
if nothing else is working to control dangerous situations clinicians are faced with. 
On ward level, staff is trained to ac quire skills including among others verbal de-
escalation techniques. As for the long-term treatment, what has been observed is 
that aggressive behaviour is associated with increased use of psychtropics. Stolker 
et al (2001) found an association between aggression symptoms and multiple drug 
use in a study population consisting of men tally disabled patients (16). Furthermore, 
on an acute psychiatric ward, medication changes were found to correlate with ag-
gression (17). Finally, studies investigating the use of (oral) as-needed medication on 
psychiatric wards show that agitation, an ag gression-related symptom, is a common 
reason for administration (18). As far as we are aware of, evidence from randomized 
controlled trials for these practices is sparse or lacking.  
A i m s  o f  t h e  t h e s i s
In this thesis we will focus on the pharmacotherapy used by aggressive (in)patients. 
We aim to evaluate the available evidence for the pharmacotherapeutic manage-
ment of aggressive behaviour, and investigate whether daily clinical practice is in 
line with evidence. Furthermore we will attempt to elucidate the reasons for the 
application of pharmacotherapy for aggressive patients. Current available research 
suggests that de spite a lack of evidence pharmacotherapy is frequently used in clini-
cal practice. A fi nal aim of this thesis is to investigate whether practices in daily 
clinical practice are effective.
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O u t l i n e  o f  t h i s  t h e s i s
C h a p t e r  2  –  E v i d e n c e  f o r  t r e a t m e n t
Whereas pharmacotherapy plays an important role in guidelines, there are no recent 
systematic reviews in which the evidence for pharmacological management of ag-
gression is analysed. In this chapter we systematically investigate the evidence for 
the pharmacological management of aggression in the acute situation (chapter 2.1)
and the maintenance pharmacotherapy of aggression (chapter 2.2). Furthermore, in 
chap ter 2.3, we aim to gain insight in the generalisability of this evidence to daily 
clinical practice.
C h a p t e r  3  –  Tr e a t m e n t  i n  p r a c t i c e
In this chapter we investigate drug treatment patterns of aggressive psychiatric inpa-
tients compared to non-aggressive psychiatric inpatients. Therefore, the registra-
tion of aggression is required. The Staff Observation Aggression Scale – Revised 
(SOAS-R) (19) is used for this purpose.  As this instrument is a quantitative, inci-
dent based ag gression-scale, there is a risk that underreporting of aggressive inci-
dents occurs. The amount and nature of this possible underreporting is investigated 
in chapter 3.1.
Medication regimen can be roughly divided into regular medication regimen 
-medi cation administrated in defined dosages at fixed time-points as-needed–  and 
as-needed medication regimen –medication administered as required by the nurse 
on either the initiative of the patient or the nurse self.
Hypothesizing that aggressive behaviour leads to reactive prescribing behaviour, 
changes in regular medication are investigated in chapter 3.2
The use of as-needed medication by aggressive patients is investigated in chapter 
3.3. Furthermore, beliefs of patients and nurses about as-needed medication are 
investi gated in chapter 3.4.
Medication is frequently used in psychiatry, especially for aggressive patients. In 
the final chapter 3.5, we aim to investigate how the use of medication affects the 
outcome of treatment. To make a distinction between a positive and negative treat-
ment out come, the place to where patients were transferred after admission is used 
as criterion. Discharge to a less restrictive environment is considered as a positive 
outcome, dis charge to a more restrictive environment as a negative outcome. The 
association of both aggression and medication use with the treatment outcomes is 
investigated. 
C h a p t e r  –   4  G e n e r a l  D i s c u s s i o n
Studies will be discussed in a broader perspective in chapter 4, the general discussion.
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Chapter 2.1
Pharmacotherapy of aggression 
in the acute situation: 
a systematic  review
Laurette E Goedhard, Joost J Stolker, Eibert R Heerdink, Henk LI Nijman, 
Berend Olivier, Toine CG Egberts
Adapted from: Richter, D., & Whittington, R. (eds.), Violence in mental health settings: 
Causes, consequences, management (pp. 173-190). New York: Springer.
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A b s t r a c t
Objective Aggression is an important issue in mental health departments. Several 
in terventions and coercive measures are used in daily clinical practice to manage 
ag gression. One of the interventions used in psychiatry to manage aggression is the 
ad ministration of psychotropic drugs. Whereas chemical restraint is frequently used 
to manage acute aggression, the evidence is scarce. In this systematic review we 
investi gated the evidence for the drugs currently used in the management of acute 
aggression in a general adult psychiatric population.
Methods We searched Medline, Embase, Psycinfo and the Cochrane library for 
meta-analyses and randomized controlled trials on the pharmacotherapy of ag-
gression. We excluded those studies referring to specialized psychiatric settings and 
non-psychiatric settings. Studies were judged to their internal validity and general-
izability to daily clinical practice. 
Results As well as for antipsychotic agents including haloperidol, droperidol and 
zu clopenthixol, promethazine as for benzodiazepines including lorazepam and 
midazo lam evidence for effectiveness was found. Study limitations comprised small 
study populations -which might result in a lack of power to show superiority of 
one drug above another- short study duration, and poor generalizability to daily 
clinical prac tice. 
Conclusion On the basis of the evaluated studies and taking into account the 
study limitations, droperidol appears to be first choice if tranquillisation is required 
as soon as possible. Furthermore the combination of haloperidol and lorazepam is 
fast acting and appears to be more sedating than monotherapy. If a calming down 
effect is more desired than sedating the patient, monotherapy of haloperidol or 
olanzapine appears to be appropriate. 
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I n t ro d u c t i o n
The occurrence of aggressive incidents in psychiatric care has a great impact on 
the well-being of staff and patients, and is associated with considerable costs (1-3). 
Consid ering the high impact of aggression in mental health care, prevention, and 
management of aggression should have high priority (4).
 Several treatment approaches to manage aggressive behaviour in psychiatry ex-
ist, in cluding psychopharmacological and behavioural approaches (5). A distinction 
can be made between pharmacotherapy in the acute situation versus maintenance 
treatment. The aim of pharmacotherapy in the two situations is different. In the 
acute situation, drugs are administered to stop a dangerous situation by sedation or 
motor interference such as muscle weakness. However, for maintenance therapy, i.e., 
pharmacotherapy for patients to whom aggression is an ongoing problem, long-
term sedation is an un desired effect as it hampers adequate psychiatric examination, 
as well as the thera peutic patient relationship. Furthermore, habituation to sedatives 
is likely to occur. A review about the pharmacological maintenance treatment of 
aggressive behaviour, i.e. pharmacotherapy for patients to whom aggression is a 
recurrent behaviour, has been published elsewhere (6). 
 In this chapter we will address the pharmacotherapy of aggression in the acute 
situa tion. An overview will be given of published randomized controlled trials 
(RCTs) ad dressing the pharmacotherapy of aggression in the acute situation in 
general adult psychiatry. Based on this overview a guideline for pharmacotherapy in 
the manage ment of aggressive behaviour in acute situations and recommendations 
for the con duct of future research will be proposed. 
M e t h o d s
As previously stated, the aim of this chapter is to review the available evidence 
for the pharmacotherapy of aggression in acute situations. For this review, only 
published randomized controlled trials (RCTs) are considered, as these are seen 
as the gold standard for obtaining evidence for drug effects (7). A literature search 
was conducted within the PsycINFO, EMBASE, Cochrane, and PubMed databases 
from 1966 through March 2005 to identify published RCTs, systematic reviews, 
and meta-analy ses assessing the efficacy of drugs for the management of aggression 
or aggression-related symptoms, including violence, hostility, and anger. As main 
search terms, we used MeSH terms, covering the words aggression, violence, anger, 
and hostility com bined with drug therapy, psychotropic drugs, antipsychotic agents, 
benzodiazepines, and promethazine. Furthermore, the retrieved publications were 
searched for addi tional references. 
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Studies were eligible for inclusion in this review if they met the following 
criteria: (1) random allocation to treatment, as mentioned in the study; (2) the study 
population consisted of adult (aged between 18 and 65 years) general psychiatric 
patients in whom aggression might be an ongoing problem. Studies applying to 
specialized psy chiatric settings—like child psychiatry, mental retardation, and or-
ganic brain dis eases—or to nonpsychiatric settings—like prisons—were excluded; 
(3) outwardly directed aggression or aggression-related symptoms were either a 
primary or secon dary outcome in the study; (4) the study did not address pharma-
cotherapy of aggres sion or aggression-related symptoms as maintenance treatment; 
(5) the study was English language and published in a peer-reviewed journal before 
March 2005; and (6) the study drug under investigation is currently registered by 
the U.S. Food and Drug Administration (FDA) or the European Agency for the 
Evaluation of Medicinal Products (EMEA). One reviewer (L.E.G.) screened ab-
stracts to determine whether studies should be included in the review. In case of 
any doubt, the full paper was retrieved. 
For the RCTs included, an acceptable methodological quality was required, 
which was defined by a Jadad score of three or more (8). The Jadad scale is an in-
strument to adjudicate methodological quality. Criteria used for this instrument 
comprise the quality of randomization, the quality of blinding, and a description of 
dropouts and withdrawals. 
There are different theoretical concepts of aggression. Symptoms associated 
with ag gression include hostility, agitation, violence, and anger (9-12). Because these 
symp toms are closely related to aggression, it is assumed that influencing them will 
also have an impact on any aggressive behaviour displayed. Therefore, we included 
all RCTs that also assessed the pharmacological management of those symptoms. 
Trials assessing the pharmacotherapy for the management of acute aggression 
have been conducted in different psychiatric and non-psychiatric settings. Given 
the het erogeneity of these populations, it seems likely that study results might not 
be directly comparable to each other. Therefore, this review is restricted to general 
adult psy chiatry, meaning that studies conducted in non-psychiatric setting, e.g. in 
prisons, and specialized psychiatric settings, i.e., organic brain diseases and mental 
retardation, were not included, as were studies that evaluated only children or eld-
erly patients. 
R e s u l t s
From previous studies it is known that most aggressive incidents in mental health 
care occur during the first days of admission (13, 14). Therefore, most available 
trials ad dressing the pharmacological management of acutely aggressive patients 
have been conducted at acute admission wards and psychiatric emergency depart-
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ments. Most trials used the “rapid tranquillization strategy” in which antipsychotics 
or benzodi azepines are administered in a compressed time-frame, titrating dosage 
against symptoms to control assaultive, hyperactive, and hostile patients (15). Ideally, 
the goal of this strategy is to calm down disturbed patients to such an extent that 
commu nication is possible, thereby enabling health workers to evaluate the psychi-
atric status. In some cases sleep can also be an appropriate goal (16, 17). 
The studies evaluated are represented in Figure 1 (17-35). The study popula-
tion pre dominantly comprised schizophrenic patients experiencing an acute exac-
erbation. Other diagnoses included mania and substance abuse. However, in most of 
the trials, substance abuse was an exclusion criterion. Another frequently established 
“diagno sis” was acute agitation. 
Outcome measures most frequently used to assess changes in aggressive be-
haviour included subscales of the BPRS (36) and the PANNS (37). Other outcome 
measures include sedation-scales and additional number of injections needed to 
calm the patient down. 
Pharmacological agents used in the evaluated RCTs comprised antipsychotic 
agents, benzodiazepines, combination therapy of benzodiazepines and antipsychot-
ics, and promethazine. In most studies, drugs were administered intramuscularly; 
one study also assessed the efficacy of oral doses (21) and one study assessed the 
efficacy of intravenous administration. 
Ty p i c a l  A n t i p s y c h o t i c s
Typical antipsychotics can be classified into high potency and low-potency antipsy-
chotics (38). Low-potency antipsychotics, like chlorpromazine, are historically used 
for the management of acute agitation and aggression. However, because low-po-
tency antipsychotics are more likely to inflict serious adverse events, e.g., excessive 
seda tion and hypotension, compared to high-potency antipsychotics, preference is 
given to the latter (31, 39, 40). 
Haloperidol, a high-potency antipsychotic, is the most frequently used drug in 
the evaluated RCTs. All formula, i.e. oral, intramuscular (IM) and intravenous (IV) 
have been studied. In one of the first placebo-controlled trials in this field, conduct-
ed in 1974, haloperidol in doses of 1, 2, and 5 mg was compared to chlorpromazine 
and placebo (31). Benefit for haloperidol in dosages of 2 and 5 mg over placebo and 
chlor promazine was reported. Other typical antipsychotics investigated included 
droperi dol, thiotixene, loxapine, and zuclopenthixol (22, 24, 27, 32). These antip-
sychotics were compared to haloperidol. Droperidol IV was also compared to the 
placebo (29). The observed differences in efficacy between the different typical an-
tipsychotics predomi nantly rest on differences in pharmacokinetic properties of the 
different drugs. Drop eridol IM induced a quicker onset of action than haloperidol 
as measured by the number of patients requiring an extra injection after 30 minutes 
(32); these results were approved by two randomized controlled trials conducted in 
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emergency departments (41, 42). These studies were not included in Figure 2, be-
cause they were not con ducted in a study population consisting solely of psychiatric 
patients. The advantage of using zuclopenthixol acetate over haloperidol was that, 
over a period of seven days, fewer injections were required to obtain the same effect, 
as zuclopenthixol acts as a short-acting depot (34). However, more extrapyramidal 
symptoms and sedation were reported for zuclopenthixol compared to haloperidol. 
Figure 1  Drugs joined by arrows have been compared to each other (in one or more studies); numbers 
along the arrows indicate the total number of study participants in each teeatment arm of the RCT(s). 
Dosages per administration are indicated under the drug name.
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B e n z o d i a z e p i n e s
Because of their anxiolytic and sedative properties and quick onset of action, benzo-
diazepines are extremely suitable to tranquillize aggressive patients. 
The benzodiazepines studied in the RCTs comprised lorazepam (18-20, 30), 
fluni trazepam (23, 26). The short-acting lorazepam is the most extensively studied 
benzodiazepine used for the management of acute aggression. Lorazepam has been 
compared to haloperidol (19, 20), placebo and olanzapine (30), and combination 
ther apy of haloperidol and promethazine (18). No significant differences between 
haloperi dol and lorazepam were observed in the trials. However, combination ther-
apy of haloperidol and lorazepam was superior over monotherapy of haloperidol or 
lorazepam in that the onset of action was more rapid (19, 20). Furthermore, heavier 
sedation was reached with combination therapy when compared to monotherapy. 
Other benzodiazepines in the evaluated studies were midazolam and clonazepam. 
Mi dazolam was found to be more rapid a sedative than the combination of ha-
loperidol and promethazine (17). No difference in agitation scores was observed 
between haloperi dol and clonazepam (23). 
A t y p i c a l  A n t i p s y c h o t i c s
At the beginning of the 1990s risperidone, the second atypical antipsychotic in the 
market after clozapine, was introduced, followed by olanzapine, quetiapine, ziprasi-
done, and aripiprazole. Recently, intramuscular forms of the atypical antipsychotics 
olanzapine and ziprasidone and an oral concentrate of risperidone became available. 
We will not discuss ziprasidone, because in Europe at the moment this drug is only 
registered for use in clinical trials, due to its association with cardiac side-effects. 
Whereas the calming and sedating effect of typical antipsychotics is principally 
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Figure 2  Proposed strategy for pharmacotherapy of aggression in an acute situation.
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medi ated through dopaminergic mechanisms, the sedating and calming effect of 
olanzap ine is likely to be mediated through histaminergic mechanisms (43, 44). 
Olanzapine, after both oral and intramuscular administration, was at least as 
effective as haloperidol in a population of mildly agitated patients (21, 28, 35). An 
advantage of the use of olanzapine over haloperidol was the decreased risk of extra-
pyramidal symptoms in the case of olanzapine (35). Oral solution of risperidone 
combined with lorazepam has been compared to intramuscular administration of 
haloperidol and lorazepam (25). For both treatments a similar effect was reached, 
with more sedation observed for the intramuscular therapy between 30 minutes 
and 120 minutes after administration. In accordance with the Dubin, et al. study 
(45), in which oral administration of haloperidol and thioridaz ine were compared 
to intramuscular administration, patients randomized on oral ther apy did not refuse 
the oral medication. In this study 30 minutes difference for time of onset was ob-
served. These study results suggest that in certain circumstances, proba bly in the case 
of mild aggressive behaviour, oral therapy can be a good alternative to parenteral 
tranquillization. Intramuscular Olanzapine has also been compared to in tramuscular 
lorazepam (30); more reduction of scores on agitation scales observed for olanzap-
ine at 2 hours after injection.
D i s c u s s i o n
L i m i t a t i o n s
Although RCTs are considered a gold standard for testing the efficacy of medical 
in terventions (7), they also have limitations. The main methodological issues that 
were encountered in this review concerned the generalizability to daily clinical 
practice and a low statistical power for detecting differences in efficacy between the 
treatment groups. 
Poor generalizability from clinical trial populations to patients seen in daily 
practice is one of the limitations particularly associated with RCTs (46). Previous 
studies have shown that psychiatric patients with comorbid disorders are frequently 
excluded from RCTs (47-49). There are indications that the aggressive patient, as 
seen in daily clini cal practice, was excluded from the RCTs evaluated in this review. 
Firstly, recruitment procedures that depend on voluntary participation (50) are 
likely to result in the exclusion of highly aggressive patients. Indeed, aggression at 
baseline was frequently low. Also, the application of strict study inclusion and exclu-
sion crite ria is likely to result in the exclusion of aggressive patients. For example, 
patients with substance abuse, which is associated with aggression, were frequently 
excluded from the RCTs we analyzed (51). Concomitant use of psychotropics was 
also fre quently used as an exclusion criterion. 
The statistical power for detecting differences between treatment groups was 
usually small, due to the small number of patients included in the trials, as can also 
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be seen in Figure 1. Besides reducing the ability to detect treatment efficacy, studies 
with small sample sizes will also have a limited value in detecting adverse effects. 
Furthermore, the baseline aggression level was frequently low. As a consequence, 
only a small re duction of aggressive behaviour can be achieved using pharmaco-
therapy and, to de tect small changes, large sample sizes are required. 
A d v i s e d  p h a r m a c o l o g i c a l  a p p r o a c h  o f  a c u t e l y  a g g r e s s i v e  p a t i e n t s 
Taking into account the limitations of the evaluated studies, a pharmacological 
treat ment strategy as depicted in Figure 2 is proposed. As different studies suggest 
that the difference between oral and parenteral medication is not the effect reached, 
but the shorter time of onset when using parenteral administration, oral therapy 
should be considered first. If the patient is unwilling to accept oral medication, 
or if a shorter time of onset is desired, intramuscular medication is the therapy of 
choice. One should choose between the administration of antipsychotics, atypical 
or typical, ben zodiazepines, or a combination therapy of typical antipsychotics and 
benzodiazepines or promethazine. The choice between these agents depends on 
the objective of the pharmacotherapy, i.e., very quick vs. quick response, sedative vs. 
calming effect, as well as the characteristics of the individual patient, for instance the 
underlying psy chiatric disorder and the risk of adverse events. 
If the underlying psychiatric disorder is unknown, the use of benzodiazepines 
seems to be the safest option as benzodiazepines interfere less with the diagnostic 
process, e.g., differentiation between substance-induced psychosis and chronic psy-
choses as sociated with chronic psychiatric disorders like schizophrenia and bipolar 
disorder. However, sometimes monotherapy with benzodiazepines might be insuf-
ficient. In those cases, combination therapy of benzodiazepines or promethazine 
with antipsy chotics could be used (see also Figure 2). If the underlying psychiatric 
disorder is known, the following strategy is advised. If the reduction of aggressive 
behaviour has to be reached as soon as possible and if there are no somatic contrain-
dications, one could opt for the administration of droperidol. 
There are some concerns regarding the association between droperidol and 
cardiac adverse events—fatal QTc prolongations. However, reports are inconsistent. 
Based upon postmarketing case reports the USA’s Food and Drug Administration 
(FDA) added a “black box” warning to the use of droperidol, which means that pre-
scribers should consider alternative medication for patients at high risk for cardiac 
arrhythmias (52). In contrast, three reviews showed that there is no clear evidence 
about the in creased risk of fatal cardiac adverse events (53-55). 
A second choice of treatment, when reduction of aggressive behaviour is ur-
gently needed, is the use of combination therapy of a typical antipsychotic and a 
benzodi azepine. Because haloperidol and lorazepam have been most extensively 
studied, we recommend the combined use of these. If the goal of therapy is of 
calming the patient rather than sedating or getting them to sleep, one could opt for 
monotherapy of an an tipsychotic agent—typical or atypical—or a benzodiazepine. 
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The lower incidence of extrapyramidal adverse events in atypical antipsychot-
ics com pared to typical antipsychotics might favour the choice of atypical antip-
sychotics. However, if the choice of therapy in the acute situation determines the 
choice of long-term therapy, as (56) showed, the long-term side-effects associated 
with the use of antipsychotics should be considered; including, in the case of atypi-
cal antipsychotics, the metabolic syndrome (57), and tardive dyskinesia in the case 
of typical antipsychot ics. Furthermore, eight cases of fatal adverse events have been 
reported after the use of intramuscular olanzapine in excessive dosages or in a com-
bination with benzodiazepines and/or other antipsychotics (58). 
When choosing benzodiazepines, paradoxical reactions, i.e., disinhibition, can 
occur (59). However, this side effect is rare. Other known side-effects include the 
risk of dependence, withdrawal, and tolerance, as well as respiratory arrest. 
R e c o m m e n d a t i o n s  f o r  f u t u r e  r e s e a r c h 
This chapter shows that the evidence obtained by RCTs is incomplete. We found 
that in quite a substantial number of RCTs, statistical power was rather small. 
Further more, generalizability of study results to daily clinical practice is question-
able. For future research, we recommend the conduct of large-scale pragmatic trials 
(49). In addition to these trials, observational study designs should be used to study 
the effec tiveness and safety of drugs used to treat aggressive patients (48). 
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A b s t r a c t
Objective To systematically review the evidence for pharmacologic management 
of outwardly directed aggressive behavior in general adult psychiatry. 
Methods Literature searches in PubMed, EMBASE, PsycINFO, and Cochrane 
li braries from 1966 through March 2005 were used to identify relevant studies. 
The keywords aggression, violence, anger, and hostility combined with drug ther-
apy, psy chotropic drugs, adrenergic β-antagonists, anticonvulsants, antidepressants, 
antipsy chotic agents, benzodiazepines, and lithium were searched. Furthermore, the 
retrieved publications were searched for additional references. 
All randomized controlled trials addressing pharmacotherapy for aggression or 
ag gression-related symptoms were included, except studies addressing the “emer-
gency situation” and studies conducted in specialized psychiatric or non-psychiat-
ric set tings. 
Evidence synthesis was performed using the best-evidence principle. Two 
authors independently adjudicated methodological quality and generalizability to 
daily clini cal practice. 
Results Thirty-five randomized controlled trials met the inclusion criteria and 
were evaluated. On the basis of a best-evidence synthesis model, weak evidence 
for antiag gressive effects of antipsychotics, antidepressants, anticonvulsants, and 
β-adrenergic blocking drugs was found. Atypical antipsychotics appeared superior 
to typical antip sychotics. The use of various outcome measures and insufficient data 
reporting in the individual studies hampered the quantitative assessment of efficacy 
across studies. Further limitations of the available randomized controlled trials in-
cluded small sample sizes, short study duration, and poor generalizability to daily 
clinical practice setting.
Conclusion Whereas pharmacotherapy is frequently applied in aggressive patients, 
only weak evidence of efficacy of various drug classes was found. Consensus about 
the use of aggression measurement scales in clinical trials is necessary for future 
re search. Furthermore, large-scale trials with more naturalistic designs, as opposed 
to classical randomized controlled trials with strict inclusion and exclusion criteria, 
may be advisable in order to obtain results that are more generalizable to daily clini-
cal practice.
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I n t ro d u c t i o n
In mental health care, aggression is an important issue, with, for example, an inci-
dence of 9.3 incidents per bed per year in Europe at acute admission wards (1). Be-
sides high costs (2), aggression influences therapeutic environment and well-being 
of both patients and staff workers (3,4). In a recent study conducted in East London, 
more than 1 out of every 5 psychiatric nurses reported that they had not been able 
to go to work owing to workplace violence during the preceding year (5). Al-
though far less investigated, aggression also appears to be a common phenomenon 
in psychiatric outpatients (6) 
Given the incidence and impact of aggression, management of aggression has 
high priority in mental health care. Most aggressive incidents occur during the first 
week following admission (7). In a small proportion of patients, aggression will re-
main an ongoing problem (8–10). 
Several interventions are used to manage aggressive behavior, including cogni-
tive therapy and training of nursing staff in the case of hospitalized patients (11–13). 
Pharmacotherapy is also frequently used in aggressive patients (14). Several drugs, 
including anticonvulsants, antipsychotics, and antidepressants, have been used for 
re petitively aggressive patients (11,12). A small number of systematic reviews have 
evaluated the evidence for the use of these drugs (15–17). However, the most recent 
reviews investigating the evidence for efficacy of pharmacotherapy for the ongoing 
management of aggression in psychiatric patients date from 1996 and 1997 (15,16). 
In these reviews, clinical trials as well as case reports were included. To our knowl-
edge, a systematic review on this subject based upon randomized controlled trials 
(RCTs)- considered as the gold standard to obtain evidence (18) -never has been 
conducted. The objective of this review is to systematically review the literature 
for the evidence of the pharmacologic management of aggression in repetitively 
aggressive patients in general adult psychiatry, restricting ourselves to RCTs. Ran-
domized controlled trials have some limitations as well, e.g., strict inclusion and 
exclusion criteria, which are likely to reduce the generalizability to daily clinical 
practice (19); we also intended to assess the generalizability of the evidence. 
M e t h o d s
D a t a  s o u r c e s 
A literature search was conducted within the PsycINFO, EMBASE, Cochrane, 
and PubMed databases from 1966 through March 2005 to identify published 
RCTs, sys tematic reviews, and meta-analyses assessing the efficacy of drugs for 
the manage ment of aggression or aggression-related symptoms, including violence, 
hostility, and anger. As main search terms, we used MeSH terms, covering the words 
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aggression, violence, anger, and hostility combined with drug therapy, psychotro-
pic drugs, adren ergic β-antagonists, anticonvulsants, antidepressants, antipsychotic 
agents, benzodi azepines, and lithium. Furthermore, the retrieved publications were 
searched for addi tional references. 
S t u d y  s e l e c t i o n 
Studies were eligible for inclusion in this review if they met the following criteria: 
(1) random allocation to treatment, as mentioned in the study; (2) the study popula-
tion consisted of adult (aged between 18 and 65 years) general psychiatric patients 
in whom aggression might be an ongoing problem. Studies applying to specialized 
psy chiatric settings -like child psychiatry, mental retardation, and organic brain dis-
eases- or to nonpsychiatric settings -like prisons- were excluded; (3) outwardly 
di rected aggression or aggression-related symptoms were either a primary or sec-
ondary outcome in the study; (4) the study did not address pharmacotherapy of 
aggression or aggression-related symptoms in the emergency situation; (5) a previ-
ously published scale was used to measure aggression or aggression-related symp-
toms; (6) the study was English language and published in a peer-reviewed journal 
before March 2005; and (7) the study drug under investigation is currently regis-
tered by the U.S. Food and Drug Administration (FDA) or the European Agency 
for the Evaluation of Medicinal Products (EMEA). One reviewer (L.E.G.) screened 
abstracts to determine whether studies should be included in the review. In case of 
any doubt, the full paper was re trieved. If there was still any doubt, the study was 
judged by a second reviewer (E.R.H. or J.J.S.). 
D a t a  e x t r a c t i o n 
Trials were categorized into subgroups according to therapeutic drug class. For 
every subgroup, evidence of efficacy was determined. Because effect sizes were dif-
ficult to compute owing to the use of a variety of continuous outcome scales, evi-
dence of effi cacy was determined using the best-evidence synthesis principle (20). 
The best-evi dence synthesis method used in this review is based on the model of 
van der Windt et al. (21) In this model, studies are weighted according to method-
ological quality, clini cal relevance, and statistical significance. Distinction was made 
between insufficient, weak, and strong evidence of efficacy or evidence of no ef-
ficacy, using decision rules presented in Figure 1 (22). 
Using this method, at least 3 studies assessing the drug are required to obtain 
weak or strong evidence of efficacy. 
Q u a l i t y  a s s e s s m e n t 
The Jadad scale (scores range from 0 to 5) was used to adjudicate the method-
ological quality of the studies (23). Two reviewers performed this assessment in-
dependently (L.E.G. and E.R.H. or J.J.S. or T.C.G.E.). Interrater agreement was 
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calculated using the kappa statistic. Subsequently, disagreement was discussed and 
resolved. Studies with Jadad scores of 3 or more were rated as having an acceptable 
methodological quality. 
Q u a n t i t a t i v e  d a t a  s y n t h e s i s 
Effect sizes were expressed as standardized mean difference (SMD) (24). The SMD 
was interpreted as described by Cohen (25) and applied using the following effect 
sizes: small 0.2, medium 0.5, and large 0.8. The SMD can only be applied to nor-
mally distributed data. In case of skewed data, the SMD cannot be computed. We 
investi gated skewness by dividing mean through standard deviation; a value of less 
than twice the standard deviation was indicative of skewed data (26). 
S t u d y  g e n e r a l i z a b i l i t y 
To our knowledge, no validated checklists or methods to rate generalizability to daily 
clinical practice are available. Therefore, we defined our own criteria. Generalizabil-
ity was defined as the probability that aggressive patients as seen in daily clinical 
practice would be included in the study. Generalizability was scored on a scale from 
1 to 5, where studies with a score of 3 or more were considered to have an accept-
able generalizability. To generate this score, the following 2 items were considered: 
(1) The source population is representative for psychiatric patients seen in daily 
clinical practice and (2) No inclusion or exclusion criteria that could exclude typi-
cal aggres sive psychiatric patients, e.g., a history of drug abuse, violence in the past, 
or the use of concurrent psychotropics, were applied. 
The same 2 independent reviewers who assessed the Jadad scores also assessed 
the generalizability. Interrater agreement was calculated using the kappa statistic. 
Subse quently, disagreement was discussed and resolved. 
R e s u l t s 
S t u d y  s e l e c t i o n 
As can be seen in Figure 2, the use of our search terms resulted in the identification 
of 467 publications. On the basis of the title and the study abstracts, 425 studies 
were excluded from further analysis; the remaining 42 full papers were retrieved 
and screened. Reasons for exclusion are shown in Figure 2. Finally, we located 35 
RCTs (27–61) describing the effect of different drugs on aggression or aggression-
related symptoms. 
S t u d y  c h a r a c t e r i s t i c s 
Detailed study characteristics are summarized in Table 1. The study outcomes are 
displayed in Table 2. 
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<2  Studies
Studies With Inconsistent Results (≥ 2 Studies)
No
Pooling of Results
Possible?
Good Internal Validity?
(Jadad Score ≥3)
Yes
Yes
Insufficient Evidence
Quantitative Analysis
Qualitative Analysis
No
Pooled Estimates of ≥ 75% of Studies
Pooled Estimates of <75% of Studies
Studies With Consistent Results (≥ 2 Studies)
Strong Evidence of Efficacy
Weak Evidence of Efficacy
Statistically Significant and Clinically Relevant Results
Statistically Significant or Clinically Relevant Results
No Statistically Significant and No Clinically Relevant Results
Insufficient Evidence of Efficacy
Weak Evidence of Efficacy
No Statistically Significant and No Clinically Relevant Results
Statistically Significant and/or Clinically Relevant Results
Strong Evidence of No Efficacy
Insufficient Evidence
Insufficient Evidence
≥75% of the Studies: Statistically Significant and
Clinically Relevant Results Favoring the Same Direction
≥75% of the Studies: Statistically Significant or
Clinically Relevant and Results
≥75% of the Studies: No Statistically Significant and
No Clinically Relevant Results
Strong Evidence of Efficacy
Weak Evidence of Efficacy
Strong Evidence of No Efficacy
or Insufficient Evidence
10.0073=goedhard;2.2-fig01.ai
126 x 206 mm=100% importeren
Figure 1  Beste-evidence synthesis adapted with permission from Smidt et al.22
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O u t c o m e  m e a s u r e s 
A whole range of different outcome measures -21 in total- were used in the RCTs 
included and involved observational scales as well as self-report scales. Furthermore, 
some scales were especially designed for measuring aggression, while others were 
subscales measuring items related to aggression in a broader perspective, for ex-
ample the anger scale of the Profile of Mood States (79) 
The most frequently used specific aggression scales were different versions of 
the Overt Aggression Scale (OAS) (62) From the 21 used outcome scales, the OAS 
modi fied for outpatients was used more often. Other outcome measures included 
diagnosis-related scales, like subscales of the Positive and Negative Syndrome Scale 
42 Full Papers Retrieved
and Screened
Manual Searching:
5 Additional Researches
425 Excluded
161 Nonpsychiatric Patients
101 Specialized Psychiatry
40 Aggression in the
Acute Situation
30 No RCT
62 No Aggression
15 Not Primary English Language/
Full-Text
8 No FDA/EMEA Registration
1 No Aggression Scale
7 No Pharmacotherapy
Computerized Searches
139 MEDLINE
103 EMBASE
77 PsycINFO
352 Cochrane
Total: 467 (without duplicates)
35 Studies Selected
For Review
4 No Aggression
4 No RCT
1 No Aggression Scale
1 No Psychiatry
2 Aggression in the
Acute Situation
12 Excluded
10.0073=goedhard;2.2-fig02.ai
126 x 206 mm=100% importeren
Abbreviations: 
EMEA = European Agency for the Evaluation of Medical Products; 
FDA = U.S. Fool and Drug Administration; 
RCT = Randomized Controlled Trial.
Figure 2  Study selection.
2.2hfdst.indd   41 27-04-10   15:33
4 2  •  Pharmacotherapy  for  maintenance  t reatment 
(PANSS) (63) and the Borderline Personality Disorder Severity Index (BPDSI) 
(64). 
P a t i e n t s 
Most studies were conducted in a schizophrenic populationi or cluster B personal-
ity disordered patients.ii The other diagnoses included posttraumatic stress disor-
der (PTSD) (35,45,58), autistic disorder (44) intermittent explosive disorder (43) 
atten tion-deficit/hyperactivity disorder (29) anorexia nervosa (38) and depressive 
disorder (36,39,41). Of the 35 studies, 15 were conducted in a population solely 
consisting of outpatients.iii 
F o l l o w - u p 
The follow-up period ranged from 3 to 24 weeks. In the majority of studies,iv the 
fol low-up period was 6 to 12 weeks, while 7 studiesv had a long-term follow-up 
(>12weeks) and 9 studiesvi had a short-term follow-up (<6 weeks). 
C o n t r o l  g r o u p 
Of the 35 RCTs, 27 compared active drug(s) to placebo. The other studiesvii used 
an active drug as control. 
Of the 35 RCTs included in this review, 33 were double blind and 2 were not 
(38,43). In 3 studies (29,32,52), a crossover design was used. In one study (43), the 
outcome measurement was assessed single blind. 
Q u a l i t y  a s s e s s m e n t 
In 31 of the 35 RCTs, the methodological quality was judged acceptable as re-
flected by a score on the Jadad list of 3 or more. The 4 studies with a Jadad score 
of less than 3 (28,38,39,43) were excluded from the evidence synthesis. Interrater 
agreement for the Jadad score was good (kappa statistic=0.73). 
G e n e r a l i z a b i l i t y 
Generalizability to daily clinical practice was judged to be acceptable for 20 of the 
35 studies (Table 2). Several factors contributed to poor generalizability. 
In most studies, eligibility criteria did not comprise a certain baseline level of 
aggression before the start of the trial, as measured by a scale. This might have con-
i References 27, 28, 30–34, 42, 47, 52, 59–61
ii References 37, 40, 46, 48–51, 53–57
iii References 35, 38–41, 45, 46, 48, 49, 53–58
iv References 27, 28, 32, 35, 38, 39, 41, 42, 44–46, 48, 54–57, 60, 61
v References 29, 34, 40, 47, 49, 52, 53
vi References 30, 31, 33, 36, 37, 50, 51, 58, 59
vii References 27, 29, 34, 36, 43, 54, 59, 60
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tributed to a low baseline level of aggression in some of the studies. Furthermore, 
current drug abuse, alcohol abuse, or other psychotropic medication use, factors 
associated with aggression (14,84) were frequently used as exclusion criteria.viii 
Furthermore, in many studies, the recruitment method did not favor inclusion 
of pa tients for whom aggression appears to be an ongoing problem: in some studies, 
pa tients were recruited through advertisement (40,48,49,53–55). As aggressive pa-
tients are less likely to give informed consent, this method might lead to “volunteer 
bias” (85). In other studies, the source population comprised patients with an acute 
exacer bation of schizophrenia (30,31,33,42,59). Acute exacerbation is associated 
with ag gression, especially in the first week of admission; however, once the patient 
is stabi lized, aggression will probably not remain as an ongoing problem (8). Inter-
rater agreement for the generalizability was good (kappa statistic=0.60). 
E v i d e n c e  s y n t h e s i s  f o r  t h e  d i f f e r e n t  d r u g  c l a s s e s 
Evidence of efficacy for the different drug classes, i.e., antipsychotics, antidepres-
sants, anticonvulsants, and β-adrenergic blockers, is displayed in Table 3. 
We were not able to calculate the SMD for most of the studies because many 
studies did not provide the required data. In those studies for which the required 
data were provided, the distribution appeared skewed (26). In the latter studies, the 
SMD can be calculated from log-transformed data, which were not available di-
rectly from the studies. Consequently, we could only perform a qualitative evidence 
synthesis. 
Antipsychotic agents 
Two 3-armed RCTs (50,51) performed by the same research group in a borderline 
personality disordered population comparing haloperidol and an antidepressant to 
pla cebo were found. In both studies (50,51), haloperidol was found to be statistical-
ly sig nificantly superior to placebo on the Hopkins Symptom Checklist-90 (SCL-
90) (74) but not on the Inpatient Multidimensional Psychiatric Scale (IMPS) (75) 
hostil ity items. In one 3-armed RCT (61) comparing risperidone to haloperidol 
and placebo in a schizophrenic population, no benefit for haloperidol as compared 
to placebo was found. 
Seven studies with acceptable methodological quality comparing atypi-
cal antipsy chotics to haloperidol and/or placebo in subjects with schizophrenia 
(27,34,59–61), borderline personality disorder (53) or posttraumatic stress disorder 
(45) were evalu ated. In 2 large-scale studies, risperidone was superior to haloperi-
dol (60,61) and pla cebo (61) on the PANSS hostility factor in dosages of more 
than 2 mg daily. In 4 studies (27,34,45,59) comparing risperidone to haloperidol 
viii References 29, 35, 37, 39–42, 44, 46, 48–50, 53–58
2.2hfdst.indd   43 27-04-10   15:33
4 4  •  Pharmacotherapy  for  maintenance  t reatment 
Study Diagnosis Aggression 
before triala
Exclusion criteria Weeksb Drugs  :  N, Nc
Antipsychotic agents
Blin59
1996
Schizophrenia, acute exacerbation with 
symptoms of anxiety, inpatients
NAR Relevant somatic disorder, history of drug 
or alcohol abuse during past year, schizo-
affect. disorder, long-acting antipsychotics
4 Haloperidol : 20, 14
Risperidone : 21, 17
Methotrimeprazine : 21, 14
Citrome et al34
2001
Schizophrenia or schizoaffective 
disorder: treatment -resistant to 
previous neuroleptics, inpatients
NAR History of treatment-resistancy to study drugs 14 Clozapine : 40, 32
Risperidone : 41, 28
Olanzapine : 39, 30
Haloperidol : 37, 25
Czobor et al28 
1995
Schizophrenia, inpatients PANSS hostility > 2 Comorbid psychiatric disorder, drug or alcohol abuse 
in the past 6 months, relevant somatic disorder
8 Risperidone : 85, ?
Haloperidol : 24, ?
Placebo : 30, ?
Marder et al61 
1997
Schizophrenia, inpatients NAR Comorbid psychiatric disorder, drug or alcohol abuse 
in the past 6 months, relevant somatic disorder
8 Risperidone : 342, 193
Haloperidol : 85, 35
Placebo : 86, 27
Min et al27
1993
Schizophrenia, inpatients NAR Relevant somatic disorder, drug or alcohol abuse 
during past year, comorbid psychiatric disorder
8 Risperidone : 16, 13
Haloperidol : 19
Monnelly et al45 
2003
Combat related PTSD, outpatients NAR History of antipsychotic use, schizophrenia, 
bipolar disorder, organic mental disorder
6 Risperidone : 8, 7
Placebo : 8, 8
Peuskens60
1995
Schizophrenia, inpatients NAR Comorbid psychiatric disorder, relevant 
somatic disorder, history of alcohol or 
drug abuse in previous 12 months,
8 Risperidone : 1136, 856
Haloperidol : 226, 205
Zanarini & Frankenburg53
2001
Borderline personality disorder, outpatients NAR Relevant somatic disorder, current drug or 
alcohol abuse, use of psychotropics
24 Olanzapine : 10, 8
Placebo : 9, 4
Beta-adrenergic blocking drugs
Allan et al30
1996
Schizophrenia, male, inpatients NAR Relevant somatic disorder 3 Nadolol : 16
Placebo : 17, 166
Alpert et al31
1990
Schizophrenia, schizoaffective disorder, 
bipolar disorder, male, inpatients
NAR Relevant somatic disorder 3 Nadolol : 16, 15
Placebo : 16, 16
Caspi et al32
2001
Schizophrenia, male, inpatients ≥ 4 incidents 
in 1 month
Relevant somatic disorder 6 Pindolol/Placebo : 30, 23
crossover
Maoz et al42
2000
Schizophrenia and schizofreniform 
disease, acute exacerbation, inpatients
NAR Physical disorder, current drug 
abuse, depot neurolepticum
8 Propranolol : 18, 18
Placebo : 16, 16
Ratey et al47
1992
Schizophrenia, schizoaffective disorder, 
mentally retarded, inpatients
NAR Relevant somatic disorder 13 Nadolol : 22, 16
Placebo : 26, 25
Anticonvulsants
Citrome et al33
2004
Schizophrenia, inpatients ≥ 6 points on 
PANSS subscale
Schizoaffective disorder, mood disorder, current 
serious violent ideas, relevant somatic disorder
4 Divalproex sodium : 125, 120        
Placebo : 124, 122
De la Fuente and 
Lotstra37 1994
Borderline personality disorder, inpatients NAR DSM-IIIR Axis 1 disorder, somatic disorder, 
suspected poor treatment compliance, 
inability to stop drug  or alcohol use.
4,5 Carbamazepine : 10, 8      
Placebo : 10, 10
Frankenburg and 
Zanarini al40
2002
Borderline personality disorder 
with a comorbid bipolar II disorder 
outpatients, women
NAR Relevant somatic disorder, current drug abuse Divalproex sodium : 20, 20
Placebo : 10, 10
Hollander et al56
2003
Cluster B personality disorder, outpatients ≥ 15 point 
on OAS-M
Psychotic disorder, mood disorder, current 
drug abuse, relevant somatic disorder
12 Divalproex sodium : 43, 39
Placebo : 48, 46
Hollander et al55
2001
Borderline personality disorder, outpatients NAR Psychotic disorder, mood disorder, 
relevant somatic disorder, no other 
psychotropics (except antidepressants)
10 Divalproex sodium : 12, 6                       
Placebo :  4, 0
Nickel et al46
2005
Borderline personality disorder, 
male outpatients
NAR Schizophrenia, major depression/bipolar disorder, 
other psychotropics, substance abuse
8 Toparimate : 22, 22
Placebo : 22, 20
Table 1 Study characteristics
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Study Diagnosis Aggression 
before triala
Exclusion criteria Weeksb Drugs  :  N, Nc
Antipsychotic agents
Blin59
1996
Schizophrenia, acute exacerbation with 
symptoms of anxiety, inpatients
NAR Relevant somatic disorder, history of drug 
or alcohol abuse during past year, schizo-
affect. disorder, long-acting antipsychotics
4 Haloperidol : 20, 14
Risperidone : 21, 17
Methotrimeprazine : 21, 14
Citrome et al34
2001
Schizophrenia or schizoaffective 
disorder: treatment -resistant to 
previous neuroleptics, inpatients
NAR History of treatment-resistancy to study drugs 14 Clozapine : 40, 32
Risperidone : 41, 28
Olanzapine : 39, 30
Haloperidol : 37, 25
Czobor et al28 
1995
Schizophrenia, inpatients PANSS hostility > 2 Comorbid psychiatric disorder, drug or alcohol abuse 
in the past 6 months, relevant somatic disorder
8 Risperidone : 85, ?
Haloperidol : 24, ?
Placebo : 30, ?
Marder et al61 
1997
Schizophrenia, inpatients NAR Comorbid psychiatric disorder, drug or alcohol abuse 
in the past 6 months, relevant somatic disorder
8 Risperidone : 342, 193
Haloperidol : 85, 35
Placebo : 86, 27
Min et al27
1993
Schizophrenia, inpatients NAR Relevant somatic disorder, drug or alcohol abuse 
during past year, comorbid psychiatric disorder
8 Risperidone : 16, 13
Haloperidol : 19
Monnelly et al45 
2003
Combat related PTSD, outpatients NAR History of antipsychotic use, schizophrenia, 
bipolar disorder, organic mental disorder
6 Risperidone : 8, 7
Placebo : 8, 8
Peuskens60
1995
Schizophrenia, inpatients NAR Comorbid psychiatric disorder, relevant 
somatic disorder, history of alcohol or 
drug abuse in previous 12 months,
8 Risperidone : 1136, 856
Haloperidol : 226, 205
Zanarini & Frankenburg53
2001
Borderline personality disorder, outpatients NAR Relevant somatic disorder, current drug or 
alcohol abuse, use of psychotropics
24 Olanzapine : 10, 8
Placebo : 9, 4
Beta-adrenergic blocking drugs
Allan et al30
1996
Schizophrenia, male, inpatients NAR Relevant somatic disorder 3 Nadolol : 16
Placebo : 17, 166
Alpert et al31
1990
Schizophrenia, schizoaffective disorder, 
bipolar disorder, male, inpatients
NAR Relevant somatic disorder 3 Nadolol : 16, 15
Placebo : 16, 16
Caspi et al32
2001
Schizophrenia, male, inpatients ≥ 4 incidents 
in 1 month
Relevant somatic disorder 6 Pindolol/Placebo : 30, 23
crossover
Maoz et al42
2000
Schizophrenia and schizofreniform 
disease, acute exacerbation, inpatients
NAR Physical disorder, current drug 
abuse, depot neurolepticum
8 Propranolol : 18, 18
Placebo : 16, 16
Ratey et al47
1992
Schizophrenia, schizoaffective disorder, 
mentally retarded, inpatients
NAR Relevant somatic disorder 13 Nadolol : 22, 16
Placebo : 26, 25
Anticonvulsants
Citrome et al33
2004
Schizophrenia, inpatients ≥ 6 points on 
PANSS subscale
Schizoaffective disorder, mood disorder, current 
serious violent ideas, relevant somatic disorder
4 Divalproex sodium : 125, 120        
Placebo : 124, 122
De la Fuente and 
Lotstra37 1994
Borderline personality disorder, inpatients NAR DSM-IIIR Axis 1 disorder, somatic disorder, 
suspected poor treatment compliance, 
inability to stop drug  or alcohol use.
4,5 Carbamazepine : 10, 8      
Placebo : 10, 10
Frankenburg and 
Zanarini al40
2002
Borderline personality disorder 
with a comorbid bipolar II disorder 
outpatients, women
NAR Relevant somatic disorder, current drug abuse Divalproex sodium : 20, 20
Placebo : 10, 10
Hollander et al56
2003
Cluster B personality disorder, outpatients ≥ 15 point 
on OAS-M
Psychotic disorder, mood disorder, current 
drug abuse, relevant somatic disorder
12 Divalproex sodium : 43, 39
Placebo : 48, 46
Hollander et al55
2001
Borderline personality disorder, outpatients NAR Psychotic disorder, mood disorder, 
relevant somatic disorder, no other 
psychotropics (except antidepressants)
10 Divalproex sodium : 12, 6                       
Placebo :  4, 0
Nickel et al46
2005
Borderline personality disorder, 
male outpatients
NAR Schizophrenia, major depression/bipolar disorder, 
other psychotropics, substance abuse
8 Toparimate : 22, 22
Placebo : 22, 20
Table 1 Study characteristics
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Study Diagnosis Aggression 
before triala
Exclusion criteria Weeksb Drugs  :  N,Nc
Antidepressants
Coccaro & Kavoussi57
1997
Personality disorder, outpatients ≥ 15 points OAS-M 
for 1 month
Schizophrenia, mood disorder, delusional 
disorder, currently drug or alcohol dependent
12 Fluoxetine : 27, 14
Placebo : 13, 9
Davidson et al36 
1981
Depressed inpatients NAR Psychotic disorder, mania, mental 
retardation, organic brain syndrome
3 Phenelzine : 24, 21
Imipramine : 25, 22
Davidson et al35
2002
PTSD, outpatients NAR Psychotic disorder, bipolar disorder, major depression, 
anxiety disorder, organic mental disorder, alcohol 
or drug dependence/use, relevant somatic disorder, 
other psychotropics, cognitive behavioral therapy
12 Sertraline : 194, 191
Placebo : 201, 194
Mc Dougle et al44
1996
Autistic disorder, in- and outpatients NAR Illicit substance abuse, notable medical condition, 
other psychotropics, psychotic disorder 
12 Fluvoxamine : 15, 15
Placebo : 15, 15
Fava et al39
1997
Depressed outpatients NAR Pregnancy, unstable medical illness, drug abuse, 
psychotic disorder, bipolar disorder, pregnancy
12 Sertraline : 17 , ?
Imipramine : 21, ?
Placebo : 19, ?
Fassino et al38
2002
Anorexia nervosa, outpatients NAR Psychiatric comorbidity 12 Citalopram : 26, 19
Placebo : 26, 20
van der Kolk et al58
1994
PTSD outpatients NAR Schizophrenia, bipolar disorder, drug or 
alcohol addiction, organic mental disorder
5 Fluoxetine : 33, 21
Placebo : 31, 27
Rinne et al48
2002
Borderline personality disorder, outpatients NAR No other psychotropics during the trial 6 Fluvoxamine : 20, 16
Placebo : 18, 14
Salzman et al49
1995
Borderline personality disorder, outpatients NAR History of hospitalization, drug or alcohol 
abuse, recent suicidal behavior, self 
mutilation, use of other psychotropics
13 Fluoxetine : 13, ?
Placebo : 9, ?
Vartiainen et al52
1995
Schizophrenia, inpatients ≥ 1 incident/ 
month on SOAS 
for 2 months
Depression, relevant somatic disorder 24 Citalopram/
placebo : 19, 14
crossover
Othersd
Dorrego et al29
2002
ADHD, inpatients NAR Substance abuse, IQ<75, neurological 
disorder, pregnancy
18 Lithium/
Methylphenidate : 32, 23
crossover
Lipman et al41 
1986
Depressive and anxiety disorder, outpatients NAR Drug/alcohol addiction, mental retardation, 
psychosis, bipolar disorder
8 Imipramine : 149, 103
Clordiazepoxide : 140, 95
Placebo : 136, 87
Mattes43
1990
Intermittent explosive disorder , inpatients NAR Diagnoses requiring other treatment Unclear Carbamazepine : ?, 22
Propranolol : ?, 29
Soloff et al51 
1989
Borderline personality disorder, inpatients NAR Schizoaffective disorder, schizophrenia, 
mania, hypomania
5 Haloperidol : 31, 28
Amitriptyline : 30, 29
Placebo : 29, 28
Soloff et al50
1993
Borderline personality disorder, inpatients; 
follow-up partly after admission
NAR Drug or alcohol dependence, 
seizures, mental retardation,
5 Haloperidol : 36, 30 
Phenelzine : 38, 34
Placebo : 34, 28
Zanarini et al54
2004
Borderline personality disorder, 
female outpatients
NAR Active drug or alcohol abuse, psychotropic use, 
suicidal, medically ill, seizures, depression
8 Olanzapine : 16, 16
Fluoxetine : 14, 13
Ol/Fl : 15, 13
a Aggression before trial: minimal required frequency and/or severity for study inclusion.
b Duration of the trial treatment phase.
c First number represents the number of participants at the beginning of the study; second number 
indicates the number of participants minus dropouts. 
d The Others category represents studies comparing active drugs of two different classes.
Table 1 Study characteristics (cont.)
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Study Diagnosis Aggression 
before triala
Exclusion criteria Weeksb Drugs  :  N,Nc
Antidepressants
Coccaro & Kavoussi57
1997
Personality disorder, outpatients ≥ 15 points OAS-M 
for 1 month
Schizophrenia, mood disorder, delusional 
disorder, currently drug or alcohol dependent
12 Fluoxetine : 27, 14
Placebo : 13, 9
Davidson et al36 
1981
Depressed inpatients NAR Psychotic disorder, mania, mental 
retardation, organic brain syndrome
3 Phenelzine : 24, 21
Imipramine : 25, 22
Davidson et al35
2002
PTSD, outpatients NAR Psychotic disorder, bipolar disorder, major depression, 
anxiety disorder, organic mental disorder, alcohol 
or drug dependence/use, relevant somatic disorder, 
other psychotropics, cognitive behavioral therapy
12 Sertraline : 194, 191
Placebo : 201, 194
Mc Dougle et al44
1996
Autistic disorder, in- and outpatients NAR Illicit substance abuse, notable medical condition, 
other psychotropics, psychotic disorder 
12 Fluvoxamine : 15, 15
Placebo : 15, 15
Fava et al39
1997
Depressed outpatients NAR Pregnancy, unstable medical illness, drug abuse, 
psychotic disorder, bipolar disorder, pregnancy
12 Sertraline : 17 , ?
Imipramine : 21, ?
Placebo : 19, ?
Fassino et al38
2002
Anorexia nervosa, outpatients NAR Psychiatric comorbidity 12 Citalopram : 26, 19
Placebo : 26, 20
van der Kolk et al58
1994
PTSD outpatients NAR Schizophrenia, bipolar disorder, drug or 
alcohol addiction, organic mental disorder
5 Fluoxetine : 33, 21
Placebo : 31, 27
Rinne et al48
2002
Borderline personality disorder, outpatients NAR No other psychotropics during the trial 6 Fluvoxamine : 20, 16
Placebo : 18, 14
Salzman et al49
1995
Borderline personality disorder, outpatients NAR History of hospitalization, drug or alcohol 
abuse, recent suicidal behavior, self 
mutilation, use of other psychotropics
13 Fluoxetine : 13, ?
Placebo : 9, ?
Vartiainen et al52
1995
Schizophrenia, inpatients ≥ 1 incident/ 
month on SOAS 
for 2 months
Depression, relevant somatic disorder 24 Citalopram/
placebo : 19, 14
crossover
Othersd
Dorrego et al29
2002
ADHD, inpatients NAR Substance abuse, IQ<75, neurological 
disorder, pregnancy
18 Lithium/
Methylphenidate : 32, 23
crossover
Lipman et al41 
1986
Depressive and anxiety disorder, outpatients NAR Drug/alcohol addiction, mental retardation, 
psychosis, bipolar disorder
8 Imipramine : 149, 103
Clordiazepoxide : 140, 95
Placebo : 136, 87
Mattes43
1990
Intermittent explosive disorder , inpatients NAR Diagnoses requiring other treatment Unclear Carbamazepine : ?, 22
Propranolol : ?, 29
Soloff et al51 
1989
Borderline personality disorder, inpatients NAR Schizoaffective disorder, schizophrenia, 
mania, hypomania
5 Haloperidol : 31, 28
Amitriptyline : 30, 29
Placebo : 29, 28
Soloff et al50
1993
Borderline personality disorder, inpatients; 
follow-up partly after admission
NAR Drug or alcohol dependence, 
seizures, mental retardation,
5 Haloperidol : 36, 30 
Phenelzine : 38, 34
Placebo : 34, 28
Zanarini et al54
2004
Borderline personality disorder, 
female outpatients
NAR Active drug or alcohol abuse, psychotropic use, 
suicidal, medically ill, seizures, depression
8 Olanzapine : 16, 16
Fluoxetine : 14, 13
Ol/Fl : 15, 13
Table 1 Study characteristics (cont.)
Abbrevations: NAR= No aggression baseline required (for study-inclusion) OAS-M = Overt Aggresion 
Scale-Modified, PANSS = Positive and Negative Syndrome Scale, PTSD = posttraumatic stress 
disorder, Symbol: ? = number not stated.
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Table 2  Study Outcomes
Study Measures Side effects Jadad Scorea Generalizabilityb Outcomec
Antipsychotic agents
Blin et al59
1996
PAS No serious side effects.
More extrapyrimidal symptoms in 
haloperidol group, except hypokinesia 
and bradykinesia, which were 
higher for risperidone group
3 1 NS
Citrome et al34
2001
PANSS hostility 7 patients with hematological problems 
and seizures (unclear which arm)
4 1 Clozapine SS to risperidone and haloperidol, but 
not to olanzapine. Improvement for clozapine, 
but not for other drugs was independent 
from overall antipsychotic effect.
Czobor et al28
1995
PANSS hostility Not mentioned 2 1 Risperidone SS superior to haloperidol and placebo
Haloperidol not SS as compared to placebo
Marder et al61
1997
PANSS hostility- 
excitement
Not mentioned 3 1 Risperidone SS superior to haloperidol and placebo
Min et al27
1993
PANSS hostility No between-group differences; 
no serious side effects.
4 1 NS
Monnelly et al45 
2003
OAS-M
STAS-S, STAS-T and BDHI
Mild side effects in both groups 3 0 NS
Peuskens60
1995
PANSS hostility More extrapyrimidal symptoms 
for haloperidol; increase of 
weight for risperidone
4 1 SS
Zanarini & 
Frankenburg53
2001
SCL-90 In the olanzapine group 1 patient with 
EPS and in the whole group weight-gain 
5 0 SS
Beta-adrenergic blocking drugs
Allan et al30
1996
BPRS hostility factor 1 dropout in both groups due 
to blood pressure drops
3 1 NS
Alpert et al31
1990
OAS 1 dropout in both groups due 
to blood pressure drops
3 1 Not presented
Caspi et al32
2001
OAS  3 dropouts due to adverse events: 
bronchitis/ syncope/ bronchospasm/ 
behavioral detoriation
3 1 SS (frequency and severity)
Maoz et al42
2000
OAS, CGI-S, STPI-
anger state, STPI 
anger-trait, MAI
Less EPS in the propranolol group 4 0 SS for STPI anger stait and trait, not for other outcomes
Ratey et al47
1992
OAS
BPRS hostility-suspicion
4 dropouts due to adverse events: low 
blood pressure/ syncope/ bronchospasm
4 1 SS for OAS 
Anticonvulsants
Citrome et al33
2001
PANSS hostility No serious side effects; no 
between- group differences
3 1 SS better results at day 3 + 7; but not at endpoint
De la Fuente and 
Lotstra37 1994
SCL-90 Not mentioned 3 0 NS
Frankenburg and 
Zanarini40 2002
SCL-90 hostility/anger ; 
OAS (McLean version)
Low rate of adverse events in both groups 5 0 SS on both scales
Hollander et al56
2003
OAS- (Modified 
for outpatients) 
Mild to moderate in severity; 
21(active drug)  vs. 4 (placebo) 
dropouts due to adverse events
3 1 SS 
Hollander et al55
2001
OAS-M, AQ Not mentioned 3 0 NS improvement
Nickel et al46
2005
Staxi (5 different 
anger subscales)
Weight reduction; no severe adverse effects. 3 0 SS improvement on 4 of the 5 sub-scales 
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Table 2  Study Outcomes
Study Measures Side effects Jadad Scorea Generalizabilityb Outcomec
Antipsychotic agents
Blin et al59
1996
PAS No serious side effects.
More extrapyrimidal symptoms in 
haloperidol group, except hypokinesia 
and bradykinesia, which were 
higher for risperidone group
3 1 NS
Citrome et al34
2001
PANSS hostility 7 patients with hematological problems 
and seizures (unclear which arm)
4 1 Clozapine SS to risperidone and haloperidol, but 
not to olanzapine. Improvement for clozapine, 
but not for other drugs was independent 
from overall antipsychotic effect.
Czobor et al28
1995
PANSS hostility Not mentioned 2 1 Risperidone SS superior to haloperidol and placebo
Haloperidol not SS as compared to placebo
Marder et al61
1997
PANSS hostility- 
excitement
Not mentioned 3 1 Risperidone SS superior to haloperidol and placebo
Min et al27
1993
PANSS hostility No between-group differences; 
no serious side effects.
4 1 NS
Monnelly et al45 
2003
OAS-M
STAS-S, STAS-T and BDHI
Mild side effects in both groups 3 0 NS
Peuskens60
1995
PANSS hostility More extrapyrimidal symptoms 
for haloperidol; increase of 
weight for risperidone
4 1 SS
Zanarini & 
Frankenburg53
2001
SCL-90 In the olanzapine group 1 patient with 
EPS and in the whole group weight-gain 
5 0 SS
Beta-adrenergic blocking drugs
Allan et al30
1996
BPRS hostility factor 1 dropout in both groups due 
to blood pressure drops
3 1 NS
Alpert et al31
1990
OAS 1 dropout in both groups due 
to blood pressure drops
3 1 Not presented
Caspi et al32
2001
OAS  3 dropouts due to adverse events: 
bronchitis/ syncope/ bronchospasm/ 
behavioral detoriation
3 1 SS (frequency and severity)
Maoz et al42
2000
OAS, CGI-S, STPI-
anger state, STPI 
anger-trait, MAI
Less EPS in the propranolol group 4 0 SS for STPI anger stait and trait, not for other outcomes
Ratey et al47
1992
OAS
BPRS hostility-suspicion
4 dropouts due to adverse events: low 
blood pressure/ syncope/ bronchospasm
4 1 SS for OAS 
Anticonvulsants
Citrome et al33
2001
PANSS hostility No serious side effects; no 
between- group differences
3 1 SS better results at day 3 + 7; but not at endpoint
De la Fuente and 
Lotstra37 1994
SCL-90 Not mentioned 3 0 NS
Frankenburg and 
Zanarini40 2002
SCL-90 hostility/anger ; 
OAS (McLean version)
Low rate of adverse events in both groups 5 0 SS on both scales
Hollander et al56
2003
OAS- (Modified 
for outpatients) 
Mild to moderate in severity; 
21(active drug)  vs. 4 (placebo) 
dropouts due to adverse events
3 1 SS 
Hollander et al55
2001
OAS-M, AQ Not mentioned 3 0 NS improvement
Nickel et al46
2005
Staxi (5 different 
anger subscales)
Weight reduction; no severe adverse effects. 3 0 SS improvement on 4 of the 5 sub-scales 
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or placebo, no benefit for risperidone was reported. However, in 3 of these stud-
ies (27,45,59) sample size was small, and in one study only a 0.5-mg daily dose of 
risperidone was used (45). One study (34) showed clozapine to be significantly 
Study Measures Side effects Jadad Scorea Generalizabilityb Outcomec
Antidepressants
Coccaro & Kavoussi57
1997
OAS-M 
AQ, CGI-I
Mild-moderate; 1 dropout 
due to adverse events
3 1 SS from week 10 till endpoint
Davidson et al36 
1981
SCL-90 anger scale Not mentioned 5 0 Imipramine SS to phenelzine
Davidson et al35
2002
Davidson Trauma Scale; 
anger irritability subscale
Not mentioned 4 0 SS
Mc Dougle et al44
1996
Brown aggression scale78 No medical significant side effects. 4 1 SS from week 4 till endpoint 
Fava et al39  
1997
AAQ Not mentioned 2 1 NS 
Fassino et al38 
2002
STAXI anger scale Not mentioned 2 0 SS
van der Kolk et al58
1994
Buss-Durkee Diarrhea, sweating and headaches 
more frequently in fluoxetine group
3 1 NS
Rinne et al48
2002
BPDSI: anger subscale More nausea in fluvoxamine group. 3 0 NS
Salzman et al49
1995
POMS, OAS (McLean 
version)
Not mentioned 4 0 POMS: SS
OAS-R: NS
Vartiainen et al52
1995
SDAS CGI-SI, SOAS No significant differences between 
active drug and placebo
3 1 SS: frequency SOAS
Othersd 
Dorrego et al29
2002
Crossover
OAS MPH: nausea, weight loss
Lithium: motor slowness
4 1 Same effect in both arms.
Lipman et al41 
1986
HSCL-80 Clordiazepoxide: drowsiness
Imipramine: higher pulse rate 
and blood pressure
4 0 No improvement from baseline for I on HSCL 
anger-hostility; for C detoriation from baseline
Mattes43
1989
Global improvement 
rating scale
Not mentioned 2 1 No difference between C and P
Soloff et al51 
1989
Buss-Durkee; SCL-90; 
IMPS hostile belligerence
Not mentioned 4 1 Haloperidol SS improvement compared 
to  amitriptyline and placebo
Amitriptyline SS only on BDHI compared to Placebo
Soloff et al50
1993
Buss-Durkee; SCL-
90; IMPS hostility
Not mentioned 3 0 Haloperidol SS improvement compared to phenelzine 
and placebo on the  IMPS (not on other scales)
Zanarini et al54
2004
OAS-M More sedation and weight gain in the 
Olanzapine monotherapy group.
3 0 Olanzapine as efficacious as OFC in reducing aggression
Table 2  Study Outcomes (cont.)
a Jadad-score: ≥3= acceptable methodological quality.
b 0= poor generalizability; 1= acceptable generalizability.
c SS: Statistically significant in favor of the active drug compared to placebo unless specified 
otherwise; NS=Not significant.
d The Others category represents studies comparing active drugs of two different classes.
Abbreviations for outcome measures and associated references: AAQ = Anger Attacks 
ºQuestionnaire74; AQ = Aggression Questionnaire75; Buss-Durkee = Buss-Durkee Hostility 
Inventory76; BPDSI = Borderline Personality Disorder Severity Index64
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Study Measures Side effects Jadad Scorea Generalizabilityb Outcomec
Antidepressants
Coccaro & Kavoussi57
1997
OAS-M 
AQ, CGI-I
Mild-moderate; 1 dropout 
due to adverse events
3 1 SS from week 10 till endpoint
Davidson et al36 
1981
SCL-90 anger scale Not mentioned 5 0 Imipramine SS to phenelzine
Davidson et al35
2002
Davidson Trauma Scale; 
anger irritability subscale
Not mentioned 4 0 SS
Mc Dougle et al44
1996
Brown aggression scale78 No medical significant side effects. 4 1 SS from week 4 till endpoint 
Fava et al39  
1997
AAQ Not mentioned 2 1 NS 
Fassino et al38 
2002
STAXI anger scale Not mentioned 2 0 SS
van der Kolk et al58
1994
Buss-Durkee Diarrhea, sweating and headaches 
more frequently in fluoxetine group
3 1 NS
Rinne et al48
2002
BPDSI: anger subscale More nausea in fluvoxamine group. 3 0 NS
Salzman et al49
1995
POMS, OAS (McLean 
version)
Not mentioned 4 0 POMS: SS
OAS-R: NS
Vartiainen et al52
1995
SDAS CGI-SI, SOAS No significant differences between 
active drug and placebo
3 1 SS: frequency SOAS
Othersd 
Dorrego et al29
2002
Crossover
OAS MPH: nausea, weight loss
Lithium: motor slowness
4 1 Same effect in both arms.
Lipman et al41 
1986
HSCL-80 Clordiazepoxide: drowsiness
Imipramine: higher pulse rate 
and blood pressure
4 0 No improvement from baseline for I on HSCL 
anger-hostility; for C detoriation from baseline
Mattes43
1989
Global improvement 
rating scale
Not mentioned 2 1 No difference between C and P
Soloff et al51 
1989
Buss-Durkee; SCL-90; 
IMPS hostile belligerence
Not mentioned 4 1 Haloperidol SS improvement compared 
to  amitriptyline and placebo
Amitriptyline SS only on BDHI compared to Placebo
Soloff et al50
1993
Buss-Durkee; SCL-
90; IMPS hostility
Not mentioned 3 0 Haloperidol SS improvement compared to phenelzine 
and placebo on the  IMPS (not on other scales)
Zanarini et al54
2004
OAS-M More sedation and weight gain in the 
Olanzapine monotherapy group.
3 0 Olanzapine as efficacious as OFC in reducing aggression
superior to haloperidol, risperidone, and olanzapine in reducing hostility apart from 
the overall antipsychotic effect in a schizophrenic population resistant to previ-
ous neuroleptic treatment. The antiaggres sive mechanism of clozapine in that study 
Table 2  Study Outcomes (cont.)
BPRS = Brief Psychiatric Rating Scale77; CGI-S/I = Clinical Global Impression: aggression Severity/ 
Improvement79; DTS = Davidsson Trauma Scale80; SCL = Hopkins Symptom Checklist; hostility/
anger items81
IMPS = Inpatient Multidimensional Psychiatric Rating Scale82; MAI = Multidimensional Anger 
Inventory83; OAS= Overt Aggression Scale (modified for outpatients) 62, 843refs in JCP; PANSS = 
Positive And Negative Syndrome Scale63; PAS = Psychotic Anxiety Scale85
POMS = Profile of Mood States86; SDAS = Social Dysfunction and Aggression Scale73; SOAS = Staff 
Observation Aggression Scale72; STAS-S = Spielberger State-Trait Anger Scale-State version, ref; 
STAS-T = Spielberger State-Trait Anger Scale-Trait version, ref; STAXI = Stait Trait Anger Expression 
Inventory87; STPI = Stait-Trait Personality Inventory88
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appeared unrelated to overall psycho pathological improvement. One study (53) 
showed olanzapine to be superior to pla cebo in borderline personality disordered 
outpatients. 
Overall, we conclude that there is weak evidence of efficacy for antipsychotic 
agents in treatment of aggression. Furthermore, weak evidence was found for the 
superiority of atypical antipsychotics over typical antipsychotics. 
β-Adrenergic blockers 
β-Adrenergic blockers are effective in decreasing aggression in organic brain diseases 
(86). For the general adult psychiatric population, we found 5 studies (30–32,42,47), 
all conducted in a schizophrenic population. In 3 studies using the β-adrenergic 
blocker pindolol, propanolol, or nadolol and conducted in a chronic schizophren-
ic population, a significant reduction of aggression was found with β-adrenergic 
block ers as compared to placebo. Two (32,47) of these 3 studies were conducted in 
a chronic schizophrenia population. The 2 studies (30,31) not showing positive re-
sults in favor of the β-blockers were conducted in a population consisting of schizo-
phrenic patients with an acute exacerbation. Thus, according to our decision rules, 
there is weak evidence for the antiaggressive properties of β-adrenergic blocking 
drugs in schizophrenic patients. However, it is unclear whether these benefits out-
weigh the ob served adverse events like syncopes and bronchospasms. 
Anticonvulsants 
Four studies were retrieved assessing antiaggressive properties of valproate (dival-
proex sodium), compared to placebo (33,40,55,56). Furthermore, in one study, topi-
ramate was used as active drug (46) and, in another study, carbamazepine was used 
(37) In 3 of the 6 studies (40,46,56) anticonvulsants were superior to placebo. The 
patient populations in these 3 studies consisted of cluster B personality disordered 
outpatients. In the 3 studies not favoring anticonvulsants over placebo, either the 
sam ple size was low (37,55) or the population consisted of patients with an acute 
exacer bation of mental illness (33), which suggests that the statistical power was low. 
With 3 of the 6 studies favoring anticonvulsants to placebo, we concluded that 
there is weak evidence of efficacy in the management of aggression with anticon-
vulsants in cluster B personality disordered outpatients. No serious adverse events 
were observed or mentioned in the different studies. 
Antidepressants 
Ten studies with acceptable methodological quality comparing antidepressants to 
pla cebo were evaluated (35,41,44,48–52,57,58). Of the 10 available studies, 6 stud-
ies (fluoxetine (57) fluvoxamine (44) sertraline (35), amitriptyline (51), imipramine 
(36), and citalopram (52) with clinical heterogeneity across studies (autism (44) 
PTSD (35) schizophrenia (52) depression (36) and cluster B personality disorder 
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(51,57)) showed a significant improvement for the active drug group compared to 
the placebo group. The total study follow-up of 4 of 6 studies with positive results 
was 12 or 13 weeks (35,44,52,57), while, in 4 studies not favoring antidepressant to 
placebo (41,48,50,58) the study duration was less than 12 weeks (a range from 5 to 
8 weeks). Additionally, in 2 of 6 studies with positive results (52,57), patients were 
required to have a certain baseline level of aggression compared to none of the 5 
studies not showing positive results. Furthermore, in 1 study (36) comparing imip-
ramine to phenelzine, superiority of imipramine was observed. We conclude that 
there is weak evidence of efficacy for the use of antidepressants for the management 
of aggression across a diversity of di agnoses. 
Comparison of dif ferent drug c lasses
We found 4 studies (29,41,43,54) that could not be classified into subgroups be-
cause drugs belonging to 2 different therapeutic drug classes were compared to 
each other (carbamazepine vs propranolol (43) lithium vs methylphenidate (29) the 
combina tion of olanzapine and fluoxetine vs monotherapy (54) and imipramine vs 
chlordi azepoxide (41). One of those studies (43) which compared carbamazepine 
to propra nolol, had poor internal validity as reflected by a Jadad score of less than 
3 and, there fore, was not evaluated for evidence synthesis. In the other 3 studies 
(29,41,54) effi cacy is suggested for both the combination therapy of olanzapine and 
fluoxetine and monotherapy of olanzapine compared to monotherapy of fluoxetine 
(54) and imi pramine compared to chlordiazepoxide (41) and no differences be-
tween lithium and methylphenidate were observed. 
Qualitative evidence 
synthesis
Drug N k SS Obtained evidence
Acceptable 
Generalizability
Classical 
antipsychotics  
vs placebo
308 3 2/3 Weak evidence of efficacy 2/3
Atypical 
antipsychotics 
vs placebo and/
or haloperidol
2122 7 3/7 Weak evidence of efficacy 
compared to placebo 
and haloperidol
5/7
Beta-adrenergic 
blockers vs placebo
169 5 3/5 Weak evidence of efficacy 4/5
Anticonvulsants 
vs placebo
450 6 3/6 Weak evidence of efficacy 2/6
Antidepressants 
vs placebo
1024 10 6/10 Weak evidence of efficacy 6/10
N= Total number of study-participants; k= number of studies; SS= Statistically Significant
Table 3  Evidence synthesis
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D i s c u s s i o n
Although aggressive patients use more psychotropics as compared to nonaggressive 
patients, no strong evidence of efficacy was found for any of the drug classes. Weak 
evidence of efficacy was found for antipsychotics, antidepressants, anticonvulsants, 
and β-adrenergic blocking drugs. Atypical antipsychotics were found to be superior 
to typical antipsychotic agents. Several methodological and generalizability issues 
complicated the evidence synthesis. 
M e t h o d o l o g i c a l  l i m i t a t i o n s 
In most studies evaluated, the follow-up period was 6 to 12 weeks, but 9 studies had 
less than 6 weeks of follow-up. 
Although 3 to 6-week trials can, in some cases, be considered adequate, for in-
stance in the case of antipsychotics (87), longer follow-up seems more appropriate 
when studying the effects of the treatment of aggression. Firstly, longer follow-up 
might be required to reach optimal drug efficacy, and, secondly, changes in ag-
gressive behavior are usually measured more reliably in a longer followup period 
when incident-based instruments or self-report questionnaires are used to measure 
changes in aggressive behavior. Incident-based measurement scales, like the OAS 
(62) and the Staff Obser vation Aggression Scale (SOAS) (65), are designed to de-
tect changes in aggressive behavior by measuring the frequency and the severity of 
observed aggressive inci dents. Especially when the baseline frequency of aggressive 
behavior is low, longer follow-up is required to be able to detect changes in ag-
gressive behavior reliably. In addition, when self-report questionnaires are used to 
measure changes in aggressive behavior, a potential lag time between the patients’ 
self-recognition that aggressive behavior has diminished in frequency and severity 
and self-perception that one is still capable of engaging in aggressive acts warrants a 
longer prospective window of pa tient assessment (57).
Different limitations influenced the statistical power of the studies. When study 
power is low, insufficient evidence of efficacy does not automatically implicate evi-
dence of no efficacy. We identified the following 4 factors that may have led to 
a lack of power in individual studies to show evidence of efficacy of one drug 
above another. Firstly, study samples tended to be small. Secondly, because we ex-
pected few trials to inves tigate drug effects as primary outcome, we also included 
RCTs investigating drug eff ects on aggression or aggression-related symptoms as a 
secondary outcome. How ever, as the studies with aggression or aggression-related 
symptoms as a secondary outcome are not primarily designed to detect reduction 
in aggressive behavior, they might lack power to show evidence of efficacy. The 
third factor that might have led to a reduction of statistical power was the low base-
line aggression in several studies. The use of a minimum baseline aggression level 
as an inclusion criterion can avoid this problem. A fourth factor that might have 
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lowered the statistical power is the use of an inadequate source population. In some 
of the studies, the study population consisted of schizophrenic patients experienc-
ing an acute exacerbation (30,31,33,42). Acute psychiatric illness is associated with 
aggression; however, once stabilized, aggression does not necessarily remain an on-
going problem. To avert the problem of low statisti cal power, we intended to meta-
analyze the study results. For meta-analysis, calcula tion of effect sizes is required. As 
numerous continuous scales were used in the indi vidual studies, study outcomes 
were not directly comparable. In such cases, the com putation of standardized effect 
sizes, i.e., SMD, is required. Unfortunately, either many studies did not provide the 
data required to calculate this effect size, or the reli ability of such data was consid-
ered doubtful. We, therefore, had to rely on qualitative evidence synthesis instead of 
quantitative data synthesis. 
The impossibility of calculating effect sizes not only precluded quantitative ev-
idence synthesis, but also hampered our qualitative evidence synthesis, while studies 
were defined as positive if the study results were statistically significant or clinically 
rele vant. Clinical relevance was defined as an effect size of 0.5 or more. This implies 
that some studies, especially those with low statistical power, might have been in-
correctly classified as not positive.
G e n e r a l i z a b i l i t y  t o  d a i l y  c l i n i c a l  p r a c t i c e 
In this review, an attempt was made to assess the generalizability of the included 
studies to daily clinical practice. Poor generalizability to patients seen in daily prac-
tice is one of the limitations particularly associated with RCTs (88–90). Previous 
studies showed that patients with comorbid disorders are often excluded from trials 
(19,89). We have indications that the aggressive patient commonly seen in daily 
clini cal practice was excluded from the evaluated trials because of the recruitment 
proce dures depending on voluntary participation, the strict inclusion and exclusion 
criteria, and the sometimes inadequate resource population. 
R e c o m m e n d a t i o n s  f o r  f u r t h e r  r e s e a r c h 
As only weak evidence of efficacy was found, further research in this field is re-
quired. For future research, consensus on the use of aggression measurement scales 
should be reached, which might facilitate the conduct of meta-analytic pooling. 
The assessment of changes in aggressive behavior should be done with observer-
rated scales. We sug gest using both an incident-based scale, like the OAS (62) or 
SOAS (65) and a scale measuring behavioral and psychopathologic changes, like 
the SDAS (66). 
Furthermore, the results of future trials should be more generalizable to daily 
clinical practice. More generalizable results can be achieved by conducting prag-
matic trials (19,90). Pharmacoepidemiologic research might be another option to 
obtain evidence generalizable to daily clinical practice (88).
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A b s t r a c t
Objective In a previous review of Randomised Controlled Trials (RCTs) on 
the pharmacotherapeutical management of aggression, it was shown that there is 
only weak evidence of effectiveness. In the present study we aim to determine 
comparabil ity of patients included in these RCTs and patients of psychiatric long-
stay wards.
Methods Exclusion criteria that were used in at least 20% of the RCTs were ap-
plied to a sample of aggressive inpatients from clinical practice, in order to find what 
pro portion of these patients would be eligible to participate in the reviewed, high 
quality RCTs.
 
Results Only 30% of aggressive psychiatric patients as seen in clinical practice 
would be eligible to participate in a typical randomized controlled trial based on 
the most frequently applied exclusion criteria.
Conclusion The low comparability of patients included in RCTs with those seen 
in clinical practice may decrease the generalizability of the findings form RCTs to 
clini cal practice.
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I n t ro d u c t i o n
Aggression is an important issue in mental health departments, as it negatively 
influ ences the well being of both patients and staff workers and results in high costs 
(4,21). Pharmacotherapy is one of the tools used to prevent or reduce aggressive 
behaviour and incidents. Our group has shown that only weak empirical evidence 
is available for the effectiveness of pharmacotherapeutical management of aggres-
sion (18). This sys tematic review was restricted to Randomised Controlled Trials 
(RCTs) as these are considered to be the gold standard to obtain the most valid 
evidence for the effect of interventions (38). However, one of the observations 
from the review was that char acteristic aggressive patients seen in clinical practice 
may be different from those in cluded in RCTs, because of recruitment procedures 
depending on voluntary participa tion, strict inclusion and exclusion criteria, and 
sometimes small populations. This selection process may hamper the comparability 
of RCT populations to daily clinical practice patients, as has been shown by others, 
especially in psychiatric populations. Zimmerman (44), for example, showed that 
only 14% of depressed patients seen in daily practice would qualify for trial partici-
pation when applying exclusion criteria that are commonly used in RCTs. Another 
recent study showed that in patients suff ering from epilepsy, less than thirty percent 
would qualify to participate in a standard RCT (39).
In the present study we aim to determine the comparability of patients in 
RCTs inves tigating the maintenance pharmacotherapy for patients to whom ag-
gression is an on going problem, with patients of psychiatric longstay wards.
M e t h o d s 
R C Ts 
In a previously published paper, we reviewed the literature for RCTs assessing the 
pharmacotherapeutical maintenance therapy of aggression (18). In brief, these trials 
were retrieved by searching Pubmed, EMBASE, Psyclit and Cochrane up to March 
2004, using MESH-terms covering both “aggression” (including aggression-related 
symptoms like violence) and pharmacotherapy (including the different psychotrop-
ic drug classes). These RCTs (1-3, 5-13, 15-17,19,20,23-30, 32-37, 40-43) studied 
the pharmacological management of aggression in adult (18-65 year) psychiatric 
patients in general psychiatric settings. This means that RCTs applying to spe-
cialized psychi atric settings—like child psychiatry, mental retardation, and organic 
brain diseases—or to nonpsychiatric settings—like prisons—were not included in 
this review. From this review, only those RCTs of sufficient methodological qual-
ity, which was defined as a Jadad-score (22) of three or more, were selected for the 
present study. 
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The selected 31 RCTs (1-3, 5-8, 10-13, 17, 19, 20, 23-25, 27-30, 32-37, 40-
43) with sufficient quality were reviewed for applied exclusion criteria. 
The population sampled from clinical practice consisted of all patients of three 
long stay wards of Altrecht Mental Health Care Institute who engaged in aggressive 
behaviour during admission. The three participating wards were units for forensic 
psychiatry, a centre for intellectually disabled adolescents and adults with severe dis-
ruptive behaviour, and a ward for juveniles with externalizing behaviour disorders. 
Aggressive behaviour at these wards was continuously monitored and recorded by 
the staff using the Staff Observation Aggression Scale-Revised (SOAS-R) (31). Pa-
tients eligible for our study populations had all had been admitted for at least two 
weeks during the period September 2004 until December 2005. Patients with one 
or more aggressive incidents during the study period, as recorded with the SOAS-
R, were selected.
For consenting patients, physical examination, medical history and laboratory 
values were determined during the first week of admission. These data as well as 
demographic information were extracted from the hospital records.
The study protocol was approved by the Institutional Review Board of the 
hospital.
D a t a  a n a l y s i s
All selected RCTs were reviewed and all exclusion criteria that were used in at least 
six (20%) of the 31 RCTs were selected. Subsequently, these criteria were applied 
to the sample of aggressive inpatients from clinical practice, in order to calculate 
what proportion of these patients would be eligible to participate in the reviewed, 
high quality RCTs. Lastly, characteristics of eligible patients were compared with 
charac teristics of ineligible patients.
As the patients from clinical practice were all inpatients, a subanalysis, with the 
use of only the exclusion criteria used in at least 20% of the RCTs conducted in 
inpatient settings, was performed.
R e s u l t s
R C Ts
The RCTs were conducted in the following patient groups: schizophrenic patients 
(N=12 [39% of the RCTs]) and patients with cluster B personality disorder (N=12 
[39% of the RCTs]), patients suffering from PTSD (N= 3 [10% of the RCTs]), 
depressive disorder (N=2 [7% of the RCTs]), ADHD (N=1 [3% of the RCTs]) and 
autistic disorder (N=1 [3% of the RCTs]). 
The exclusion criteria extracted from the RCTs are presented in Table 1.
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A number of exclusion criteria, including “relevant somatic disorder”, “physi-
cal disorder”, “unstable medical disease” and “abnormal routine lab”, were generally 
not well-defined. The authors of studies in which these exclusion criteria were not 
well-defined, were contacted by email for further specification of these criteria. 
Response rate was low (3 out of 15 = 20%). On basis of the responses and the other 
reviewed RCTs in which somatic illnesses or deviant laboratory values as exclusion 
criteria were defined more precisely, we decided to further specify the criteria as 
follows: 
“relevant somatic disorder”, “physical disorder” and “unstable medical disease” 
included neurological diseases, COPD and asthma, cardiovascular disease, liver dis-
ease and renal failure, whereas “abnormal routine lab” comprised deviant labora-
tory tests findings, including liver function, kidney function, thyroid function and 
haemogramme.
The exclusion criterion “the use of psychotropics other than the study medi-
cation” was used in 58% of the trials with borderline patients, but in none of the 
trials conducted in a study population consisting of schizophrenic patients.
Table 1  Exclusion criteria used in the RCTs
Exclusion criteria Percentage of all 
trials in which the 
criterion was used
Percentage of trials, conducted 
in inpatient setting, in which the 
criterion was used
Substance abuse (alcohol 
  or drugs)
54.8 44.4
Abnormal routine laboratory 
  values
51.6 66.7
Clinically relevant systemic  
  somatic disorder (heart, renal, 
  hepatic, neurological, asthma 
  and COPD) 
51.6 61.1
Pregnancy 38.7 33.3
Use of other psychotropics than 
  the study drug
35.5 16.7
Lactating 32.2 27.8
Suicidal ideation 19.3 0.0
Without contraception 16.1 11.1
Unstable medical disorder 16.1 16.7
Organic brain disorder 9.7 38.9
Psychotherapy 9.7 0.0
Depot neurolepticum 9.7 16.7
Women 6.4 0.0
Men 3.2 0.0
History of psychiatric 
  hospitalization
3.2 0.0
IQ < 75 3.2 5.6
Drug induced psychosis 3.2 5.6
Selfmutilation 3.2 0.0
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C l i n i c a l  p r a c t i c e  s a m p l e
The clinical practice sample consisted of 106 aggressive patients. Patients’ character-
istics are displayed in Table 2. Exclusion criteria were applied in descending order of 
appearance in the trials. Current drugs and/or alcohol abuse was observed in 29% 
of the patients. Fourteen patients (13%) had a relevant somatic disorder. Further-
more, three patients (3%) refused to undergo a physical examination, which would 
be reason for exclusion in an RCT. Abnormal routine lab was observed in 13% of 
the patients, whereas 5% of the patients refused to give a blood sample. No patients 
were pregnant or lactating. Finally, in several studies patients were excluded if other 
psychotropics were used concomitantly with the study drug. We assumed that pa-
tients from our study sample using two or more psychotropics would not likely be 
switched to only one study-drug. 
Therefore, from our study sample patients using more than one psychotropic, 
i.e. al most one third (34%), were considered ineligible for a trial.
Table 2  Clinical study sample
Characteristic Patients with 
aggressive incident(s)
(n=106)
Age (mean, SD) 27.3 (10.4)
Aggressive incidents per month (mean, SD) 1.9 (4.2)
N (%)
Male sex 76 (71.7)
Diagnosis (DSM IV)
Axis I
Psychotic disorder 49 (46.2)
Mood disorder 11 (10.4)
Anxiety 6 (8.8)
Alcohol dependence/abuse 9 (8.5)
Drug dependence/abuse 27 (25.5)
Pervasive disorder 10 (9.4)
ADHD & disruptive behaviour 24 (22.6)
Other 11 (10.4)
Axis II
Personality disorder 14 (13.2)
Mental retardation 40 (37.7)
Regular medication use
Antidepressants 18 (17.0)
Antipsychotics 54 (50.9)
Benzodiazepines 33 (31.1)
Moodstabilizer 11 (10.4)
Somatic medication 33 (31.1)
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With the application of these criteria on the study population, only 30% of 
the patients would be eligible for trial participation (Figure 1). As use of other psy-
chotropics was not a frequently used exclusion criterion in the RCTs conducted 
in patients with schizophrenia, we also calculated the percentage of eligible schizo-
phrenic patients, without application of this criterion, which resulted in a percent-
age of 43% of patients that would be eligible.
Lastly, in the subanalysis in which only exclusion criteria of the RCTs con-
ducted in inpatients setting were applied to the clinical practice sample, 46% of 
patients ap peared to be eligible. 
10.0073=goedhard;2.3-fig01.ai
126 x 206 mm=100% imp rter n
All aggressive patients N = 106
Substance abuse
Clinically relevant somatic disorder
Abnormal routine laboratoria values
Pregnancy
Lactation
Use of two or more psychotropics
N=75 (70,8%)
N=62 (58,5%)
 N=49 (46.2%)
 N=49 (46.2%)
N=32 (30,2%)
N=32 (30,2%)
Figure 1  Sequential application of exclusion criteria to the whole group of patients.
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E l i g i b l e  v e r s u s  i n e l i g i b l e  p a t i e n t s
The eligible patients were compared with the ineligible patients, results of this 
com parison are shown in Table 3.
Eligible patients were significantly younger and were less frequently diagnosed 
with a personality disorder. Concerning the frequency and severity of aggression, 
no differ ences were observed between eligible and ineligible patients.
D i s c u s s i o n 
The current results suggest that, based upon the most frequently applied exclu-
sion criteria, only 30% of aggressive psychiatric patients as seen in clinical practice 
would be eligible to participate in a typical randomized controlled trial investigat-
ing the pharmacological maintenance treatment of aggression. This finding is in 
line with the proportions reported in two previous studies, in which 14% and 30% 
of patients from clinical practice were found to be eligible for trial participation in a 
clinical practice population treated for depression and epilepsy, respectively (44,39). 
These findings warrant the conclusion that the evidence for the pharmaco-
logical man agement of aggression not only appears to be weak (18), but that, ad-
ditionally, the patients in trials are different from the patient of clinical practice, or 
at least different from typical psychiatric long-stay inpatients. Subsequently this 
raises the question if the trial outcomes are generalisable to clinical practice. It is 
quite well imaginable that they are not. For example, it is likely that more somatic 
comorbidity influences the generalizability of trials, e.g. due to the use of co-medi-
Table 3  Comparison of eligible and ineligible patients
Characteristic Eligible
patients
Ineligible
patients
p value
N      (%) N      (%)
Age (mean, SD) 23.5 9.9 28.9 10.3 0.003
Aggressive incidents per 100 days (median) 4.2 2.5 0.19
Severely aggressive 28 (87.5) 55 (74.3) 0.13
Male sex 20 (62.5) 56 (75.7) 0.17
Diagnosis (DSM IV)
Axis I
Psychotic disorder 11 (34.4) 38 (51.4) 0.11
Mood disorder 4 (12.5) 7 (9.5) 0.64
Pervasive disorder 6 (18.8) 4 (5.4) 0.06
ADHD & disruptive behaviour 11 (34.4) 13 (17.6) 0.06
Axis II
Personality disorder 2 (6.2) 17 (23) 0.04
Mental retardation 10 (31.2) 30 (40.5) 0.37
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cation. Furthermore, compari son of the group of the eligible with the non-eligible 
patients shows that the eligible patients differ from the non-eligible patients, at least 
for diagnosis and age.
In addition to the exclusion criteria applied, other characteristics of the evalu-
ated RCTs are likely to decrease the comparability of trials to clinical practice. 
Firstly, previous research suggests that aggressive patients are less likely to give in-
formed consent (14). This might lead to an underrepresentation of severely ag-
gressive pa tients. Furthermore, the setting of many RCTs (~40% in outpatient 
departments) and the recruitment methods (e.g. advertisement) might also have 
contributed to an under representation of severely aggressive patients in the RCTs. 
It is well imaginable that the aetiology of aggression of severely aggressive patients 
differs from the aetiology in mildly aggressive patients, thereby requiring different 
pharmacotherapeutical strategies. 
In conclusion, it is likely that the low comparability of the patients in RCTs 
with the patients from practice affects the generalizability of the efficacy of trial 
medication and observed side effects. However, with the available data we were 
not able to in vestigate this. To investigate this, other research, such as conducted 
by Wisniewski et al. (45), is needed. In that study the researchers showed that de-
pressive patients who would be ineligible for a phase III trial with antidepressants, 
experienced more severe side effects and had lower remission and response rates 
compared to the eligible pa tients. 
From a clinical point of view we therefore conclude that it might be under-
standable that with only weak evidence for efficacy, psychotropics are used (off-
label) in an at tempt to manage such a difficult behaviour as aggression. However, 
to our point of view, prescribers should be well aware of the limited available evi-
dence with a prob able low generalizability to clinical practice, and certainly stop the 
medication if no effect is observed.
This study has some limitations. The criterion “multiple psychotropic use” was 
ob served in the trials conducted in populations consisting of patients with cluster 
B per sonality disorder, but not in the trials conducted in populations consisting of 
schizo phrenic patients. The percentage of patients that could be included in a study 
would increase to 46% if multiple psychotropic use would be allowed. This suggests 
that an analysis, stratified for diagnosis would be more appropriate. However, the 
number of included trials was not enough to conduct such an analysis.
Furthermore, because the methodology of the trials was not always clearly 
described, we may have interpreted the criteria concerning somatic disorders and 
abnormal rou tine laboratory values not strictly enough or too strictly when cut-off 
points were not mentioned in the RCTs. Future studies possibly could give more 
insight, with the cur rent regulations binding researchers to publish their study pro-
tocols in an internet da tabase.
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C o n c l u s i o n
With an eligibility percentage of 30-46%, we conclude that the patient compa-
rability of trials, investigating the pharmacological management of aggression, to 
clinical practice is low. Furthermore, other RCT characteristics suggest that patients 
display ing severe aggression are not eligible in RCTs. The low comparability may 
decrease the generalizability of RCT findings to clinical practice.
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Chapter 3.1
The correspondence between the 
Staff  Observation Aggression Scale-
Revised and two other indicators 
for aggressive incidents
Nienke H Tenneij, Laurette E Goedhard, Joost J Stolker, Henk LI Nijman,
Hans M Koot
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A b s t r a c t
Objective Previous research has shown good psychometric properties of the Staff 
Observation Aggression Scale-Revised (SOAS-R). However, it has never been 
inves tigated what proportion of aggressive incidents occurring in facilities is docu-
mented with the SOAS-R. Furthermore, if incidents are underreported, the con-
sequences for the categorization of clients into aggressive and non-aggressive sub-
groups based on the SOAS-R are unknown. 
Methods In four inpatient psychiatric facilities for adults with mild intellectual 
dis abilities, aggressive incidents were documented with the SOAS-R and two other 
indi cators of aggressive incidents: the daily staff reports on clients’ behavior and 
reports on of the use of restraints. 
Results Less than half of the incidents documented with the staff and restraint re-
ports were also documented with the SOAS-R. On the other way around, however, 
it was also found that a substantial proportion of incidents reported on SOAS-R 
forms were not documented in the daily staff reports, which points to a more gen-
eral problem of underreporting aggressive behavior. Apart from that, categorization 
of clients into an aggressive and a non-aggressive subgroup with SOAS-R data col-
lected during one month or longer corresponded largely with the categorization 
based on both other in dicators. 
Conclusion This study showed that underreporting of aggressive incidents is likely 
to occur with the SOAS-R, making the instrument less suitable to assess absolute 
ag gression incidence in facilities. Still, the SOAS-R seems a good instrument to 
catego rize clients into aggressive and non-aggressive subgroups. Ways to improve 
the com pliance of the ward team to document all aggressive incidents are addressed 
in the Discussion section of this article. 
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I n t ro d u c t i o n
The staff observation Aggression Scale-Revised (SOAS-R) (1, 2) has been devel-
oped to assess inpatient aggression. The SOAS-R is an incident-based scale, and it is 
sup posed to be completed every time a staff member witnesses aggressive behavior 
by a client. In a broad variety of psychiatric facilities, the SOAS-R has been used to 
study incidence, causes, and determinants of inpatient aggression (see, for a review, 
(3)). Besides, the SOAS-R has been used to categorize clients into aggressive and 
non-ag gressive subgroups (4). A recent review about the psy chometric properties of 
the SOAS-R suggested fair to good interrater reliability and validity for SOAS-R 
assessments (3). For example, two raters judging the same inci dent come to com-
parable severity ratings (5, 6) and significant correlations are ob served with other 
methods for assessing aggressive behavior (6, 7). When using the SOAS-R, the un-
derlying assumption is that all aggressive incidents occurring in inpa tient facilities 
are documented with it. If documentation is incomplete, this may have implications 
for the reliability and validity of the categorization of clients into aggres sive sub-
groups based on the SOAS-R. In the fore-mentioned review of SOAS-R studies, 
it was concluded that “there have not been any studies conducted on this po tential 
reliability problem (3). Furthermore, it was assumed by the authors that especially 
milder forms of aggressive behavior may run a risk of being underre ported. 
In this study, we examined the correspondence between the SOAS-R and two 
other indicators of inpatient aggression, namely, the daily staff reports on clients’ be-
havior and the documentation of the use of restraints, in four treatment facilities for 
adults with mild intellectual disability (ID) and severe behavioral and/or psychiatric 
prob lems. The research questions were the following: (a) Are all incidents docu-
mented by both other means also reported with the SOAS-R, and if not, are some 
types of inci dents, that is, mild or severe, selectively missed by the SOAS-R? (b) 
Is the categori zation of clients into aggressive and non-aggressive subgroups based 
on SOAS-R data comparable with categorization based on both other indicators? 
M e t h o d s 
S e t t i n g
This study was conducted in four inpatient treatment facilities, together including 
138 beds, for adults with mild ID and severe behavioral and/ or psychiatric prob-
lems. Data of 76 clients, 25 women and 51 men with an average age of 25.8 years 
(SD = 7.6 years), were included in this study. 
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A s s e s s m e n t s 
The SOAS-R 
In the SOAS-R, aggressive behavior is defined as “any verbal, non-verbal, or physi-
cal behavior that was threatening (to self, others or property), and/or physical be-
havior that actually did harm (to self, others, or property)” (8). The SOAS-R is 
com posed of five columns: (a) antecedents provoking the incident (provocation), 
(b) ag gressive means used by the client, (c) target of aggression, (d) consequence(s) 
for victim(s), and (e) measures taken to stop the incident. Every time a staff member 
wit nessed aggressive behavior displayed by a client in one of the four facilities under 
study, an SOAS-R form was supposed to be completed. 
 Autoaggressive incidents were excluded, that is, incidents in which the “pa-
tient self ” was the target of the aggressive incident. The other incidents reported 
with the SOAS-R were categorized as being either “mild” or “severe.” Incidents 
were categorized as mild if the targets were nothing/ nobody or objects or if the 
aggressive means used exclusively consisted of verbal aggression. Incidents were cat-
egorized as severe if targets were persons, and the means used during the incident 
concerned some form of physical aggression. The SOAS-R was implemented for a 
6-month trial. In this study, SOAS-R data of the last 3 months of the trial (Months 
4–6) were used. 
Alternative indicators of inpatient aggression 
Restraint forms 
According to the Dutch law, the use of involuntarily administrated restrictive meas-
ures has to be recorded by the doctor in charge on a restraint form. Restrictive 
measures include mechanical restraints, involuntarily medications, and seclusion. 
Re straint forms of each facility over a period of 3 months were requested, that is, 
Months 4 to 6 of the SOAS-R trial. This yielded a total number of 96 restraint 
forms. Two raters, a research assistant and a clinical psychologist, independently 
judged whether the restraint was applied to stop an—outwardly directed—aggres-
sive inci dent. For one form (1%), no agreement was reached; it stated that “X got 
frantic and started slamming with doors.” Both raters judged differently whether 
this concerned an aggressive incident or not. This form was excluded from analyses. 
The description of the behavior of clients that leads to the use of restrictive meas-
ures on the forms was judged not to be detailed enough to be able to make distinc-
tions between mild and se vere incidents. 
Daily staf f report 
The daily staff report is a short report about the behavior of each client during each 
shift, which is written by a (psychiatric) nurse to facilitate transference of informa-
tion between shifts. Of a random selection of 64 clients, the daily reports during the 
fourth month of the SOAS-R trial were evaluated independently by two raters, that 
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is, a re search assistant and a psychiatrist. Daily reports were screened for aggressive 
inci dents, as defined in the SOAS-R. These aggressive incidents were categorized as 
mild or severe using the same criteria as for the incidents reported with the SOAS-
R. Dis agreements, less than 5% of all incidents, concerning the interpretation of the 
daily reports between raters were discussed and resolved. 
P r o c e d u r e 
Before the implementation of the SOAS-R registration in each facility, the SOAS-
R was introduced to staff members on all participating wards. The importance of 
com plete documentation of all aggressive incidents was explained, and instructions 
on how to use the SOAS-R forms were provided. The definition of aggressive 
behavior as printed on the SOAS-R forms was also discussed and explained to 
the ward staff. Writing daily reports and completing restraint forms were both part 
of general proce dures in the facilities. No additional instructions were given. Staff 
members responsi ble for the daily reports and restraint forms did not know that 
these reports would be used to examine the reliability of the SOAS-R. The raters, 
who assessed the daily re ports and restraint forms, were unaware of the SOAS-R 
results. 
A n a l y s e s 
Correspondence on inc ident level 
To study correspondence on the incident level, we examined how many of the 
inci dents reported in the daily reports and on restraint forms were also documented 
with the SOAS-R; this was expressed as a percentage of all incidents reported in 
the daily reports and on the restraint forms. To investigate if SOAS-R reporting was 
dependent on participating facilities, we compared facilities with regard to these 
percentages us ing the χ2test. Besides, we examined whether the type of incident 
reported in the daily reports, that is, severe or mild, was related to whether or not 
an SOAS-R form was completed, again using a χ2 test. Vice versa, we examined 
whether the type of incident reported with the SOAS-R, that is, severe or mild, was 
related to whether or not this incident was reported in the daily report. We could 
not perform the above-mentioned analyses with the restraint form data as we did 
with the daily report data. Main reasons for this are that the restraint form incidents 
could no be catego rized into mild and severe and not all aggressive incidents oc-
curring in the facilities are expected to be documented with restraints forms, that 
is, only incidents that led to involuntarily restraints are recorded with it. 
Correspondence on c l ient level 
To examine correspondence on the client level, we assessed the number of clients 
with at least one restraint form and at least one SOAS-R report during the assess-
ment period of 3 months; this was expressed as a percentage of all clients with at 
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least one restraint form. On the basis of the daily reports data, clients were assigned 
either to a non-aggressive group, that is, clients caused no aggressive incident, or to 
an aggres sive group, that is, clients caused at least one incident during the month 
the daily re ports were evaluated. We determined correspondence between this cat-
egorization and the equivalent categorization based on the collected SOAS-R data 
during the same month and during 3 months. Kappa value was calculated as a 
measure of agreement and evaluated according to the criteria of Landis and Koch 
(9). 
R e s u l t s 
The evaluation of the daily reports of 1 month, the fourth month of the SOAS-R 
trial, of 64 clients resulted in 109 aggressive incidents. In the corresponding month, 
for these 64 clients, 56 incidents were documented with the SOAS-R. In the 3 
months the restraint forms were evaluated, Months 4–6 of the SOAS-R trial, 54 re-
straint forms were related to aggressive incidents, in which 20 clients were involved. 
C o r r e s p o n d e n c e  o n  i n c i d e n t  l e v e l 
For 32 (29.4%) of the 109 incidents documented in the daily reports, an incident 
documented with the SOAS-R on the same day on the same client was available. 
The four facilities did not differ with regard to this percentage, χ2 (3) = 5.44, P = 
.14. Of the 77 aggressive incidents that had been documented exclusively in the 
daily reports but not with the SOAS-R, 51 (66%) incidents were categorized as 
being mild and 26 (34%) as being severe; of the 32 incidents documented with 
both the daily reports and the SOAS-R, categorization of incidents based on the 
daily reports resulted in 19 (59%) of the incidents categorized as mild and 13 (41%) 
as severe. Differences in these percentages did not reach statistical significance, χ2 
(1) = .46, P = .49. On the other way around, it was found that not all incidents 
documented with the SOAS-R, that is, 24 (43%) of the 56, were documented in 
daily reports. Of the 32 incidents documented with both methods, according to the 
categorization of incidents based on the SOAS-R, 22 (69%) of the incidents could 
be considered as being severe and 10 (31%) as being mild. Of the 24 incidents only 
documented with the SOAS-R, 15 (63%) were categorized as severe and 9 (37%) 
as mild. The difference in these per centages was not statistically significant, χ2 (1) = 
.24, P = .63. For 22 (40.7%) of the 54 aggressive incidents documented with the re-
straint forms, an SOAS-R form was available. In one unit, no restraint forms related 
to aggressive behavior by clients. Between the other three facilities, no significant 
difference in the percentage of re straint forms for which an SOAS-R form was 
available was observed, χ2 (2) = 2.75, P = .25. 
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C o r r e s p o n d e n c e  o n  c l i e n t  l e v e l 
Thirty (46.9%) of the 64 clients of whom the daily reports were evaluated could be 
considered aggressive, that is, at least one aggressive incident was documented in the 
daily report. According to the SOAS-R data collected during the same month, 19 
(63.3%) out of these 30 clients could be considered aggressive, that is, at least one 
aggressive incident was documented with the SOAS-R. In Table 1, the correspon-
dence between the categorization of clients into an aggressive versus a non-ag-
gressive group based on the daily reports and SOAS-R data documented during 
the same month is presented. With the daily reports categorization as reference, 11 
clients were incorrectly categorized as non-aggressive with the SOAS-R data (Ta-
ble 1). Overall, the SOAS-R classification corresponded with the daily reports data 
classification for 52 (81%) of the 64 clients. The kappa value for this agreement was 
.62, indicating good agreement. However, it should be noted that the observations 
of the aggressive behavior could have taken place at different moments in time. 
Categorization im proved when 3 months, instead of 1 month, of SOAS-R docu-
mentation was used to categorize clients, that is, this resulted in 4 clients, in contrast 
to 11, being incorrectly categorized as non-aggressive (Table 1). In other words, 
26 (86.7%) of the 30 clients who had been aggressive according to the daily staff 
reports had also been observed to behave aggressively by means of the SOAS-R. 
The kappa value for the overall agreement was .75, indicating good agreement 
(56 [88%] of the 64 clients were correctly classified). 
Of all 20 clients (100%) for whom one or more restraint forms were available, 
there was also one or more incidents documented with the SOAS-R during the 
correspond ing 3-month period. 
Table 1  number and percentage of clients categorized aggressive versus non-aggressive groups 
according to the daily reports data and soas-r data and soas-r categorization based on data collected 
during 1 and 3 months 
SOAS-R categorisation
1 month 3 months
Daily Reports  
  categorization
Non-
aggressive* Aggressive †
Non-
aggressive*
Aggressive † Total
Non-aggressive*, 
  n (%)
33 (97.1) 1 (2.9) 30 (88.2) 4 (11.8) 34
Aggressive †, 
  n (%)
11 (36.7) 19 (63.3) 4 (13.3) 26 (86.7) 30
Total 44 20 34 30 64
* Clients without documented aggressive incidents. 
† Clients with one or more documented aggressive incidents. 
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D i s c u s s i o n 
Results of this study indicate that when the SOAS-R is used to assess the incidence 
of aggressive incidents in inpatient facilities for individuals with mild ID, under-
reporting forms a threat to the reliability of the assessments. Less than half of the 
aggressive incidents documented by other means (i.e., daily reports and restraint 
forms) were also documented with the SOAS-R. However, also in the daily reports, 
not all inci dents were reported; approximately 4 (i.e., 42.9%) out of 10 incidents 
that were documented with the SOAS-R were not reported in the daily reports 
about clients’ be havior. These results suggest that underreporting of aggressive inci-
dents poses a gen eral problem. Clearly, the reliability of any aggression observation 
method relies on the preparedness of the ward staff to record every aggressive oc-
currence. However, we assume that the ward staff in this study in this respect did 
not differ from the ward staff in other studies. The ward staff in the current study 
seemed motivated to record aggressive behavior, and no significant differences be-
tween wards were discovered as far as their documentation “performances” with 
the SOAS-R were concerned. That is, no statistically significant differences in the 
percentages of daily report incidents and restraint form incidents, for which an 
SOAS-R incident on the same client on the same day was available, were found 
between the facilities. Besides, the derived an nual number of 10.5 incidents per year 
per client found in this study (56 incidents documented with the SOAS-R in 1 
month / 64 clients × 12) is comparable to the an nual number of 9.3 incidents per 
client found on acute psychiatric wards reported by Nijman (3). 
It has been suggested that especially mild incidents may run the risk of not 
being documented with the SOAS-R (3, 10); however, this appears not to be sup-
ported by the present findings. The proportion of severe and mild incidents was not 
different for the daily report incidents documented (59% mild) and daily reports 
not documented (66% mild) with the SOAS-R. Furthermore, almost 60% of the 
aggressive incidents that resulted in involuntarily restraints, and therefore may be 
considered relatively se vere, were not documented with the SOAS-R. 
An explanation for the underreporting might be that a staff member becomes 
reluctant to complete an SOAS-R form if a patient frequently shows the same 
pattern of ag gressive behavior, especially when the staff member knows how to 
intervene and does not feel threatened anymore. Alternatively, reporting of aggres-
sive incidents might wane as time progresses and no additional (standardized) ef-
forts are made to keep the ward team aware of the necessity to document incidents. 
This may be particularly true for the SOAS-R reporting system in case it is not the 
regular way of reporting aggres sive incidents. New or temporary staff members will 
not have been present at the in struction about the SOAS-R and thus might be less 
attentive on completing SOAS-R forms, whereas they generally will be used to, 
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and aware of, the necessity of writing daily reports and completing the mandatory 
restraint forms. 
In contrast to the results on incident level, the SOAS-R results with regard to 
the cate gorization of clients into aggressive and non-aggressive groups were more 
promising. With the daily reports data as reference, 81% of the clients were cor-
rectly classified with the SOAS-R data registered during the same month. The ka-
ppa statistic sug gested good agreement between both modes of categorization. The 
number of clients categorized incorrectly as non-aggressive was further reduced 
when using a longer period of SOAS-R data to categorize clients, as the results 
concerning the restraint forms and the categorization with the SOAS-R over a 
period of 3 months indicated. 
L i m i t a t i o n s 
A limitation of this study is that the two indicators used to compare the SOAS-R 
data with do not reflect the true incidence of aggressive incidents in facilities. As 
men tioned previously, not all incidents documented with the SOAS-R were re-
ported in the daily reports, and incidents documented with the restraint forms only 
concern those incidents that were followed by the use of involuntarily restraints. 
The results of this study only indicate that by using the SOAS-R, an underreport-
ing of the true incidence of aggressive incidents can be expected. However, the 
same seems to be true for other ways of reporting aggressive incidents, such as daily 
staff reports. Because of this, the absolute amount of underreporting cannot be es-
timated from these results. As under reporting of aggressive incidents appears to be 
a general problem and no significant differences between the wards in documenta-
tion compliance were found, data ob tained with the SOAS-R may still be valid for 
comparison purposes between wards and institutions with respect to their relative 
levels of aggressiveness. 
R e c o m m e n d a t i o n s 
The substantial underreporting of aggressive incidents with the SOAS-R, but also 
in the daily reports, observed in this study, stresses the importance of reminding staff 
repeatedly and structurally about the necessity to record all aggressive behavior. An 
effective way to prevent underreporting of aggression with the SOAS-R that is 
used in practice is to put aggression and its documentation as a fixed item on the 
agenda of the weekly or even the daily team meetings (i.e., the shift transference 
meetings). By spending a moment at the beginning of such meetings on whether 
aggressive incidents have occurred and, if so, whether they have been documented 
adequately, the focus on documenting aggression will be maintained. 
For studying the effects of interventions, however, it seems advisable that the 
use of incident-based aggression observation tools is combined with a period-based 
ag gression measurement scale, such as the Social Dysfunction and Aggression Scale 
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(11), which has to be completed at predetermined times. On the other hand, com-
pared with period-based aggression scales, incident-based aggression assessments 
may have the advantage that they provide more opportunities to study the specific 
circumstances and temporal factors involved in triggering aggressive outbursts (12). 
Possibly, combin ing SOAS-R with weekly performed assessments such as the SDAS 
would be the most optimal way to assess inpatient aggression. To assess the absolute 
number of aggressive incidents in facilities, probably, researcher-based observations 
on the ward for a certain period could serve as a criterion. However, direct obser-
vation can be an intrusive technique and may also influence behavior on a ward. 
Aggressive incidents in psychiatric patients with behavioural problems trigger reac-
tive prescribing behaviour
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A b s t r a c t
Objective: To investigate the association between aggressive incidents in psychiat-
ric patients and changes in prescribing of regular medication.
Methods: A 16-months prospective observational study was conducted in three 
psy chiatric wards where all aggressive incidents were prospectively registered using 
the SOAS-R scale. Patients with and without aggressive incidents were compared 
with respect to the frequency (expressed as incidence density per personyear (ID)) 
of psy chotropic and somatic medication changes (start, discontinuation, dosage-
increase, dosage-decrease, switch to another drug within the same therapeutic drug 
class and formula change). Furthermore, in aggressive patients only, the frequencies 
of changes in psychotropic medication a) during a day before versus a day following 
episodes of aggression, b) during episodes of aggression versus remaining follow-up 
time, i.e. non-aggressive episodes, were compared.
Results: A total of 106 (61%) out of the 174 included patients exhibited 1107 
aggres sive incidents. For aggressive patients 653 psychotropic medication changes 
were ob served versus 167 changes for non-aggressive patients (ID: 8.6 and 5.9 per 
person year, respectively; ID Ratio (IDR): 1.5, 95%CI [1.3-1.8]). Overall, for ag-
gressive pa tients, significantly higher IDs were observed for start of psychotropic 
medication and dosage-increases (IDR 1.8, 95%CI 1.2-2.6 and 2.1, 95%CI 1.4-3.1, 
respectively); IDs for other changes were non-significantly increased. ID of somatic 
medication changes for aggressive patients and non-aggressive patients did not dif-
fer significantly (IDR 1.2 95%CI 0.8-1.9). Within the group of aggressive patients, 
the number of changes on the day before and following aggressive episodes did not 
differ. However, in the period of one day before untill one day following aggressive 
episodes, an ID of 19.5 per personyear was observed, versus 7.8 during the remain-
ing aggression-free follow-up time (IDR= 2.5; 95% CI 2.0-3.1).
Conclusion: Regular medication patterns of aggressive patients in general are fre-
quently subject to change during their hospitalisation. Apparently, difficult patient 
behaviour, such as aggression, triggers reactive prescribing behaviour.
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I n t ro d u c t i o n
Several pharmacoepidemiological studies have shown that medication changes - 
such as dosage changes, switching, starting, or stopping of medication- can be either 
the heralds of or the reaction to disease or treatment related trouble, such as the 
onset of a disease, treatment failure, worsening of disease, or the occurrence of side 
effects (1-3). Stuffken et al., for example, found an increased initiation of benzo-
diazepine pre scriptions during the three months prior to admission in a general 
hospital. (1) They hypothesized that the increased prescriptions were a reaction to 
mental manifestations linked to an underlying physical disease, which may occur 
before hospitalization. Ex amples of an increased frequency of medication changes 
associated with disease or treatment related trouble, in mental health care include 
antipsychotic polypharmacy for schizophrenic patients with a high relapse rate or 
comorbidity (3) and frequent switching of antidepressants for patients poorly re-
sponding to therapy (2). 
In one of our previous studies, we found that aggressive behaviour of long-stay 
psy chiatric patients - a particularly difficult to manage troublesome behaviour with 
large impact on health care workers and patients- is associated with a significant 
increase in the use of as-needed medication, not only psychotropics but also medi-
cations for so matic disorders such as analgesics (5). The prescribing and administra-
tion of psycho tropic as-needed medication as a reaction to aggressive incidents is 
not surprising; it will often be administered to sedate the patient as a response to 
aggressive behaviour. One might hypothesize that signs of imminent aggression or 
aggressive incidents, given their impact on patients and their environment, trigger 
changes not only in as needed medication, but also in regular medication, either as 
a rational effort to treat aggression or possibly as a behavioural reaction of the physi-
cian ‘to do something’. In that case, more changes are likely to occur following ag-
gressive incidents. Therefore, in this study we aim to quantify and specify the type of 
the changes in the prescribing of regular psychotropic and somatic medication use 
of aggressive psychiatric long-stay patients, compared to non-aggressive psychiatric 
long-stay patients. Furthermore, the temporal relationship between the occurrence 
of aggression and changes in pre scriptions of medication is investigated.
M e t h o d s
S e t t i n g ,  d e s i g n  a n d  s u b j e c t s
This observational study was conducted on three wards of the Altrecht centre for 
mental healthcare. These three wards have a total capacity of 90 beds with a mixed 
patient population (i.e., forensic psychiatric patients, patients with severe psychiatric 
disorders combined with mild learning disabilities, and juveniles with severe behav-
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ioural problems) and were selected for the current study because of the anticipated 
high prevalence of aggressive behaviour. 
All patients admitted to these wards, with at least one week of their admission 
during the studyperiod, were included in the study. Start of follow-up was defined 
as either the start of the studyperiod (September 2004), or the day of admission, 
whichever came first. Follow-up ended either on the day of discharge from the 
participating wards or the end of the study period (December 2005).
Patients were informed about the study and included if they did not object 
to participation. The Institutional Review Board of the mental health care centre 
approved the study protocol. 
D a t a  c o l l e c t i o n
Aggressive incidents were prospectively documented using the Staff Observation 
Aggression Scale Revised (SOAS-R), a widely used instrument to measure the 
frequency, severity and nature of aggression (6). Aggressive incidents were clustered 
into one episode of aggressive incidents if the time-period between incidents was 
shorter than three days. Patients who had been outwardly aggressive at least once 
during the study period, as recorded with the SOAS-R were categorized as aggres-
sive, patients without aggressive incidents during the study period as non-aggressive 
control patients. Medication prescriptions of the participating patients were ex-
tracted from the pharmacy database of the hospital. In this database, information 
on drug prescribing is registered on an individual patient level, including the name 
of the drug, start and stop dates of the administration, dosages, and the name of 
the prescriber. Additional background data concerning the patients included in the 
study were collected from the hospital administration database. Data were directly 
anonymized by one of the researchers (LG), who also works as a medical doctor in 
the hospital.
 
O u t c o m e
The outcome of interest was a change in regular medication (psychotropic as well 
as somatic). Regular medication, in contrast to as needed medications, was de-
fined as medication administered regularly according to a dosing-scheme. A medi-
cation change was defined as either a start of a new medication, a discontinua-
tion, a dosage increase or decrease, and a switch from one drug to another of the 
same pharma cotherapeutical drug class, and a change in formulation (see Table 1). 
Drugs were classified into psychotropic and somatic drugs. The psychotropic drugs 
were subclas sified into the following four groups: antidepressants, antipsychotics, 
benzodiazepi nes, and moodstabilizers (valproate, lithium and carbamazepine).
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D a t a  a n a l y s e s
Incidence densities (IDs) of medication changes, i.e. the total number of medication 
changes divided by the total follow-up time, for the group of aggressive and non-
ag gressive patients were calculated. The IDs for the two groups were compared to 
each other and expressed as Incidence Density Ratios (IDRs) with corresponding 
95% Confidence Intervals (95%CI). IDRs for psychotropic and somatic medication 
were calculated separately. Furthermore, for psychotropic medication subanalyses 
were performed for the different types of medication changes, and for the different 
thera peutical drug classes.
Change in total number of psychotropics, from start of the study to end of the 
study was calculated. Changes from start to end of the study for aggressive patients 
were compared with non-aggressive patients.
In order to investigate the time-relationship between aggressive incidents and 
medi cation changes, the number of medication changes one day before an aggres-
sive inci dent or episode of aggressive incidents were compared with the number of 
medication changes during one day following this aggressive incident or episode, 
using the Wil coxon signed rank test. 
 
R e s u l t s
P a t i e n t s
In the study period, 176 patients were hospitalized for more than one week and 
there fore could be included in the study sample. Two of them objected to participa-
tion and were excluded from the study. At the end of the 15-month observation pe-
riod, 106 of the 174 included patients (61%) turned out to have displayed aggressive 
behaviour and were responsible for a total of 1,107 outwardly directed aggressive 
Table 1  Definitions of changes investigated
Start Start of drug administration. An administration-free period of at least 
seven days between a possible previous administration-period of the 
same drug was required. 
Discontinuation Discontinuation of drug administration. An administration-free period 
of at least seven days between a possible next administration-period of 
the same drug was required.
Dosage increase Increase of the Prescribed Daily Dosage
Dosage decrease Decrease of the Prescribed Daily Dosage
Switch Change to another drug within the same pharmacotherapeutical drug 
class. The maximal period between the discontinuation of the first drug 
and the start of the other drug was 7 days
Formulation change Change to another formulation. Formulations comprise: parenteral, oral 
tablet/ capsule, oral solution and orodispersable tablets
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incidents dur ing the study period. These aggressive incidents were clustered into 
624 episodes of aggression.
Aggressive patients were significantly younger and had a longer follow-up 
period compared to non-aggressive patients (Table 2). Concerning the diagnostic 
distribu tions of both groups, significant differences in the frequency of drug abuse 
and ADHD or disruptive behaviour disorder were observed. At baseline, however, 
there were no differences in use of psychotropics between both groups (see Table 2). 
M e d i c a t i o n  c h a n g e s
During the study period, 820 changes in regular psychotropic medication were 
ob served in 143 patients; 653 took place in 94 aggressive patients, and 167 in 49 
non-aggressive patients (ID: 8.6 and 5.9, respectively; IDR: 1.5, 95% CI 1.3-1.8; see 
table 3). A subanalysis for the different changes in psychotropic medication revealed 
that in the group of aggressive patients, more frequently new drugs were started and 
more frequently drug dosages were increased. 
Table 2  Characteristics of the study population
Characteristic Patients with
aggressive incident(s)
(n=106)
Patients without
aggressive incident(s)
(n=68)
p value
Mean (SD) Mean (SD)
Age (mean, SD) 27.3 (10.4) 29.5 (8.7) .04
Median duration of follow-up (days) 260 (154.2) 151.1 (142.8) .00
N (%) N (%)
Male sex 76 (71.7) 54 (79.4) .25
Diagnosis (DSM IV)
Axis I
Psychotic disorder 49 (46.2) 41 (60.3) .07
Mood disorder 11 (10.4) 7 (10.3) .53
Anxiety 6 (8.8) 6 (5.7) .42
Alcohol dependence/abuse 9 (8.5) 8 (11.8) .48
Drug dependence/abuse 27 (25.5) 19 (27.9) .72
Pervasive disorder 10 (9.4) 8 (11.8) .62
ADHD & disruptive behaviour 24 (22.6) 5 (7.4) .01
Other 11 (10.4) 3 (4.4) .16
Axis II
Personality disorder 14 (13.2) 10 (14.7) .78
Mental retardation 40 (37.7) 23 (33.8) .60
Regular medication users at inclusion
Antidepressants 18 (17.0) 11 (16.2) .90
Antipsychotics 54 (50.9) 41 (60.3) .23
Benzodiazepines 33 (31.1) 21 (30.9) .97
Moodstabilizer 11 (10.4) 4 (5.9) .30
Somatic medication 33 (31.1) 22 (32.4) .87
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No significant differences for the other types of medication changes were 
observed (see Table 3). Most changes occurred within the pharmacotherapeutical 
drug classes of antipsychotics and sedatives; these were also the most frequently 
prescribed types of drugs (see Table 2). 
Additionally, per patient, the change from baseline to the end of the study for 
the used number of psychotropics were calculated. These changes for aggressive 
patients were compared with non-aggressive patients. The change in number of 
used psychotropics ranged from -4 to 3 (mean -0.09, median 0.00) and from -3.00 
to 1.00 (mean -0.20, median 0.00) for aggressive and non-aggressive patients, re-
spectively (not statistically significant difference: Z= -0.89, p = 0.40). For somatic 
medication a total of 118 changes were observed resulting in an ID for aggressive 
and non-aggressive patients of 1.3 and 1.0, respectively (IDR 1.2, 95% CI 0.8-1.9) 
(see Table 3).
Te m p o r a l  a s s o c i a t i o n  b e t w e e n  a g g r e s s i v e  i n c i d e n t s  a n d 
m e d i c a t i o n  c h a n g e s
In the time period of one day before and following aggressive episodes along with 
the time period of the aggressive episodes, an ID of 19.5 per personyear was ob-
served, versus 7.8 during the remaining aggression-free follow-up time (IDR= 2.5; 
95% CI 2.0-3.1). 
Also during the aggression-free follow-up time of aggressive patients more 
changes took place than during the follow-up time of non-aggressive patients (ID 
= 7.8 and 5.9 respectively, IDR= 1.3; 95% CI 1.1-1.6). 
Table 3  Medication changes per drug class
Incidence density per personyear
Aggressive 
patients
Non-
aggressive 
patients
IDR
95%Confidence 
interval
Any psychotropic 8.6 5.9 1.5 (1.3 - 1.8)
Antidepressants 0.8 0.6 1.3 (0.8 - 2.2)
Antipsychotics 3.8 2.6 1.5 (1.1 - 1.9)
Benzodiazepines 2.8 1.9 1.5 (1.1 - 2.0)
Moodstabilizers 0.6 0.5 1.3 (0.7 - 2.3)
Start 2.0 1.2 1.8 (1.2 - 2.6)
Discontinuation 1.8 1.4 1.3 (0.9 - 1.9)
Dosage increase 2.3 1.1 2.1 (1.4 - 3.1)
Dosage decrease 1.9 1.8 1.1 (0.8 - 1.5)
Switch 0.3 0.2 1.4 (0.5 - 3.7)
Formulation change 0.3 0.2 1.6 (0.7 - 3.9)
Somatic medication 1.3 1.04 1.2 (0.8 – 1.9)
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D i s c u s s i o n
The present results indicate that for patients displaying aggressive behaviour, regular 
psychotropic medication is frequently subject to change, especially in the time win-
dow of 24 hours around aggressive episodes. Starting new psychotropic medication 
and dosage-increases in particular occur more frequently in regular medication 
regi mens of aggressive patients. Other changes, like discontinuation of regularly 
pre scribed medication, medication switches, and formulation changes do not ap-
pear to occur more frequently in aggressive patients. This shows that aggressive 
patients in general receive an increasing number of medications during their ad-
mission. Appar ently, difficult behaviour, like aggression, triggers reactive prescribing 
behaviour, leading to increased use of medication.
The question is why medication changes occur more frequently for aggressive 
pa tients. As relatively more changes took place during or directly around aggression 
episodes -compared to the remaining follow-up time- changes in medication might 
be an attempt to prevent or stop aggressive incidents. In contrast to our previous 
study, in which aggression was found to be associated with more administrations 
of as-needed medication in the three hours following aggressive incidents (4), the 
increase in changes shortly following aggressive episodes was not significant. This 
could well be explained by the presumption that if regular medication is changed in 
a reaction on aggression or imminent aggression, this is most likely to occur when 
the treating phy sician is on duty, whereas aggression can occur any time; by day 
and night, week and weekend. Furthermore, changes in regular medication are to 
be discussed with the patient beforehand, which generally may be difficult directly 
after an aggressive inci dent.
However, medication changes as a (direct) reaction on the occurrence of ag-
gression is an inconclusive explanation, as during the aggression-free follow-up of 
aggressive patients, also an increased number of changes was observed, compared 
to the follow-up time of non-aggressive patients. Possibly, the regularly prescribed 
medication is increased by the physician with the aim of reducing more general 
patterns of agitated and disruptive behaviour that may be more prevalent in the ag-
gressive patient group in between aggressive incidents.
Alternatively, an explanation might be that the increased number of changes 
observed in the group of aggressive patients reflects the treatment of severe or 
worsening psy chopathology -which has been shown to be associated with aggres-
sion in some studies (6)- instead of the (direct) pharmacological management of 
aggression.
Despite the high number of pharmacological interventions in aggressive pa-
tients, the present study, as well as earlier results (7, 8), suggests that the length of 
stay is still substantially longer than that of non aggressive patients. Furthermore, 
taking into ac count potential side effects and the sparse evidence for effectiveness 
3.2hfdst.indd   98 27-04-10   15:43
Chapter  3 .2  •  9 9
of the pharma cological management of aggression (9), these findings cast doubt on 
the pharmacol ogical interventions that are currently used in clinical practice for 
aggressive patients. This brings us to a final explanation for the increased number 
of changes amongst ag gressive patients: irrational drug therapy, i.e. drugs are used 
whereas “there is little likelihood that it will have a beneficial effect” (10). In litera-
ture several factors con tributing to irrational prescribing have been described (10-
12). Amongst these, fol lowing might have increased drug prescribing in our study: 
the seductiveness of drugs (drugs appear more effective than they are), prescriber’s 
fear (of the unstable condi tion of the patient, but also to withdraw drugs when no 
effect is observed), drugs can be a relatively easy way out when staff feel powerless 
and finally, the patient self be ing sometimes keen on medication, especially benzo-
diazepines.
Aggression was not associated with an increase in changes of somatic medica-
tion. Somatic medication is not likely to be used for the management of aggression. 
How ever, in our previous study investigating the use of as-needed medication, we 
did find that aggression is also associated with an increased use of as-needed somatic 
medica tion - namely analgesics like acetaminophen (5). In that study we hypoth-
esized that this increased use could be a manifestation of demanding behaviour, as 
aggression is associated with demanding behaviour (13). As in this hospital analge-
sics are adminis trated predominantly on as-needed basis, it still would be interesting 
to investigate the use of somatic medication, especially analgesics in a studypopula-
tion where analge sics are usually administered on regular basis.
This study has a number of methodological limitations. The current patient 
sample was rather heterogeneous and may not reflect daily clinical practice of more 
general psychiatric admission wards. The diagnoses of the subjects included psy-
chotic and mood disorders, as well as ADHD and disruptive behaviour disorders. 
One might ask if changes in regular medication regimens for those disorders can be 
analyzed to gether, as pharmacotherapeutical treatment strategies are different. On 
the other hand in a stratified analysis for the different wards, although not signifi-
cant, results in the same directions were found (data not shown). We hypothesized 
that aggressive be haviour is a strong determinant, influencing medication patterns 
across the psychiatric diagnoses. A second limitation is that while we used a vali-
dated quantitative, incident based aggression-scale, for the registration of aggression 
we still may have missed aggressive incidents (14). The use of a periodically admin-
istered aggression scale, like the OAS (15) might have reduced underreporting, but 
would have provided fewer possibilities to study temporal associations between 
aggression and medication changes. Furthermore, the study period seems to have 
been long enough to reduce the problem of underreporting.
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C o n c l u s i o n
In conclusion, our study reveals that for patients displaying aggressive behaviour, 
many changes in regular medication regimens occur. This is in line with other stud-
ies showing that changes in pharmacotherapy indicate trouble, such as comorbidity, 
ad verse events, therapy-resistance and exacerbation of disease (e.g. 1,16,17) and, as 
was the case in the current study, with challenging behaviour such as aggression. 
Future research should unravel the reasons why regular medication regimens of ag-
gressive patients are frequently subject to change, by focusing on the (rationality of 
the) deci sion making process associated with these changes.
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A b s t r a c t 
Objective Previous studies showed that aggression is an important reason to pre-
scribe as-needed medication. The objective of this study was to compare the use 
of as-needed medication in aggressive and non-aggressive psychiatric patients and 
to ex plore patterns of administration of as-needed medication around aggressive 
incidents.
Methods An observational study in three psychiatric wards was conducted. Inci-
dence densities of as-needed medication were determined for aggressive and non-
aggressive patients and expressed as incidence density ratios (IDRs). Intensity of as-
needed medication used before and following aggressive incidents was determined 
within a 48-hours time-window. 
Results Aggressive patients had an increased use of both psychotropic and somatic 
as-needed medication (IDR, 2.5; 95% CI, 2.2 - 2.7 and IDR, 2.1; 95% CI, 1.8 - 
2.4, respectively). Of the psychotropic medication for aggressive patients, 15% was 
ad ministered in a time-window of 48 hours around an aggressive incident; in this 
time-window more as-needed medication was administered following an aggres-
sive inci dent compared to earlier treatments. 
Conclusion An increased use of both psychotropic and somatic as-needed medi-
cation is associated with aggressive behaviour. Psychotropic as-needed medication 
is more frequently administered shortly after an aggressive incident than shortly 
before. How ever, more often as-needed medication is administered outside the 48 
hours time-win dow around an aggressive incident.
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I n t ro d u c t i o n 
Aggression by psychiatric patients has a large impact on well-being of patients and 
staff and is associated with high costs (1). The incidence of aggressive incidents 
re ported in different studies ranges from 0.4 to 59.9 incidents per patient-year, 
depend ing upon the type of ward and country in which the study was conducted 
(2). To man age aggression, several intervention strategies are currently used, includ-
ing pharma cotherapy, physical restraint and seclusion. Increased use of psychotrop-
ics by aggres sive patients has been observed in observational studies. Higher dosages 
of psycho tropics and polypharmacy are more common for aggressive patients than 
non-aggres sive patients (3, 4). However, evidence for the effectiveness of phar-
macological man agement of aggression is scarce (5). Psychotropics generally are 
prescribed in a ﬁxed dose regimen, but as-needed regimens for the management of 
aggression and aggres sion-related symptoms like agitation and disruptive behaviour 
are also used (6-8) giv ing nursing staff greater freedom in administering medication, 
allowing them to administer rapidly in acute situations or at the patient’s request 
(9). Especially anti histamines, antipsychotics and benzodiazepines are frequently 
used on an as-needed basis (3). Although prescription of as-needed medication 
appears to be widespread in psychiatry, evidence for effectiveness is lacking (9, 10). 
We are unaware of clinical trials that speciﬁcally looked at the efﬁcacy of as-needed 
regimens in adult psychiatry, and even descriptive and more exploratory studies 
about current practices of as-needed regimens are scarce. 
Our study aims to investigate whether aggressive psychiatric patients have an 
in creased use of as-needed medication, compared to non-aggressive patients. In 
addi tion, this study investigates the time-relationship between the occurrence of 
aggres sive incidents and the administration of as-needed medication in this patient 
group. 
M e t h o d s
 
S e t t i n g ,  d e s i g n  a n d  s u b j e c t s 
A prospective observational study was conducted in three different psychiatric 
wards, located in the centre of the Netherlands. All patients, hospitalized for at 
least two weeks during the study-period of September 2004 until May 2005, were 
included. All the three participating wards were long-stay wards specialized in dis-
ruptive behav iour, i.e., a forensic ward, a centre for patients with mild learning dis-
abilities and dis ruptive behaviour, and an orthopsychiatric ward.
The study protocol was approved by the Scientiﬁc Committee and the Board 
of the hospital. Patients were informed about the study and patients were not in-
cluded in case of objection to participation in the study. 
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D a t a  c o l l e c t i o n 
Patient characteristics were collected from the hospital database. This database con-
tains information about demographics, DSM-IV diagnoses at admission as estab-
lished by psychiatrists of the ward, compulsory hospitalization and their history of 
earlier admissions. When information in the patient administration database was 
incomplete, additional data were collected from the medical records. 
Aggressive behaviour was assessed by using the Staff Observation Aggression 
Scale-Revised (SOAS-R), a validated aggression measurement instrument (11). 
This scale measures the frequency, nature, and severity of both outwardly and in-
wardly directed aggressive behaviour. SOAS-R scores range from 0 (no aggression) 
up to 22 (ex tremely severe aggression). For this study only outwardly directed ag-
gressive inci dents were analyzed, i.e., all forms of self-harming and suicidal behav-
iour were ex cluded. 
Patients were categorized as aggressive if one or more aggressive incidents 
were re corded on the SOAS-R during the study period. Furthermore, aggressive 
patients were sub-classiﬁed as being mildly or severely aggressive. A patient was 
deﬁned as being severely aggressive in case he or she was involved in one or more 
episodes of physi cal aggression towards person(s). In case a patient had exclusively 
displayed verbal aggression and/or aggression towards objects he or she was catego-
rized as being mildly aggressive. If two aggressive incidents of one patient occurred 
within one hour, they were regarded as one incident. 
As-needed medication was deﬁned as medication which was not administered 
on a regular basis, but on the patient’s or nurse’s initiative. Hospital policy requires 
ward personnel to register all administrations of as-needed medications to every 
indi vidual patient on standard forms. Patient name, drug name, date, time and dos-
age were registered. The pharmacy database was used to obtain additional informa-
tion about the medication the patients received as part of their regular treatment 
regimens.
O u t c o m e 
Firstly, we aimed to investigate whether aggressive patients have an increased use 
of as-needed medication compared to non-aggressive patients. The primary out-
come of this research question was the incidence density (ID) of psychotropic as-
needed medi cation administrations for aggressive and non-aggressive patients. The 
ID was calcu lated by dividing the sum of administrated as-needed medications in 
one group by the total duration of follow-up in that group. The IDs for aggressive 
and non-aggressive patients were compared and expressed as an Incidence Density 
Ratio (IDR). Selected psychotropic drugs included benzodiazepines, antipsychotics 
and promethazine. Sec ondary outcome was the ID of somatic as-needed medica-
tion administrations, e.g., analgesics like acetaminophen and ibuprofen. 
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The second aim of this study was to investigate the temporal association be-
tween the occurrence of aggressive incidents and the administration of psychotrop-
ic as-needed medication. Outcome for this research study was the intensity of psy-
chotropic as-needed medication use – i.e., the number of as-needed medications in 
a deﬁned in terval of time divided by the total number of aggressive incidents – for 
different time-windows before and following aggressive incidents. To avoid overlap 
of the time-windows around consecutive aggressive incidents, only aggressive inci-
dents with a preceding 24-hours incident free period were included.  
A n a l y s i s 
Between-group characteristics were analyzed using the chi-square for categorical 
variables and the Mann – Whitney U test for continuous, skewed variables. 
For the comparison of the incidence densities between aggressive and non-aggres-
sive patients, incidence density ratios (IDRs) and their 95% CI were computed. To 
check the validity of this method, the use of aggressive patients compared to non-
aggressive patients was also analyzed using a multiplicative intensity model (12) , a 
generaliza tion of cox proportional hazards regression model. 
To investigate the temporal association between the administration of psy-
chotropic as-needed medication and the occurrence of aggressive incidents, the 
frequencies of as-needed medication administrations (= intensity) before and fol-
lowing an aggressive incident were compared. A Poisson distribution was observed 
for the administration, which could be analyzed using a multiplicative intensity 
model. Differences in inten sity of use before and following aggressive incidents 
were expressed as intensity ra tios (IR). Data were analyzed using S-PLUS 6.  
R e s u l t s 
The initial study population was comprised of 130 patients. Three patients, how-
ever, objected to study participation and were therefore not included in the analysis. 
Fur thermore, two patients who were hospitalized for less than two weeks were 
excluded. The mean follow-up was 170 days (range 14 – 273 days). Characteristics 
of the re maining 125 included patients are presented in Table 1. 
Aggressive patients (n =76) turned out to differ signiﬁcantly from non-aggres-
sive pa tients (n = 49) in terms of age, ward, sex, and a diagnosis of conduct disorder. 
During the study period, 551 aggressive incidents caused by 76 patients, were re-
corded. Of these 76 patients, 61 were subclassiﬁed as severely aggressive and 15 as 
mildly aggressive. Characteristics of the aggressive incidents are displayed in Table 
2. More, but less severe, incidents were recorded at the orthopsychiatric ward. At 
the centre for mildly mentally disabled patients a higher frequency and severity of 
aggres sive incidents was observed compared to the two other wards. 
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In the nine-month of study period, 4,427 as-needed medications were ad-
ministered to 44 (60%) aggressive and 20 (41%) non-aggressive patients. The most 
frequently ad ministered types of psychotropic medications (n = 2940) were ben-
zodiazepines (96.1 %) -predominantly oxazepam, diazepam, and temazepam- fol-
Table 1  Characteristics of the study population
Characteristic Patients with
aggressive incident(s) 
(n=76)
Patients without
aggressive incident(s)
(n=49)
p value
No. (%) No. (%)
Age (mean) 27.2 years 31.7 years 0.004
Ward
Forensic psychiatry 25 32.9 31 63.3
Mentally disabled 
  patients
29 38.2 14 28.6 0.001
Orthopsychiatry 22 28.9 4 8.2
Male sex 54 71.1 43 87.8 0.03
Mean duration of 
  follow up (days)
181.4 157.1 0.28
Involuntary admission 
  (mean percentage of 
  total follow up)
41% 42% 0.92
Diagnosis at hospital admission (DSM IV)
Axis I
Psychotic disorder 37 48.7 28 57.1 0.34
Schizophrenia 33 43.4 23 46.9 0.70
Alcohol dependence/
 abuse
6 7.9 7 14.3 0.25
Drug dependence/
 abuse
18 23.7 13 26.5 0.72
Mood disorder 5 6.6 4 8.2 0.74
Development disorder 11 14.5 0 0 0.01
More than one Axis I 
 diagnosis
22 28.9 14 28.6 0.96
Axis II
Personality disorder 12 15.8 13 26.5 0.14
Cluster B 9 11.8 6 12.2 0.95
Mental retardation 30 39.5 13 26.5 0.14
Regular medication users at inclusion
Antipsychotics 37 48.7 30 61.2 0.17
Antidepressants 15 19.7 8 16.3 0.63
Anticonvulsants 6 7.9 3 6.1 0.71
Benzodiazepines 25 32.9 16 32.7 0.98
Promethazine 2 2.6 2 4.1 0.65
Polypharmacy** 53 69.7 34 69.4 0.97
Somatic medication 23 30.3 18 36.7 0.45
*The χ2 test was used for categorical variables and the Mann-Whitney U test for the non-parametric 
variables. **More than one regular psychothropic drug prescribed.
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lowed by pro methazine (3.0%), and antipsychotics (0.9%). Psychotropic as-needed 
medication was most frequently administered orally (96.1%). In the time-window 
of 48 hours around the aggressive incidents, 15% of the psychotropic as-needed 
medication was administered. Main reasons for administration of psychotropics 
were comprised of  “patient’s demand” (53%), distress (16.6%), and sleep (13.7 %) 
for non-aggressive patients, and distress (36.6%), sleep (17.3%), patient’s demand 
(16.6 %), and restless ness (13.1 %) for aggressive patients. Acetaminophen was the 
most frequently ad ministered somatic as-needed medication (72.2%), followed by 
ibuprofen (16.1%). Main reasons for administration of somatic as-needed medica-
tion were comprised of headache (33.3%), other somatic problems (23.7 %), pain 
other than headache (22.1%), and patient’s demand (14.9%) for non-aggressive pa-
tients, and headache (45.9%), pain other than headache (39.8%), and patient’s de-
mand (5.4%) for aggres sive patients.  
U s e  o f  a s - n e e d e d  m e d i c a t i o n  i n  a g g r e s s i v e  v s .  n o n - a g g r e s s i v e 
p a t i e n t s 
The ID for the use of psychotropic as-needed medication in aggressive patients 
was 5.2 administrations per person-month compared to 2.1 administrations per 
person-month for non-aggressive patients, corresponding to an IDR of 2.4 (95% 
conﬁdence interval [CI] 2.2 - 2.7). In the multiplicative intensity model these re-
sults appeared to be valid. For oxazepam, which was administered most frequently 
to both aggressive and non- aggressive patients, the highest IDR was observed 
(IDR, 6.9; 95%CI 5.6 - 8.5). 
The same analysis was performed for the use of somatic as- needed medica-
tion, re sulting in IDs for aggressive patients and non-aggressive patients of 2.1 and 
1.0 per person-month, respectively. The IDR was 2.1 (95% CI 1.8 - 2.4). The 
observed in creased use of as-needed medication for aggressive patients was higher 
for severely aggressive patients compared to mildly aggressive patients, except for 
diazepam. (Ta ble 3). 
Table 2  Characteristics of the aggressive incidents
Ward Incidents per bed 
per year
Score Only verbal 
aggression
Victim of the aggressive 
incident needs treatment
Mean SD Mean SD (%) (%)
Forensic psychiatry 6.0 0.4 9.2 4.6 42.3 1.2
Mentally disabled 
  patients
10.6 0.7 11.0 4.3 31.6 4.2
Orthopsychiatry 14.7 1.2 6.9 4.0 42.0 1.1
Total 9.1 0.4 9.1 4.6 37.8 2.3
*SOAS-R scores range from 0 to 22.
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Stratiﬁed analyses for the three different wards for psychotropics and somatic 
as-needed medication revealed statistically signiﬁcant increased use of as-needed 
medi cation for the aggressive patients in all three wards.  
T i m e  r e l a t i o n s h i p  b e t w e e n  a s - n e e d e d  m e d i c a t i o n  a n d  a g g r e s s i v e 
i n c i d e n t s 
During the nine-month study period, 551 outward directed aggressive incidents 
were recorded. For 75% of the registered aggressive incidents, no as-needed medi-
cation was administered during the 48-hours time-window around the aggressive 
incident. For most incidents, the number of administrations before an aggressive 
incident equalled the number of administrations following an aggressive incident 
(no differ ence of use at 3h: 86%, 12h: 83% , 24h: 82% , 48h: 78% ). Intensity of use of 
psy chotropic as-needed medication per 3 hours periods within the 24 hours time 
window before and following an aggressive incident was calculated and displayed 
in Fig. 1. The highest intensity of as-needed medication use was observed in the 
three hours following an aggressive incident. Comparing the intensity of use in this 
period with the intensity of use in the six hours before resulted in a ratio of 3.0 
(95% CI 1.3 - 6.8). More as-needed medications were administered in the 36 hours 
following an aggres sive incident compared to the 36 hours before (intensity ratio 
[IR]1.4; 95% CI 1.1 - 1.8). Furthermore, the intensity of use in the three-hour pe-
riod following an aggres sive incident was compared with the period from 36 hours 
to three hours before an aggressive incident and on the other hand with the period 
from three hours to 36 hours following aggressive incidents (IR 3.9; 95% CI 2.0 - 
7.7 and IR 1.84; 95% CI 1.2 - 2.9, respectively).  
Table 3  The use of as-needed medication of non-aggressive, mildly and severely aggressive  patient
As-needed 
medication
Patients 
without 
aggressive 
incident(s) 
(n=49)
Patients with mild aggressive 
incident(s) (n=15)
Patients with severe aggressive 
incident(s) (n=61)
Users ID* Users ID* IDR** 95%CI Users ID* IDR** 95%CI
N % N % N %
Psychotropic 20 41 2.1 7 47 3.3 1.6 1.4-1.8 37 61 5.8 2.7 2.5-3.0
Oxazepam 13 27 0.4 4 27 1.1 2.9 2.2-3.8 26 43 3.0 8.1 6.6-10.0
Diazepam 5 10 0.9 1 7 1.2 1.4 1.1-1.7 10 16 1.2 1.3 1.1-1.6
Temazepam 10 20 0.6 4 27 0.6 0.9 0.7-1.3 11 18 0.8 1.2 1.0-1.5
Other 4 8 0.2 3 20 0.4 1.7 1.1-2.6 15 25 0.8 3.6 2.7-4.8
Somatic 22 45 1.0 13 87 1.6 1.7 1.4-2.0 43 70 2.2 2.2 1.9-2.5
*Incidence density per person-month. **Incidence density ratio; reference-group is the group of 
patients without aggressive incidents.
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D i s c u s s i o n
 
In this observational study, conducted in three Dutch long stay wards, the associa-
tion between the use of as-needed medication and aggressive behaviour was inves-
tigated. In line with previous ﬁndings that aggressive patients have an increased use 
of psy chotropics – higher dosages and more polypharmacy (3, 4) – an increased use 
of psy chotropic as-needed medication was observed. Interestingly, in addition to an 
in creased use of psychotropic as-needed medication the use of somatic as-needed 
medi cation was also found to be increased. Apparently, aggressive behaviour triggers 
the use of as-needed medication. 
Strengths of our study include the use of a validated aggression measurement 
instru ment (the SOAS-R) and the actual use of as-needed medication as study out-
come in stead of the prescription of as-needed medication. Previous studies either 
assessed the reasons for prescription or administration of as-needed medication 
without the use of an aggression measurement instrument and without a group of 
non-aggressive patients as reference group (6-8). To our knowledge, only Soliman 
and Reza compared non-aggressive patients to aggressive patients (3). However, in 
that study, not the use of as-needed medication was analyzed, but the prescription 
of as-needed medication. Furthermore, in the study of Soliman and Reza, aggres-
sion was retrospectively as sessed from hospital records by the researchers with the 
use of the SOAS-R, although the SOAS-R is designed to record aggression as soon 
as possible after the aggressive incident by the staff witnessing the incident. 
Looking at the temporal associations between episodes of aggressive incidents 
and the administration of as-needed medication immediately preceding and fol-
lowing these aggressive incidents, an increased intensity of use was observed shortly 
after the aggressive incident. It seems fair to conclude that in those cases as-needed 
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Figure 1  Intensity of as-needed medication use around aggressive incidents.
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medication is used to regain control and / or prevent further escalation. From a 
pharmacological point of view, the choice for oxazepam seems irrational, as the op-
timal effect of ox azepam is only reached after two to three hours. A better choice, to 
our point of view, would be lorazepam or midazolam, which have a shorter Tmax. 
The interval between the administration of as-needed medication and an ag-
gressive incident was frequently much larger than 48 hours, which suggests that 
aggressive behaviour leads to the administration of as-needed medication, not only 
immediately following aggressive incidents but also on other moments. This sug-
gestion was rein forced by the observation that the intensity of use in the time-win-
dow of three to 36 hours following the aggressive incident was increased compared 
to the intensity of use in the time window of three to 36 hours before an aggressive 
incident. We, there fore, hypothesized that as-needed medication is not only used for 
the (direct) man agement of aggression. This hypothesis was further strengthened by 
the observation that not only the use of psychotropic as needed medications was 
increased, but also the use of somatic as-needed medications. One could think of 
different explanations, which could not be investigated with the available data. A 
plausible reason for an in creased use of as-needed medication might be that the 
staff tends to administrate more as-needed medication to patients, once they have 
shown aggressive behaviour, in or der to prevent future aggressive incidents. How-
ever, it might also well be possible that aggressive patients are keener on as-needed 
medication than non-aggressive pa tients and make a stronger appeal on the staff 
to obtain as-needed medication. Still another explanation might be that aggressive 
patients are more severely ill, thereby needing more medication, e.g., for insomnia. 
Limitations of this study are the following. Firstly, due to the observational 
study-de sign, an association between aggression and as-needed medication could 
be deter mined, but we could not investigate the causality of this observation, i.e., is 
the in creased use of as-needed medication caused by aggression itself or by other 
determi nants associates with aggression? ; only hypotheses could be formulated. 
Secondly, for the assessment of aggression, only the SOAS-R was used. By 
measur ing aggression with the SOAS-R, we had to rely on staff ’s willingness to 
report wit nessed aggressive behaviour. Such measurement probably resulted in a 
certain degree of underreporting, especially in the case of mildly aggressive behav-
iour. The degree of underreporting was not assessed. However, the incidence of ag-
gressive incidents was higher than the median incidence observed in the review of 
Nijman et al. (8), in which studies with aggression data, measured by the SOAS-R, 
were analyzed. 
Furthermore, reporter-bias could have been occurred as the staff, who regis-
tered both the administration of medication and aggression, could be more willing 
to report an aggressive incident after administering as-needed medication. On the 
other hand, as the registration of as-needed medication is in practice for many years 
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and as around many aggressive incidents no as-needed medication was adminis-
tered, the risk of such bias seems small. 
Lastly, the heterogeneity of the study population might have resulted in biased 
risk estimation. With a dynamic study population, both chronically and newly ad-
mitted patients were included in this study, which resulted in a heterogeneous study 
popula tion. With the participation of three different wards, the heterogeneity of the 
study population was further increased. Some heterogeneity of these three wards 
was reﬂected in the differences in severity and frequency of the aggressive incidents. 
Mean incidence and the percentage of victims requiring treatment, however, all fell 
in the range observed in the review (2). It, therefore, seemed reasonable to analyze 
the data of the three wards together instead of conducting stratiﬁed analyses, which 
would have decreased signiﬁcantly the statistical power. 
Taking into account our study limitations, we conclude that aggressive patients 
use more as-needed medication than non-aggressive patients. However, to a cer-
tain ex tent, the function of as-needed medication practices is unclear. As-needed 
medication administered immediately preceding or following the occurrence of 
aggressive inci dents, is mainly administered to regain control and / or prevent fur-
ther escalation. For the other as-needed medications administrations we can only 
make guesses about their function and effectiveness. A tempting hypothesis is that 
aggressive patients are keen on as-needed medication, which they might obtain by 
showing demanding be haviour. However, on the basis of this study it also might 
be possible that aggressive behaviour in the past leads to the administration of as-
needed medication in the future, with the aim of preventing the occurrence of 
other aggressive incidents. 
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A b s t r a c t 
Objective To investigate the reasons for the increased use of as-needed medication 
by aggressive psychiatric patients, by focusing on the beliefs of both patients and 
nurses about as-needed medication.
Methods Semi-structured interviews, conducted within 24 hours after an as-
needed medication administration, were used to compare the beliefs of aggressive 
and non-aggressive  patients concerning (the indications for and efficacy) of 
‘as-needed’ medication. A sub-analysis was done for severely aggressive patients 
compared to non-aggressive patients.
The structured interviews were also completed by the administering nurses and 
their views were compared with the patient’s views. 
Results For severely aggressive patients, as compared to non-aggressive patients, 
medication was more frequently administered on the basis of the nurse’s initiative 
(in stead of the patient’s initiative) (48 and 19%, respectively, p=0.02). Furthermore, 
ag gressive patients more frequently perceived the dosage of the as-needed 
medication as high enough, compared to non-aggressive patients (65 and 35%, 
respectively). The perceived time of onset of medication was significantly shorter 
for patients as com pared to nurses.
Conclusion Results show that nurses are more likely to administrate as-needed 
medi cation to aggressive patients -especially severely aggressive patients- compared 
to non-aggressive patients. Another important finding is that aggressive patients are 
more likely to receive satisfying dosages than non-aggressive patients. Combining 
these findings helps partially explain why aggressive patients are very likely to be 
ex posed to as-needed medication. Overall, as- needed medication seems to fulfill 
both a patient’s and a nurse’s need.
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I n t ro d u c t i o n
The use of as-needed, medication, i.e. medication administered on the nurse’s 
initia tive or patient’s request, is common practice in psychiatric wards as pointed 
out in a recent review (1). Previous research suggests that nurses beliefs about 
possible indica tions for the use of as-needed medication strongly influence the 
administration of as-needed medication (2). Thus, besides doctors, nurses have a 
great impact on the decision-making process with regard to their administration. 
Moreover, the patient-nurse interaction may also influence the administration of 
as-needed medication, since previous studies have reported that a patient’s request 
is a frequently mentioned rea son for nurses to administer as-needed medication (1, 
3, 4). 
In a previous study we found that aggressive patients use more as-needed 
medication, compared to non-aggressive patients (3). The use of psychotropic as 
well as non-psy chotropic (particularly non-opioid analgesics) as-needed medication 
use was higher amongst these patients. Furthermore, as-needed medication use 
by aggressive patients was also higher during aggression-free follow-up time. This 
possibly suggests that for aggressive patients, as-needed medication is also used 
for other purposes than the (direct) management of aggression. It is currently 
unclear what these other purposes are. Additionally, evidence indicating that as-
needed regimens are effective for the treatment of behavioral disturbances (in 
psychotic patients) compared to regular regi mens of the same drugs is lacking 
(5). Furthermore, there is only weak evidence for the efficacy of pharmacological 
treatment of aggression in general (6).
In this study, we aim to gain more insight into the reasons for the increased 
use of as-needed medication by aggressive psychiatric patients, by focusing on the 
beliefs of both patients and nurses about as-needed medication.
M e t h o d s
S e t t i n g ,  d e s i g n  a n d  s u b j e c t s
An observational follow-up study was conducted at two acute admission wards and 
two long-stay wards of the Altrecht Mental Health Institute in the Netherlands. The 
study period was January 1st 2007 - September 14th 2008. The consecutive study 
sample consisted of 91 patients, admitted during the study-period and using one 
or more as-needed medications. Patients were included if psychotropic or analgesic 
drugs were administered orally on an as-needed basis (the oral route being the 
most common for as-needed administrations (7)). These drugs included: hypnot-
ics/sedatives (benzodiazepines and others), antipsychotics, promethazine, analgesics 
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(NSAIDs, opioids, and others). Anticholinergic medication was not included. No 
ex clusion criteria were applied.
The study was approved by the Institutional Scientific Review Board, according 
to Dutch law. Written informed consent was obtained from patients willing to 
participate.
S e m i - s t r u c t u r e d  i n t e r v i e w s
Patients using as-needed medication during the study period and nurses 
administering as-needed medication were invited to participate. A semi-structured 
interview was developed, in order to investigate the beliefs of both patients and 
nurses about the reasons for the administration and the perceived effect of used as-
needed medication. To explore these topics, the following items were included in the 
interviews for both patients and nurses: who took the initiative for administration of 
the as-needed medication (i.e., the patient or a nurse), the persistence of asking for it 
(once, more than once), the reason for asking/giving the medication (tension, anger, 
fear, restlessness, pain, aggression, sleep, other), the perceived effectiveness (yes, no), 
time to onset of effect (<15 min, 15-60 min, 1-2 hours, >2 hours), the duration of 
effect (1 hour, 6 hours, 12 hours, >12 hours), frequency of administration (frequent 
enough, not frequent enough), and perceived strength of the administered dose 
(high enough, not high enough). 
Furthermore, interviews with the nurses contained two additional items about 
the way the patient asked for the medication (calmly, agitated, friendly, pushy, or 
angry) and the necessity of administration as perceived by the nurse (necessary or 
not necessary). The interviews were pre-tested both in one of the acute wards and 
in one of the long-stay wards. 
To reduce recall bias, patients were interviewed within 24 hours after as-needed 
medication was administered (LG and DM). Patients with multiple as-needed 
medi cation administrations were asked to participate only once for each different 
drug ad ministered. Due to irregular shifts, nurses were allowed to complete the 
semi-struc tured interview up to 96 hours after administration. 
A g g r e s s i o n  m e a s u r e m e n t
Daily staff reports were used to assess aggressive behavior. These are reports about 
the behavior of individual patients. They are written during each shift by medical 
per sonnel to facilitate the transfer of information between shifts. Staff reports of a 
time-window from seven days before to seven days following the administration of 
as-needed medication were retrospectively screened for aggressive incidents. The 
re searcher screening the staff reports (DM) was not aware of aggressive incidents 
at the time of the interview. Aggressive incidents were classified according to 
Hildebrand et al. (8), as verbal aggression (VA, i.e. aggressive verbalizations directed 
at an individ ual), verbal threat (VT, i.e. verbal threats or gestures that evoke fear in 
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staff, patients or others), or physical violence (PV, including physical force directed 
at both per sons and objects, but excluding auto-mutilation). In the study of 
Hildebrand, De Ruiter et al., a good interrater reliability was observed on whether 
the events reported were actual aggressive incidents (Cohen’s kappa =.86) (8). 
Patients were as signed to the aggressive group if one or more aggressive incidents 
were identified; patients without aggressive incidents were assigned to the non-
aggressive group. Furthermore, aggressive patients were sub-classified into patients 
with verbal aggres sion (VA or VT) and physical aggression (PV). In cases of doubt 
about screening, consensus was reached between the main researchers (LG, DM).
D a t a  a n a l y s i s 
Data on patient characteristics were collected from the hospital administration 
data base and information about medication use was collected from the hospital 
pharmacy database.
To compare aggressive patients to non-aggressive patients, two analyses were 
per formed: 1) all aggressive patients versus non-aggressive patients, and 2) patients 
with incidents of physical violence (i.e. the more severely aggressive patients) 
versus non-aggressive patients. Furthermore, separate analyses were performed for 
psychotropic and analgesic drugs. χ2 tests (or Fisher’s Exact tests when appropriate) 
were used for dichotomous categorical variables and Mann-Whitney U-tests for 
ordinal categorical variables. 
To compare the answers of patients and nurses, only the data on administrations 
for which both patient and nurse completed the semi-structured interview were 
used in the analysis. McNemar tests (or Sign tests when appropriate) were used in 
this analy sis. For all statistical tests, the criterion for significance was p < 0.05. All 
statistical analyses were carried out using SPSS v16.0 (SPSS Inc., Chicago, Illinois).
R e s u l t s
P a r t i c i p a n t s
In total, 91 patients were included of which 45 (49.5%) were identified as being ag-
gressive. VA was most commonly observed, and occurred in 31 patients (74%), fol-
lowed by PV in 27 patients (62%), and VT in 16 patients (38%). Aggressive behavior 
was also assessed for 12 patients that could not be interviewed. Of these 12 patients, 
eight (67%) were scored as aggressive, compared to 46% in the included population. 
Patient characteristics of aggressive and non-aggressive patients are shown in 
Table 1. 
A significantly higher proportion of patients in the aggressive group had a 
diagnosis consistent with a form of psychotic disorder (OR: 2.7, p = 0.03). 
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The patients completed a total of 108 semi-structured interviews. Nurses 
filled in a total of 77 semi-structured interviews (response rate: 71%). Of these 
interviews, 65 were complementary to patient semi-structured interviews, whereas 
12 interviews concerned patients who either refused to participate, were not able 
to participate (for instance because of seclusion), or about whom the nurse strongly 
advised not to invite the patient for participation (for safety reasons or for the 
benefit of the patient). 
The semi-structured interviews involved, in descending rate of occurrence, the 
ad ministration of benzodiazepines (N=64; 59.3%: oxazepam, temazepam, diazepam, 
lorazepam, clonazepam, clorazepate), analgesics (N=39; 36.1%: acetaminophen, 
ibu profen, acetaminophen/codeine, tramadol), antihistamines (N=3; 2.8%: pro-
methazine), hypnotics (N=1; 0.9%, zopiclon), and antipsychotics (N=1; 0.9%, zu-
clopenthixol). 
Table 1  Patient characteristics of aggressive and non-aggressive patients
Demographic data Patients with 
aggressive 
incidents (n = 45)
Patients without 
aggressive incidents 
(n = 46)
p valuea
Age (median) 34.0 - 38.4 - 0.08
Gender male 27 60.0 29 63.0% 0.80
Diagnoses at admission
Axis I
Psychotic disorder 22 48.9 12 26.1 0.03*
Schizophrenia 11 24.4 5 10.9 0.09
Autistic 3 6.7 2 4.3 0.70
Mood disorder 7 15.2 4 8.9 0.40
Alcohol abuse 6 13.0 5 11.1 0.78
Drug abuse 10 22.2 15 32.6 0.27
AD(H)D 4 8.9 3 6.5 0.71
Anxiety disorder 0 0.0 2 4.3 0.50
Somatoform disorder 1 2.2 1 2.2 1.00
Dementia 1 2.2 1 2.2 1.00
Adjustment 1 2.2 2 4.3 1.00
Axis II
Personality disorder NOS 7 15.6 6 13.0 0.73
Cluster B personality disorder 5 11.1 8 17.4 0.39
Mental retardation 13 28.9 8 17.4 0.20
Hospitalization data
Length ward stay (median (range))b 27 (0 – 752) 60 (0 –981) 0.54
a  For categorical variables, χ2 test was used when appropriate, otherwise Fisher’s Exact test was used. 
 For continuous skewed variables Mann-Whitney U-test was used.
b  Time between admission to hospital and administration of as-needed medication.
*  statistically significant, p < 0.05 
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A g g r e s s i v e  v e r s u s  n o n - a g g r e s s i v e  p a t i e n t s
The interviews of all non-aggressive patients were compared with all aggressive 
pa tients and physically aggressive patients only. Results of these analyses, for psycho-
tropic and analgesic as-needed medication, are shown in Table 2. 
Aggressive patients did not differ with regard to DDD-equivalent dosage (for both 
psychotropic and non-psychotropic drugs, data not shown). Although not statistically 
significant, physically aggressive patients received higher DDD compared to non-
ag gressive patients (median 0.29 and 0.50, respectively; p= 0.08). 
Overall 88 (81%) of the as-needed medications were administered at the 
request of the patient, which was more frequently the case for analgesic medication 
(N=37; 95%) than for psychotropics (N = 88; 74%) (Fisher’s Exact test, p = 0.01). 
Further more, the overall analysis showed a significantly increased initiative by the 
nurses to administer as-needed medication to aggressive patients, compared to non-
aggressive patients for all medication (p = 0.05). When physically violent patients 
(n = 27) were compared with non-aggressive patients (n = 46), it was observed 
that physically vio lent patients were significantly more likely to be administered 
both “any” and psy chotropic as-needed medication on the nurse’s initiative than 
non-aggressive patients (OR= 4.6; p = 0.01 and OR = 6.9; p= 0.009, respectively). 
Moreover, also within the aggressive group, physically violent patients were 
significantly more likely to be ad ministered as-needed medication on the nurse’s 
initiative (OR 5.4; p= 0.03).
Patients’ views on indications for administration of their as-needed medication 
did not significantly differ between aggressive and non-aggressive patients. However, 
aggres sive patients were more likely to agree that the dosage of their as-needed 
medication was high enough compared to non-aggressive patients (OR: 2.36, 
p=0.04). This diff erence remained statistically significant for psychotropic drugs 
(OR: 3.0, p=0.04), but not for analgesics (Fisher’s Exact test, OR 2.6 p = 0.47). 
Differences were observed in nurses´ views on the way aggressive and non-
aggressive patients asked for their medication. Aggressive patients were less likely to 
be re garded as asking in a friendly way for their as-needed medication compared 
to non-aggressive patients (OR: 0.29, p=0.02). Also, there was a trend towards 
aggressive patients more often being demanding (OR: 7.13, p = 0.06). When 
patients with inci dents of physical violence (n = 13) were compared with non-
aggressive patients (n = 31), nurses perceived physically aggressive patients to be 
significantly more de manding in asking for their medication (OR: 10.00, Fisher 
Exact test, p = 0.02). With regard to the reasons for administration of psychotropic 
drugs, nurses reported rest lessness as a reason significantly more often when patients 
with incidents of physical aggression were involved, as compared to non-aggressive 
patients (OR= 6.18, p=0.001).
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O u t c o m e  m e a s u r e s :  p a t i e n t s  v e r s u s  n u r s e s
For 65 interviews completed by patients a matching interview completed by a nurse 
was available. The matched pairs concerned 55 patients of which 27 were scored 
Table 2  Comparative answers of aggressive and non-aggressive patients
Patient questions
Answers
Non-aggressive patients 
(n interviews = 54)
Aggressive patients 
(VA, VT)
(n interviews = 21)
Aggressive patients (PV)
(n interviews = 33)
p valuea p valueb
N % N % N %
Initiative Patient 48 88.9 19 90.5 21 63.6 0.05* 0.01*
Nurse 6 11.1 2 9.5 12 36.4
Amount of asking Once 44 91.7 18 94.7 21 100.0 0.24 0.31
More than once 4 8.3 1 5.3 0 0.0
Indicationc Tension 5 9.3 2 9.5 3 9.1 1.00 1.00
Anger 3 5.6 0 0.0 0 0.0 0.62 1.00
Fear 1 1.9 2 9.5 3 9.1 0.21 0.15
Restlessness 10 16.7 2 9.5 8 24.2 0.81 0.42
Pain 22 40.7 5 23.8 9 27.3 0.10 0.25
Aggression 0 0.0 1 4.8 0 0.0 1.00 NA
Sleep 10 18.5 7 33.3 4 12.1 1.00 0.24
Other 4 7.4 3 14.3 6 18.2 0.25 0.32
Effectiveness Effective 45 83.3 17 81.0 29 87.9 0.17 0.15
Not effective 9 16.7 4 19.0 4 12.1
Time to onset < 15 min 11 26.2 5 27.8 12 48.0 0.34 0.19
15-60 min 28 66.7 10 55.6 12 48.0
1-2 hours 3 7.1 3 16.7 1 4.0
>2 hours 0 0.0 0 0.0 0 0.0
Duration of effect 1 hour 8 21.1 1 6.2 1 4.5 0.06 0.09
6 hours 16 42.1 8 50.0 15 68.2
12 hours 12 31.6 4 25.0 3 13.6
>12 hours 2 5.3 3 18.8 2 13.6
Frequency of dosing Enough 30 57.7 15 71.4 20 60.6 0.45 0.79
Not enough 22 42.3 6 28.6 13 39.4
Strength of dose High enough 23 45.1 14 70.0 19 63.3 0.04* 0.17
Not high enough 28 54.9 6 30.0 11 36.7
Nurse questions Answers Non-aggressive patients 
(n interviews = 39)
Aggressive patients 
(VA, VT)
(n interviews = 13)
Aggressive patients (PV)
(n interviews = 24)
Way of asking Calm 25 64.1 8 61.5 12 54.2 0.58 0.43
Friendly 17 43.6 4 30.8 3 12.5 0.02* 0.01*
Demanding 1 2.6 1 7.7 5 20.8 0.06 0.03
Agitated 2 5.1 0 0.0 0 0.0 0.49 0.52
Angry 0 0.0 0 0.0 0 0.0 - -
Necessity of 
  medication
Yes 26 81.2 5 71.4 15 100.0 0.45 0.16
No 6 18.8 2 28.6 0 0.0
Abbreviations: VA = verbal aggression; VT = verbal threat; PV = physical violence
For categorical variables, χ2 test was used when appropriate, otherwise Fisher’s Exact test was used. 
Time to onset and duration of effect were analyzed using Mann-Whitney U-test.
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as aggressive (49%) and 28 as non-aggressive (51%). The main results are displayed 
in table 3. Nurses tended to ascribe, more often than the patients, the reasons for 
Table 2  Comparative answers of aggressive and non-aggressive patients
Patient questions
Answers
Non-aggressive patients 
(n interviews = 54)
Aggressive patients 
(VA, VT)
(n interviews = 21)
Aggressive patients (PV)
(n interviews = 33)
p valuea p valueb
N % N % N %
Initiative Patient 48 88.9 19 90.5 21 63.6 0.05* 0.01*
Nurse 6 11.1 2 9.5 12 36.4
Amount of asking Once 44 91.7 18 94.7 21 100.0 0.24 0.31
More than once 4 8.3 1 5.3 0 0.0
Indicationc Tension 5 9.3 2 9.5 3 9.1 1.00 1.00
Anger 3 5.6 0 0.0 0 0.0 0.62 1.00
Fear 1 1.9 2 9.5 3 9.1 0.21 0.15
Restlessness 10 16.7 2 9.5 8 24.2 0.81 0.42
Pain 22 40.7 5 23.8 9 27.3 0.10 0.25
Aggression 0 0.0 1 4.8 0 0.0 1.00 NA
Sleep 10 18.5 7 33.3 4 12.1 1.00 0.24
Other 4 7.4 3 14.3 6 18.2 0.25 0.32
Effectiveness Effective 45 83.3 17 81.0 29 87.9 0.17 0.15
Not effective 9 16.7 4 19.0 4 12.1
Time to onset < 15 min 11 26.2 5 27.8 12 48.0 0.34 0.19
15-60 min 28 66.7 10 55.6 12 48.0
1-2 hours 3 7.1 3 16.7 1 4.0
>2 hours 0 0.0 0 0.0 0 0.0
Duration of effect 1 hour 8 21.1 1 6.2 1 4.5 0.06 0.09
6 hours 16 42.1 8 50.0 15 68.2
12 hours 12 31.6 4 25.0 3 13.6
>12 hours 2 5.3 3 18.8 2 13.6
Frequency of dosing Enough 30 57.7 15 71.4 20 60.6 0.45 0.79
Not enough 22 42.3 6 28.6 13 39.4
Strength of dose High enough 23 45.1 14 70.0 19 63.3 0.04* 0.17
Not high enough 28 54.9 6 30.0 11 36.7
Nurse questions Answers Non-aggressive patients 
(n interviews = 39)
Aggressive patients 
(VA, VT)
(n interviews = 13)
Aggressive patients (PV)
(n interviews = 24)
Way of asking Calm 25 64.1 8 61.5 12 54.2 0.58 0.43
Friendly 17 43.6 4 30.8 3 12.5 0.02* 0.01*
Demanding 1 2.6 1 7.7 5 20.8 0.06 0.03
Agitated 2 5.1 0 0.0 0 0.0 0.49 0.52
Angry 0 0.0 0 0.0 0 0.0 - -
Necessity of 
  medication
Yes 26 81.2 5 71.4 15 100.0 0.45 0.16
No 6 18.8 2 28.6 0 0.0
a  Aggressive patients compared to non-aggressive patients.
b  Aggressive patients with incidents of physical violence (PV) compared to non-aggressive patients.
c  Total number of indications mentioned is more than 100% because more than 1 indication could be 
 mentioned.
*  statistically significant, p < 0.05
**  statistically significant, p < 0.01
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administering psychotropic as-needed medication to tension (Sign test, p = 0.003) 
and restlessness (Sign test, p = 0.001). In contrast, patients significantly more often 
named sleep (Sign test, p = 0.004) and ‘other reasons’ (n.s.), which included: suicidal 
ideation, strengthening the sedative effect of another as-needed drug, and sadness. 
Table 3  Comparative answers of patients and nurses
Question Answer n
total
Patient answers Nurse answers p valuea
n % n %
Initiative Patient 65 56 86.2 54 83.1 0.625
Nurse 9 13.8 11 16.9
Amount of asking Once 53 51 96.2 49 92.5 0.687
More than once 2 3.8 4 7.5
Indication Tension 65b 8 12.3 19 29.2 0.003**
Anger 2 3.1 2 3.1 1.000
Fear 3 4.6 4 6.2 1.000
Restlessness 11 16.9 26 40.0 0.001**
Pain 22 33.8 25 38.5 0.250
  headache 8 57.1 10 66.7 0.500
  other 7 42.9 5 33.3
Aggression 1 1.5 1 1.5 1.000
Sleep 14 21.5 5 7.7 0.004**
Other 9 13.8 3 4.6 0.109
Effectiveness Effective 59 52 88.1 51 86.4 1.000
Not Effective 7 11.9 8 13.6
Reported effect Effect =   
  Indication
42 39 92.9 28 66.7 0.021*
Effect ≠ 
  Indication
3 7.1 14 33.3
Time to onset < 15 min 33 13 39.4 2 6.1 0.003**
15-60 min 17 51.5 26 78.8
1-2 hours 3 9.1 4 12.1
>2 hours 0 0.0 1 3.0
Frequency of dosing Frequent 
  enough
58 35 60.3 51 87.9 0.001**
Not freq. 
  enough
23 39.7 7 12.1
a  McNemar test when appropriate, Sign test was used when the cumulative marginal frequencies 
were lower than 20. Time to onset and duration of effect were analyzed using Wilcoxon signed-
ranks test.
b  Total number of indications mentioned is more than 100% because more than 1 indication could be 
mentioned. 
*  statistically significant, p < 0.05
**  statistically significant, p < 0.01
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In all cases where patient or nurse answered that the medication had an effect 
(n = 42), the reported reason for administration was compared with the reported 
effect. The effect reported by patients was highly concordant with the indication 
for administra tion that they reported (92.9%). For nurses in 14 cases (66.7%) the 
reported effect was not concordant with the indication, which was significantly 
more as compared to the concordance for patients (Sign test, p = 0.02). In 13 of 
these 14 cases the reported an swers showed that the effect was a decrease of contact 
between patient and nurse, e.g. ´the patient did not ask for medication anymore´ 
or ´patient did not come back with complaints about symptoms´ or ‘went to sleep’. 
Furthermore, nurses reported four times (9%) that they could not answer the 
question about the effect for reasons such as ‘off-duty quickly after administration’ 
or ‘did not observe the patient after admini stration because patient went to bed’.
With regard to time to onset of effect, patients reported an effect to start 
significantly earlier than the nurses did (T = 15, p = 0.003, r = -0.37). This 
difference remained statistically significant for psychotropics (n = 42, T = 5, p = 
0.01), and a trend was observed for analgesics (n = 24, T = 3, p = 0.01). Duration 
of effect was not perceived as being significantly different in both groups. When 
patients and nurses were asked if the as-needed medication could be administered 
frequently enough, i.e. as prescribed by the doctor’s prescription, nurses tended 
to agree significantly more often with the fact that administration was frequent 
enough compared to patients (88% vs. 60%, Sign test, p = 0.001). This was observed 
especially for psychotropic drugs; nurses agreed that administration was frequent 
enough in 94.4% of the cases, compared to 58.3% of the patients (Sign test, p = 
0.001). Interestingly, a rather high proportion of both patients and nurses (47% and 
39%, respectively, n.s.) reported that the dosage was not high enough.
D i s c u s s i o n
In this study we focused on beliefs of patients and nurses about the administration 
of as-needed medication to aggressive and non-aggressive patients. The results 
empha size the importance of the patient him or herself in the administration of as-
needed medication, since in the majority of cases (almost 85%) the medication was 
adminis tered on the patient’s initiative. Additionally, we found that the interviewed 
patients rarely had to ask more than once for the as-needed medication to get 
it. Although we did not record how often patients’ requests were rejected, these 
results further indicate that prescribed as-needed medication is easily obtained by 
patients when asking for it. A credible conclusion of this study is that patients are 
keen on as-needed medication, predominantly benzodiazepines. This hypothesis 
is further supported by the observa tion that more than one-third of all patients in 
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both groups answered they would like to receive their as-needed medication more 
frequently than prescribed.
Initiative by the nurse to administer as-needed medication was more frequently 
ob served with severely (physically) aggressive patients. The increased initiative 
of nurses in administrating as-needed medication -in addition to the previously 
presumed keenness of patients on as-needed medication- is an answer our research 
question, aimed at finding a reason for the increased use of as-needed medication by 
aggressive patients compared to non-aggressive patients (3, 9, 10). The observation 
that aggres sive patients were significantly more likely to be satisfied with their (high) 
dosage is also an indication that nurses are more likely to give satisfying amounts of 
as-needed medication to aggressive patients.
Combining this willingness of caretakers to administer as-needed medication 
to (physically) aggressive patients with the keenness of patients in general on as-
needed medication, leads to the following vicious circle risk hypothesis: (physical) 
violence leads to the administration of more as-needed medication, in this study 
mainly benzo diazepines. Patients are satisfied with this practice which thus sustains 
the occurrence of aggression. Comparing patients’ and nurses’ views about as-
needed drug admini strations, shows patients’ perceived time to onset of medication-
effect to be signifi cantly shorter than that of the nurses. 40% of the patients reported 
time to onset to be within the first 15 minutes, which is likely to be a placebo-effect. 
Another noticeable observation is that whereas patients named sleep disturbance as 
a reason for more than 30% of the administrations, nurses reported sleep disturbance 
in only 12% of the cases. This is in line with McKenzie et al. (11), who found 
that, while temazepam (pre dominantly given during the night shift) accounted for 
27.8% of total administrations, sleep disturbance was only given as a reason by the 
nurses in 5.8% of the administra tions. 
The strength of our study is that we obtained information from both patients 
and nurses on their beliefs about as-needed medications directly, concerning the 
same ad ministration, in contrast with previous studies using (retrospective) chart 
reports. The current study also has some limitations. Firstly, the fact that both newly 
admitted pa tients and more chronic patients were included, as well as patients from 
different wards, resulted in a heterogeneous sample, which may have affected our 
results. Lastly, one might speculate whether the results obtained in this study are 
generaliz able to settings in other countries. Whereas a recent review shows that 
typical antip sychotics are frequently used as as-needed medication (10-100% of 
all administra tions) (1), in our study antipsychotics only accounted for 0.9 % of 
all administrations. On the other hand, the kind of drug used might not be so 
important when assuming that as-needed practices is more about needs of patients 
and nurses and that the effect is (partly) placebo instead of a pharmacological one.
From an evidence-based point of view, benzodiazepines administered as as-
needed medication are likely to be effective for sleep disturbances. However, less 
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evidence is available for vague complaints like tension and restlessness and therefore 
the use of as needed medication for these reasons, might be less advisable. On 
the other hand, re sults of this study show that as-needed medication fulfills both 
patients’ and nurses’ needs. It is quite plausible to conclude therefore that reducing 
as-needed medication practices will result in an increased use of regular medication. 
Moreover, a switch from as-needed medication to regular medication is likely to 
result in an overall in crease of psychotropic use, as supported by the results of pain 
studies where more an algesics are used if they are administered on a regular as 
compared to an as-needed basis (12). Furthermore, it is questionable whether the 
perceived efficacy of medica tion administered on as-needed basis will be as strong 
when medication is adminis tered on regular basis, i.e. will the assumed placebo-
effect be the same and as strong when administered on regular basis. This brings us 
to our final point, that future re search should focus on unraveling the psychological 
function of as-needed medica tion, instead of (only) focusing on clinical efficacy 
and. By doing so, clues might be found to potential alternatives. Without alternatives 
for as-needed medication, at tempts to cut down or regulate as-needed medication 
practices are likely to fail. 
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A b s t r a c t
Background: Aggression is a difficult to manage behaviour in psychiatric wards. 
Pharmacotherapy is frequently used to manage aggression, despite insufficient evi­
dence. 
Objectives: To investigate the association between both aggression and psycho­
tropic use on the one hand, and treatment outcome of hospitalized psychiatric 
patients on the other. 
Methods: A case­control study was conducted in three psychiatric wards. Cases 
were patients with a negative treatment outcome defined as a transfer to a more 
restrictive ward or no transfer during the study period. Controls were patients with 
a positive treatment outcome defined as a transfer to a less restrictive ward. Logistic 
regression was used to estimate the strength of the association of aggression and the 
use of medi cation with the outcome, and expressed as odds ratios (adjusted for age, 
gender and diagnosis).
Results: A total of 48 (36.4%) patients of the 132 included patients had a negative 
treatment outcome, 84 (63.6%) had a positive treatment outcome. Patients were 
di vided in four subgroups: not aggressive and without psychotropic polypharmacy 
(N=31), not aggressive and with psychotropic polypharmacy (N=15), aggressive 
and without psychotropic polypharmacy (N=50), and aggressive with psychotropic 
polypharmacy (N=36). Aggressive patients using psychotropic polypharmacy were 
at highest risk for a negative treatment outcome (Odds ratio 7.6; 95%CI 2.0­29.9; 
reference = patients without aggression, without polypharmacy)
Conclusion: Aggressive patients are at higher risk for a negative treatment out­
come, especially those using psychotropic polypharmacy. As psychotropic polyp­
harmacy does not seem to positively influence treatment outcome and considering 
the lack of evidence for the pharmacological management of aggression, cautious­
ness is recommended for the pharmacological management of aggression. 
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I n t ro d u c t i o n 
Aggression is a difficult to manage behaviour, which is frequently observed on psy­
chiatric wards (1). Inpatient aggression not only negatively influences the safety and 
wellbeing of staff and patients, but also the length of stay (2­4). Empirical research 
has also shown that aggression is associated with increased use of psychotropics, 
both in the acute situation and for the ongoing management of aggression (1, 5, 6). 
For the maintenance management of aggression, an increased use of psychotrop­
ics can hardly be justified given the lack of evidence (7). The fact that clinicians 
try to manage diffi cult behaviour with psychotropic drugs, while empirical evi­
dence is scarce, might be the high impact of aggressive behaviour pressuring to act, 
combined with clinical ex perience that medication for some patients can reduce 
aggressive behaviour. How ever, it remains unclear whether the use of psychotrop­
ics for aggressive behaviour indeed positively influences treatment in daily clinical 
practice. Ideally, such a ques tion is answered by conducting randomized controlled 
trials (RCTs) ­which are con sidered gold standard to obtain evidence. Previous re­
search, however, suggests that such trials are difficult to conduct, because aggressive 
patients of clinical are difficult to include in randomized controlled trials (RCTs) 
(8). Furthermore the generalizabil ity of RCTs to clinical practice is low. In such 
cases, where RCTs are difficult to con duct observational research can contribute to 
evidence of treatment effectiveness (9). 
In this study we aim to investigate the associations between both aggressive 
behaviour and medication on the one hand, with treatment outcome of patients 
admitted to psy chiatric wards on the other. 
M e t h o d s
S t u d y  s e t t i n g ,  d e s i g n  a n d  s u b j e c t s
The setting of this observational study was the Altrecht Mental Health Care Insti­
tute. Patients admitted during the period of September 2004­ November 2005 at 
three diff erent wards, i.e. a forensic ward, a ward for patients with severe psychiatric 
disorders combined with mild learning disabilities, and a ward for juveniles with se­
vere behav ioural problems, were included. The wards have both restrictive (locked) 
and less re strictive (open) wards. 
A minimal observation period of 30 days was required for inclusion in the 
present study. Excluded were those patients who both a) were not transferred to 
another ward or discharged during the study period, and b) were admitted for a 
period shorter than six months, were excluded. No other exclusion criteria were 
applied.
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The individual patient was observed until transfer or, in case of no transfer, 
until the end of the study period.
Demographic, diagnostic and medication information for this study was 
gathered from the hospital databases and hospital records. Aggressive behaviour of 
the patients was measured using the Staff Observation Aggression Scale­Revised 
(SOAS­R) (10). 
Patients were informed about the study, and were only included if they did not 
object to participation; two patients objected to study participation and therefore 
were excluded. The Scientific Committee and the Board of the mental health care 
centre approved the study protocol. 
O u t c o m e
Treatment outcome was classified as either negative (cases) or positive (controls) 
ac cording to the level of restrictiveness of the ward to which patients were trans­
ferred. Patients were considered having a negative treatment outcome if they were 
transferred to a more restrictive ward, i.e. either from an open to a semi­locked or 
a locked ward, or from a semi­locked to a locked ward. In addition, patients who 
were admitted for at least six months at the same ward (i.e. without a transfer) were 
also defined as having a negative treatment outcome. Patients who were transferred 
to a ward with a lower level of restrictiveness, i.e. from a locked ward to either a 
semi­locked or open ward, or patients who were transferred from a semi­locked 
ward to an open ward, were con sidered to have a positive treatment outcome, as 
were patients who were discharged from the hospital. 
D e t e r m i n a n t s
The main determinants under investigation are aggressive behaviour and the use 
of psychotropics. Patients were classified as aggressive if they displayed aggression 
on one or more occasions during the their observation time, as recorded with the 
SOAS­R (10) were classified as aggressive patients. Patients without such aggressive 
incidents were categorized as being non­aggressive. 
For the use of psychotropics we determined for every patient whether or not 
they were using anxiolytics, hypnotics, antidepressants, antipsychotics or moodsta­
bilizers at the time of treatment outcome. Subsequently the total number of differ­
ent psychotropics used at time of treatment outcome was calculated. 
Furthermore, other patient characteristics including age, gender and DSM­IV 
diagnosis were collected, as these were considered as potential confounders.
D a t a  a n a l y s i s
A logistic regression model was used to estimate the strength of the association be­
tween the determinants under investigation and the outcome and expressed as odds 
ratios (OR) (adjusted for age, gender and diagnosis).
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In the multivariate logistic regression model, determinants univariately associ­
ated with a p value of <0.2 were entered. Unadjusted as well as multivariate ad­
justed odds ratios and corresponding 95% confidence intervals (CI) are reported in 
the current pa per.
Furthermore, the same analysis was used to determine the interaction of the 
two main determinants under investigation and their association with treatment 
outcome, by classifying the patients into four subgroups: 
1) patients without aggressive behaviour and using less than two psychotropics;
2) patients without aggressive behaviour and using two or more psychotropics;
3) patients with aggressive behaviour and using less than two psychotropics and;
4) patients with aggressive behaviour and using two or more psychotropics. 
The group of patients without aggressive behaviour and using less than two 
psycho tropics was used as reference group.
Table 1  Patient characteristics
Negative treatment 
outcome (N=48)
Positive treatment 
outcome (N=84)
p value
N % N %
Aggressive 36 75.0 50 59.5 0.07
Sex, male 38 79.2 57 67.9 0.16
Age (median) 33 23 0.00
DSM IV diagnosis
Substance 17 35.4 18 21.4 0.08
Drugs 14 29.2 18 21.4 0.32
Alcohol 5 10.4 6 7.1 0.53
Psychotic disorder 34 70.8 40 52.4 0.01
   Schizophrenia 26 54.2 24 28.6 0.01
Mooddisorder 1 2.1 13 15.5 0.02
ADHD & disruptive
  behaviour
1 2.1 19 22.6 0.002
Autism 2 4.2 12 14.3 0.07
Personality disorder 16 33.3 9 10.7 0.001
   Cluster B 9 18.8 6 7.1 0.04
   NOS 7 14.6 3 3.6 0.04
Mental retardation 16 33.3 31 36.9 0.68
Medication
Use of =>2 psychotropics 24 50.0 27 32.1 0.04
Antipsychotics use 26 54.2 39 46.4 0.40
Benzodiazepines use 20 41.7 13 15.5 0.001
Antidepressants use 12 25.0 13 15.5 0.18
Moodstabilizers, yes 5 10.4 3 3.6 0.14
Medication changes 1   
  month prior to event , yes
8 16.7 15 17.9 0.86
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R e s u l t s
P a t i e n t s
In this study 132 patients met the in­ and exclusion criteria. Of these patients 
84 (63.6%) had a positive treatment outcome. Of the 48 (36.4%) patients with a 
negative treatment outcome, 18 were transferred to a ward with a higher level of 
restrictiveness and the remaining 30 had no outcome but stayed for six months or 
longer at the same ward. 
Characteristics of the cases and controls are represented in Table 1. In the 
univariate analysis seven variables— higher age, having a psychotic disorder or per­
sonality dis order, not having a mood disorder or ADHD / a disruptive behaviour 
disorder, using more than one psychotropic and the use of benzodiazepines —were 
individually asso ciated at the p < 0.05 level with an increased likelihood of having 
a negative treatment outcome. 
In the multivariate logistic regression analysis, the following were statistically 
signifi cant associated with having a negative treatment outcome: aggressive behav­
iour, having a personality disorder and not having ADHD/disruptive behaviour 
disorder (see Table 2). The variable “use of benzodiazepines”, univariately associated 
with p< 0.2, was not entered in the model as this variable is part of a determinant 
already en tered in the model, i.e. the number of psychotropics used at time of treat­
ment out come. For patients with aggressive behaviour an OR of 4.3 (95% CI 1.6­
11.6) was observed. For the use of two or more psychotropics an OR of 2.1 (95% 
CI 1.02­4.3) was observed.
In a separate multivariate logistic regression analysis, where the determinants 
aggres sion and using two or more psychotropics (yes/no) were combined, aggres­
Table 2  Association of aggression and medication with a negative treatment outcome.
Unadjusted OR (95% CI) Adjusted OR (95%CI)*
Aggression 2.0 (0.9-4.5) 4.4 (1.6-11.8)
Use of =>2 psychotropics 2.3 (1.1-4.9) 1.8 (0.7-4.7)
Sex, male 1.8 (0.8-4.1) 2.0 (0.6-6.3)
Age 1.1 (1.0-1.1) 1.0 (0.9-1.1)
DSM IV diagnosis
Substance abuse 2.0 (0.9-4.4) 1.0 (0.4-2.9)
Psychotic disorder 2.7 (1.3-5.7) 1.6  (0.5-5.0)
Mooddisorder 0.1 (0.02-0.9) 0.1  (0.01-1.4)
ADHD & disruptive 
behaviour
0.1 (0.01-0.6) 0.1  (0.01-0.7)
Autism 0.3 (0.1-1.2) 0.5  (0.1-2.8)
Personality disorder 4.2 (1.7-10.4) 5.2  (1.5-17.9)
 * Adjusted for aggression, use psychotropics, sex, age, substance abuse/ dependency, psychotic 
 disorder, mooddisorder, ADHD & disruptive behaviour disorder, autism, personality disorder.
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sive pa tients using two or more psychotropics appeared to be at highest risk of 
having a poor treatment prognosis (i.e., being transferred to another locked ward 
or having to stay at the current locked ward) (OR 7.9, 95% CI 2.0­29.9) (Table 3). 
D i s c u s s i o n
In the present study we found that especially aggression, and in a lesser extent the 
use of medication, is associated with a higher likelihood of having a negative treat­
ment outcome, i.e. being transferred to a more restrictive ward or to stay for a long 
time (at least six months) at the same ward. The finding that aggression is strongly 
associated with a negative treatment outcome is in line with previous studies con­
ducted in acute psychiatric wards (2­4), showing that aggression is a predictor of 
lengthy hospitaliza tion. The question is how these results could be interpreted.
It could be for example that the patients with aggressive behaviour and poly­
pharmacy have a more severe psychiatric disorder, like schizophrenia, thereby re­
quiring more medication. However, in this study we adjusted for diagnoses, which 
implies that the observed association of aggressive behaviour and medication use 
with a negative treatment outcome is independent of diagnosis. What we cannot 
rule out is that this might have to do with the severity within the disease. A previ­
ous study showed that (psychotic) patients who are more severely ill at admission 
are at higher risk for poly pharmacy and high dosages of medication; possibly these 
patients who are more se verely ill are also at higher risk to have a negative treatment 
outcome. However, con sidering one of our previous studies (submitted) showing a 
temporal association of medication changes and aggression, we think that severity 
of illness might partly but certainly not fully explain our findings.
We therefore hypothesize that a subgroup of aggressive patients ends up with 
a high level of polypharmacy in an attempt to manage and reduce their aggressive 
behaviour. In this subgroup this apparently did not lead to a positive treatment out­
Table 3  Association of both aggression and medication with a negative treatment outcome.
Patients without 
aggressive behaviour
Patients with 
aggressive behaviour
N Unadjusted / adjusted 
OR (95% CI)
N Unadjusted / 
adjusted OR (95% CI)
Patients using 
< 2 psychotropics
31 reference 50 1.4 (0.5-3.7) /
3.4 (1.0-11.8)*
Patients using 
2 or more psychotropics
15 1.0 (0.3-4.2) /
1.2 (0.2-6.0)*
36 3.6 (1.3-10.2) /
7.6 (2.0-29.9)*
* Adjusted for gender, age, substance abuse/ dependency, psychotic disorder, 
 mooddisorder, ADHD & disruptive behaviour disorder, autism, personality disorder.
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come, although we cannot tell whether the disruptive behaviour would not have 
been even more se vere without the use of (multiple) psychotropics. 
But if polypharmacy does not improve the treatment outcome, at least in 
terms of be ing able to go to a less restrictive living environment, then why do ag­
gressive patients with a negative treatment outcome use more psychotropics? On 
the basis of our re sults, we hypothesize that aggression is a transnosological factor 
associated with a negative treatment outcome. In that case polypharmacy might 
reflect the need of cli nicians to do something when facing aggression, as it is a be­
haviour known to be one of the characteristics of difficult patients (11). 
Another finding further supporting that the results have to do with difficult 
patients, is the observation that (cluster B) personality disorder ­a diagnosis consid­
ered to be a characteristic of difficult patients (11)­ was also found to be strongly 
associated with a negative treatment outcome.
Concluding that polypharmacy is probably a proxy for difficult to treat pa­
tients, the question remains if it is adequate to enhance polypharmacy in the case 
of aggression, considering the paucity of available evidence for the pharmacological 
management of aggression (7). With regard to this, we refer to a recent pilot study 
of Mistler et al. (12) showing that reducing polypharmacy by using a medication­
reduction algorithm, re sulted in the same amount of symptom reduction as meas­
ured with the Brief Psychiat ric Rating Scale, but a slightly longer, although not 
significant, duration of hospitali zation. Further research is needed to investigate 
whether similar results can be ob served when reducing medication use for aggres­
sive patients.
The study also has some obvious limitations. The most important limitation 
is that no data about the occurrence of aggression were available from the patients 
admitted be fore the start of the study period. This means that patients might be 
classified incor rectly as non­aggressive, if they were aggressive before the start of 
the study period. This possible incorrect classification therefore might have led to 
an underestimation of our results. Another study limitation, which we believe to 
be a strength at the same time, is the heterogeneity of the study population. It can 
be considered as a limitation as a heterogeneous population increases the risk on 
confounding. On the other hand it is a strength, as in a homogeneous popula­
tion we could not demonstrate the trans­nosological association of aggression and 
polypharmacy with a negative treatment outcome. A last limitation is the way in 
which treatment outcome was put into op eration, i.e. as a transfer to a more or less 
restrictive environment. This way of defin ing might be too global. Patients, who for 
example are on a waiting list for a transfer to a less restrictive environment, could 
have been wrongly classified as having a negative treatment outcome. The use of 
scales, e.g. a quality of life scale or a clinical global impression­improvement scale 
(CGI­I) (13) could have prevented such misclassi fication. 
3.5hfdst.indd   140 27-04-10   16:05
Chapter  3 .5  •  1 4 1
Taking into account the study limitations, we conclude that patients showing 
aggres sive behaviour, especially when using more than one psychotropic, are at an 
increased risk of having a negative treatment outcome. As polypharmacy does not 
seem to posi tively influence treatment outcome and considering the potential side 
effects of medi cation, from a clinical point of view, cautiousness is recommended 
when prescribing psychotropics for the management of aggression, e.g. by system­
atic evaluating the effect. Tapering or withdrawal should be considered in the case 
of no effect. This rec ommendation is in line with a recent study of Kleijer et al. (14). 
These authors found that of the patients with dementia treated with antipsychotics 
for behavioural prob lems, only one out of six patients improved, whereas in most 
patients behavioural problems continued to increase. Furthermore, after antipsy­
chotic withdrawal 58% of the patients remained stable. From a broader perspective, 
the development of guide lines for repetitively aggressive patients, also embedding 
maintenance pharmacother apy, is recommended. To our knowledge, current guide­
lines especially focus on the management of acute aggression and workplace safety, 
whereas clinical guidelines on the individual patient level are sparse.
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General  discussion
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I n t ro d u c t i o n
In the introduction of this thesis we have outlined the impact of aggression on 
psychi atric care. Aggression is an important trigger for hospitalisation of psychiatric 
pa tients. Furthermore, aggressive behaviour on psychiatric wards has a severe impact 
on the well being of patients and staff, and leads to high costs (1). Subsequently, we 
re viewed the management of aggressive behaviour in psychiatric patients through 
the years. Roughly, it appears that the interventions used can be classified into three 
main categories: restricting freedom of movement (either by seclusion or mechani-
cal re straints), the use of pharmacologically active substances, and a variety of more 
be havioural and interactional approaches.
Many of the interventions that have been used in the past -like prolonged 
bathing therapy, insulin induced coma and lobotomy- are currently highly outdated 
and deemed irrational when not viewed in their historical background. In the 
Netherlands in particular, seclusion has been, and still is, a frequently used response 
to inpatient aggression, (2, 3); however, the use of this measure is heavily debated 
and getting more and more in discredit (4). Another intervention that has been in 
use for a long time is the psychopharmacological approach; hyoscine and barbitu-
rates in the past, antipsychotics and benzodiazepines in the present. In this thesis, 
we focused on the evidence available from clinical trials for the pharmacological 
management of aggres sive behaviour, and juxtaposed that against clinical practice. 
Patterns in the use of medication by aggressive psychiatric inpatients were investi-
gated in daily clinical practice, aiming to elucidate the reasons for, and effectiveness 
of, increased use of medication among aggressive patients.
What attracted attention throughout this thesis, is the lack of clarity about the 
concept aggressive behaviour; e.g. in the two systematic reviews (chapter 2.1 and 
2.2) where it was found that numerous scales have been used to measure aggres-
sive behaviour and in chapter 3.1 in which we found underreporting of aggressive 
behaviour, which may be due to a lack of registration, but may also be linked to a 
difference in percep tion of what should be considered as aggression (5). Another 
important theme, which we encountered, is the highly reactive character of the 
way in which pharmacological interventions are applied in response to aggressive 
behaviour, which sometimes, at least at face value, seems irrational. In this general 
discussion we will elaborate on these two themes by combining current available 
knowledge with the results of the studies in this thesis.
First, we will discuss the concept of aggressive behaviour: should it be ap-
proached as (a symptom of) certain specific psychiatric diseases, or rather be viewed 
as a distinct difficult behavioural problem that may, or may not need treatment and 
how can it be measured? Subsequently, we will discuss the management of aggres-
sion in daily practice, especially the pharmacological management. Finally, we will 
4.0hfdst.indd   146 27-04-10   16:05
Chapter  4  •  1 4 7
propose a number of strategies to make progress in the development and study of 
(pharmacol ogical) interventions for the management of aggressive behaviour. 
A g g re s s i v e  b e h a v i o u r :  s y m p t o m  o f  c e r t a i n 
p s y c h i a t r i c  d i s o rd e r s  o r  s e p a r a t e  t r a n s - n o s o l o g i c a l 
p ro b l e m  b e h a v i o u r ?
Aggression is a very heterogeneous phenomenon; it encompasses a group of behav-
iours having in common that they are threatening, hostile, injurious, or destructive 
against persons or things. Several theories -including biological, sociological and 
psy chological ones- exist about aggressive behaviour, of which most state that some 
forms of aggressive behaviour are useful (e.g. for survival) and other forms can be 
viewed as pathological (6-8). Clearly, what causes aggression is as heterogeneous as 
the various forms in which the behaviour is expressed.
In this thesis we focussed on aggressive behaviour in mental health institutes, 
which is also generally prevalent in society, as shown e.g. by numbers of the po-
lice statistics and victimization surveys (9). Considering both the trans-nosologi-
cal character of aggressive behaviour in mental health care and the prevalence of 
(pathological) ag gressive behaviour in community brings up the question whether 
aggressive behav iour should be viewed as a distinct problem, apart from the present 
psychiatric disor der, or if there are reasons to consider aggression as a behaviour 
associated with spe cific psychiatric disorders. And thereupon, what are the conse-
quences for diagnostics? Should aggressive behaviour possibly be included in the 
DSM –V, e.g. as a main di agnosis / category, besides the already existing DSM –IV 
diagnoses “ Intermittent explosive disorder” and diagnoses for which aggression or 
aggression related symp toms already are already considered a core psychopathologi-
cal symptom, e.g. antiso cial personality disorder and conduct disorder? Or: should 
aggressive behaviour per haps be placed on a separate DSM-axis to reflect that this 
symptom is more of a di mensional nature and can be present in various degrees 
of severity in combination with a variety of the dichotomous Axis I and Axis II 
diagnostic categories? In the following paragraphs we will attempt to answer these 
questions by exploring the na ture of the associations between psychiatric disorders 
and aggressive behaviour from several perspectives.
If there is a link between mental illness and aggressive behaviour, an increased 
fre quency of aggressive incidents can be expected in psychiatric people with a 
psychiat ric disorder compared to people without a psychiatric disorder. A large 
epidemiologi cal study in the US does show that patients with severe mental illness 
–schizophrenia, bipolar disorder and major depression- were two to three times as 
likely to be assaul tive compared to people without such an illness (10). This has been 
investigated thor oughly and confirmed for schizophrenia in particular by Hodgins 
et al. who studied a large birth cohort showing that for patients with schizophre-
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nia and at least one hospi talization in a psychiatric ward, the risk of violent crime 
is 4.6 times higher for men and 23.2 times higher for women compared to those 
without an admission to a psy chiatric ward (11). A recent review shows, that within 
the population of patients with a severe mental disorder, the lowest prevalence of 
violence (2.3 -11.0%) was ob served among outpatients; highest prevalence was ob-
served during the months prior to admission of inpatients, with a range of 19.2% 
in emergency departments to 50% for committed inpatients (12). For inpatients 
prevalence during hospitalization ranged from 16-23%. In our study sample of pa-
tients on wards for externalizing behaviour disorders we observed a relatively high 
percentage of patients displaying one or more aggressive incidents (e.g., 61% for all 
kinds of aggressive behaviour in the studies described in chapter 3.2 and 3.5 and 
nearly 50% for physical aggressive behaviour in chapter 3.4), as compared to acute 
psychiatric wards In a recent review the percentage of patients involved in an ag-
gressive incident was lower than 25% in nine of the 12 included studies whereas in 
the three other studies this percentage ranged from 35 – 45%. Evidence for a link 
with aggression and schizophrenia is robust –especially in patients with untreated 
psychosis (13). Other studies, however, indicated that mental illness in itself does not 
increase the risk of aggressive behaviour, but rather the pres ence of (multiple) risk 
factors leading to aggression (14, 15). Other psychiatric disor ders for which an in-
creased risk of aggressive behaviour was observed include antiso cial and borderline 
personality disorder, mental retardation, mania and post traumatic stress disorder, 
though contradictory results with regards to this association has been observed in 
some studies (16). Imperative hallucinations, have been mentioned to be associated 
with aggressive behaviour in some studies, but not in others(17). Formal thought 
disorder is a psychopathological symptom, consistently found to be associ ated with 
aggressive behaviour (18-20). Another disease factor increasing the risk of aggres-
sive behaviour among psychiatric patients is acute mental illness. Supporting this 
association is the observation that on psychiatric wards most aggressive incidents 
occur within the first few days of admission (21). Furthermore, Steadman et al have 
shown that there is no difference in the prevalence of violence among discharged 
mental patients without symptoms and without substance compared to other peo-
ple in their neighbourhood (22). For the studies in this thesis, we did not measure 
acute psychi atric illness over time, e.g. by periodically assessing GAF scores. This is a 
limitation of our studies, as the lack of such information hampered us to determine 
whether the increased number of medication changes, as described in chapter 3.2, 
is a reaction on aggressive behaviour solely, or a contribution of the severity of the 
psy chiatric main diagnosis as well. 
From a neurobiological point of view, the neurotransmitters serotonin, GABA 
and dopamine are likely to play a key role in aggression modulation (23), of which 
sero tonin has been investigated most extensively. This neurotransmitter can inter-
act with 14 different serotonergic receptors and the regulation of its activity also 
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uses a very efficient 5-HT transporter system (24). Although the 5-HT 1A and 
5-HT1B receptors are postulated as potential important modulators of aggression, 
several other seroton ergic receptors can still play an important role. Dysfunction of 
the serotonergic func tion has been suggested as a factor contributing to aggressive 
behaviour in several mental disorders, including borderline personality disorder and 
ADHD. However, this is not backed by extensive research literature (25). 
The previously mentioned observation that there is no difference in the preva-
lence of violence among discharged mental patients compared to their neighbour-
hood also suggests that treatment decreases the risk of aggressive behaviour and 
grounds the association between acute mental illness and aggressive behaviour. In 
line with this hypothesis are the results of the CATIE study, in which a 6-month 
decrease in vio lence was observed for medication adherent schizophrenic patients 
(13). 
The patient characteristic univocally (26) associated with an increased risk of 
aggres sive behaviour in all studies, is a previous history of violence (17). This fac-
tor proba bly contributed to the high proportion of patients displaying aggressive 
behaviour in our study population that consisted of patients with externalizing 
behaviour disorders. Evidence for the association of a history of violence with 
aggression on psychiatric wards is available for previous inpatient aggression, ag-
gression prior to admission, aggression outside of institutions and aggression in the 
family of origin (17). Besides perpetration of violence, victimization, i.e. physical 
abuse throughout life, is also as sociated with aggressive behaviour (22). Substance 
abuse is another determinant strongly associated with aggressive behaviour. Sub-
stance abuse is a strong risk factor for aggressive behaviour in general community, 
and it seems an even higher risk fac tor in the population of psychiatric patients 
(22). Interestingly, in our study population aggressive patients were not diagnosed 
more frequently with substance abuse or de pendency compared to non-aggressive 
patients (see chapter 3.2, 3.3 and 3.5). The ward rules prohibiting substance use may 
only partly explain this observation. Al though substance use is not allowed in the 
wards, clinical experience shows that also during admissions patients are able to ob-
tain drugs or alcohol, be it far not as abun dantly as in their home situation. An other 
explanation may be that in wards special ized in externalizing behaviour disorders 
like in our study population, where most patients have a history of violence before 
admission which is a predictor of future ag gressive behaviour, substance abuse is not 
a discriminating risk factor anymore. Al ternatively, there may be an underreporting 
of substance abuse and dependency in the hospital administration database. 
Besides patient characteristics, it is well imaginable that environmental factors 
on psychiatric wards also influence the occurrence of aggression. However, to our 
knowledge, little is known about this relationship. An exception is the recent study 
of Bowers et al, who gathered data of 136 wards and found that high structure 
on a ward, for which teamwork is critical, lowers both rates of conflict -including 
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aggressive be haviour- and containment including coercive measures (27). Other 
research indicates that crowding (28) is associated with aggressive behaviour. Fur-
thermore, one study showed that mixing wards for severely disturbed psychiatric 
patients with less dis turbed psychiatric patients resulted in a decrease of aggressive 
incidents (29) This is remarkable, to our point of view, considering that the old 
policy is to separate patients into different wards according to the categorization of 
“easy” and “difficult”. 
Overall we conclude that there is a link between psychiatric disorders and ag-
gressive behaviour. However this link is complex: aggressive behaviour is observed 
through a whole range of psychiatric disorders where increased risk of aggression 
in the indi vidual patient results from multiple risk factors. 
W h a t  i s  t h e  c o n s e q u e n c e  o f  t h e  u n c l e a r  s t a t u s  o f  a g g r e s s i o n 
w i t h i n  p s y c h i a t r y ? 
Despite a vast amount of studies investigating aggressive behaviour in mental health 
care, previous paragraphs show that still much needs to be elucidated about the 
con cept of aggression.
The unclear concept hinders further progress in research, e.g. in the search 
of medica tion with anti-aggressive properties. This is illustrated by the regulatory 
agency, the FDA, who states that “for approval of a drug treatment for any condi-
tion, requires that the condition be identified and defined unambiguously, that 
appropriate instruments be used for assessment and measurement, and that appro-
priately designed clinical trials demonstrate safety and effectiveness” (30) . These 
regulations may have been one of the contributing factors that hindered further 
investigation into the anti-aggres sive properties of eltoprazine and are probably the 
reason that until now just few eff orts are put into the development of drugs with 
specific anti-aggressive properties without sedating the patient, for the maintenance 
treatment of aggressive behaviour.
In daily clinical practice a consequence of the unclear concept of aggressive 
behav iour is that in many wards no systematic attention is paid to aggression, e.g. by 
moni toring it. Furthermore, it seems like education about aggressive behaviour in 
training for psychiatrists only receives little attention, as far as we are aware of. This 
is quite remarkable, considering the impact, and the negative treatment outcome 
associated with aggression, as shown in chapter 3.4.
Despite the elusiveness of the concept, we conclude that there is a strong link 
between the occurrence of aggression and mental illness. At the same time we real-
ise that ag gressive behaviour is something interactional and that, although less inves-
tigated, ex ternal factors, like the restrictive character on psychiatric wards, are very 
likely to contribute to aggressive behaviour, at least in the way it occurs. Therefore, 
one should be careful in labelling it as a psychiatric symptom or disease. Taking this 
into account, we still give an affirmative answer on the question whether aggres-
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sive behaviour should be included in one way or another into the DSM-V. The 
first reason for this is that link between mental disorder has been shown in several 
studies, particularly for schizophrenia but also for several other psychiatric disorders 
and psychopathological symptoms. Furthermore, aggressive behaviour is associated 
with negative conse quences for the patient, thereby deserving attention both in the 
way of treatment and research. Including aggressive behaviour into the DSM V as 
a separate entity could lead to a more systematically approach of aggressive behav-
iour and more awareness of and care for aggressive behaviour. With regard how to 
include aggressive behaviour into the DSM we believe the most appropriate way 
is through cross cutting assessment as proposed in the draft of DSM V, which came 
available for public re view the tenth of February 2010. “The aim of this kind of 
cross cutting assessment is to provide quantitative measures of important clinical 
areas that will be relevant beyond any set of syndromal criteria. It is designed to be 
used at an initial evaluation to es tablish a baseline, and on follow-up visits to track 
changes. It does not relate to any specific disorder and does not serve as a screening 
test for DSM disorders” (31). Consid ering the trans-nosological nature of aggres-
sive behaviour, which is influenced by multiple risk factors, we believe aggressive 
behaviour fits this kind of assessment. 
Aggressive behaviour :  measurement
The various available methods of measuring of aggression appear to reflect disagree-
ment on the definition of aggression. Currently, numerous different tools are in 
use for the measurement of aggression; among these are diagnosis-related scales 
as well as incident-based scales. To date, in our study see chapter 2.2, systematically 
re viewing the evidence for the pharmacological management of aggression, we 
counted 21 different outcome measures in the 35 evaluated randomized controlled 
trials. This was an important cause that in this systematic review we were unable 
to perform a quantitative evidence synthesis in addition to the qualitative evidence 
synthesis. This strongly suggests that for research, but also for clinical practice, more 
uniformity for the measurement of aggressive behaviour is desirable. 
When aiming for uniformity in measurement, the choice for a particular scale 
is of paramount importance. Aggression measurement can be:
•	 based upon actually occurring aggressive behaviour, like the SOAS-R used 
in this thesis, versus measured correlates of aggression, like anger and hostil-
ity. Examples of psychiatric diagnostics tests also measuring aggression related 
symptoms comprise the Positive And Negative Symptom Scale (PANSS)(32) 
and Brief Psychiatric Rating Scale (BPRS) (33) hostility items.
•	 self-report measures versus aggression observation-scales
Choice for a specific instrument or combination of instruments depends on 
the goal of the assessments, which can be: measuring the effect of interventions 
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but also predic tion. Furthermore, the setting and time window of measurement 
and, in the case of research, the study design (prospective versus retrospective) are 
likely to influence the choice. Furthermore, practical issues such as available time of 
researchers and/or cli nicians, as well as financial (research) budgets can play a role.
Disadvantages of self-report scales include recall-bias, and tendency of patients 
to give socially desirable answers (34). In addition, when self-report questionnaires 
are used to measure changes in aggressive behaviour, a potential lag time between 
the patients’ self-recognition that aggressive behaviour has diminished in frequency 
and severity and the patients’ self-perception that one is still capable of engaging 
in ag gressive acts warrants a longer prospective window of patient assessment (see 
chapter 2.2). As far as we can judge, preference should be given to the use of observ-
er-rated instruments, especially in inpatients. For outpatients, however, self-report 
may be the only feasible way to measure aggressive behaviour or aggression-related 
symptoms.
M e a s u r i n g  a g g r e s s i o n  r e l a t e d  s y m p t o m s
The measurement of aggression-related symptoms seems useful when these data 
are used for prevention in clinical practice, allowing for early intervention in case 
of high risk of aggressive behaviour. An example of an instrument measuring ag-
gression re lated symptoms and used for prevention is the Brøsset Violence Checklist 
(35). An other (practical) reason for using such instruments may be a lack of study 
power to detect aggressive behaviour. One could think of a short study period and/
or a study population consisting of patients with a low incidence of aggression 
where most pa tients will be classified as non-aggressive when not displaying actual 
aggressive be haviour. When measuring aggression related symptoms, more differen-
tiation can be made. Finally, especially in retrospective studies, scales like the PANSS 
or BPRS may be the only available measures. 
M e a s u r i n g  a g g r e s s i v e  b e h a v i o u r
Instruments measuring actually occurring aggressive behaviour can basically be 
di vided into period based observation scales -including the Social Dysfunction 
and Ag gression Scale (36) and the modified version of the Overt Aggression Scale 
(MOAS) (37)- and incident-based observation scales -including the Staff Observa-
tion Scale-Revised used in this thesis (38) and the first version of the OAS (39). 
Disadvantage of incident-based observer scales is that they are prone for under-
reporting as was shown in chapter 3.1. We especially expected underreporting of 
verbal aggressive incidents, assuming that these incidents occur more frequently and 
may have less impact com pared to physical aggressive behaviour. However, the ob-
served underreporting ap peared to be non-selective with respect to the severity of 
the aggressive incidents. Clearly, the staff does experience verbal aggression as being 
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important as physical aggression, and we feel it is important not to restrict aggres-
sion measurement to physical aggression if it is possible to record both. 
With period based observation scales, underreporting is less likely to occur. 
However, recall-bias may be more likely to occur. Another limitation of a period 
based observer scale is that it does not allow for an accurate investigation of time 
relationship be tween the occurrence of aggressive incidents and interventions, as 
we did in chapter 3.2 and 3.3. Furthermore, it hampers analysis of the context of 
aggressive incidents, e.g. the provocation but also time of occurrence and used in-
terventions cannot be de rived from such a scale, whereas the SOAS-R allows for 
that. In clinical practice such information is important as it can give clues of factors 
influencing the occurrence of aggression on the individual patient level. 
H o w  h a s  t h e  ( t y p e  o f )  m e a s u r e m e n t  o f  a g g r e s s i o n  f o r  t h i s  t h e s i s 
i n f l u e n c e d  t h e  s t u d y  o u t c o m e s ? 
In this thesis, we measured aggression prospectively with the SOAS-R on three 
diff erent wards during 15 months. The length of measuring may partly explain the 
rather high percentage of patients in our study population (60%) displaying ag-
gressive be haviour compared to other shorter studies on acute psychiatric wards in 
which lower percentages were reported (40). With the SOAS-R being an incident 
based aggression observation scale, we were able to investigate the temporal asso-
ciation of aggression with medication changes and the administration of as-needed 
medication (see chapter 3.2 and 3.3). It also allowed us to divide patients into se-
verely and mildly aggressive patients based upon the type of aggressive behaviour, 
which was based upon means used (verbal versus physical aggression) and the con-
sequence. As mentioned earlier, however, a limitation of this method is the under-
reporting. Despite the underreporting, it appears the SOAS-R was a valid method 
to roughly divide patients into aggressive and non-aggressive, as in chapter 3.1 we 
found that for 87% of all patients with aggressive behaviour as reported in the daily 
reports, at least one aggressive incident was re corded with the SOAS-R. However, 
the underreporting has affected our results in the sense that we cannot be sure 
whether the observed increased number of medication changes during the aggres-
sion-free follow-up time of aggressive patients compared to the number of changes 
for non-aggressive patients in chapter 3.2 is a real effect or an overestimation. 
In chapter 3.4 investigating patients’ and nurses’ beliefs about as-needed medi-
cation, aggression was measured retrospectively by using the daily reports of nursing 
staff, which are used for transference of information between shifts. Using daily-re-
ports also can result in underreporting as shown in chapter 3.1, although we found 
the amount of underreporting to be lower than using the SOAS-R. This implies 
that some patients may have been classified wrongly as non-aggressive. We are not 
sure how this could have affected our study results.
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Aggressive behaviour :  (pharmacological )  management
Our hypothesis is that the management or treatment of aggressive behaviour is 
reac tive and in the following paragraph we will substantiate this, for the pharma-
cological management of aggressive behaviour in particular, by means of the study 
results pre sented in this thesis and available literature. 
In a broad sense the reactive character of the management of aggressive behav-
iour is reflected in the (lack of) official guidelines concerning aggressive behaviour. 
For the major psychiatric disorders, diagnostic procedures, treatment and treatment 
evaluation are embedded in protocols defining good clinical practice However, in 
the Nether lands, for example, the only available official guideline in relation to ag-
gressive be haviour is a guideline dealing with coercive measures. In the UK, NICE 
issued a guideline dealing with short-term management of aggressive behaviour, 
which pro vides strategies on how to intervene in the acute situation by addressing 
short-term risk assessment, interventions and general ward safety issues, including 
training. Long-term management is not addressed.
The lack of long-term management strategies of aggressive behaviour on a 
patient-level in guidelines is likely to be a result of the limited evidence base for 
interven tions. We showed that the evidence for the pharmacological management 
of acute aggression is based upon 19 trials, of which the study population often was 
small (see chapter 2.1). For the long-term management of aggressive behaviour only 
weak evi dence is available (see chapter 2.2). This limited evidence base for phar-
macological management in particular and other interventions in general makes it 
impossible to draw strong evidence-based conclusions.
In clinical practice, reactive management is observed in chapter 3.3, in which 
we in vestigated the use of as needed medication by aggressive patients. In this study 
we did not only find that aggressive patients have an increased use of as needed 
medication (both sedatives and analgesics) compared to non-aggressive patients, but 
what is more, we found an increased number of administrations in the three hours 
following an aggressive incident. 
In chapter 3.2, we showed that in clinical practice the reactive management of 
aggres sive behaviour not only concerns short-term interventions like restraint and 
acute se dation. Regular medication regimens of aggressive patients also appeared to 
be fre quently subject of change. Furthermore, more medication changes took place 
around aggressive episodes compared to aggression free episodes.
The reactive character of aggression management can probably be explained 
by the impact of aggressive behaviour; it seems plausible that difficult behaviour 
such as aggression calls for action. In case of acute aggressive behaviour, sedation 
of a patient might be rational with the aim of preventing further escalation of the 
aggressive be haviour. However, available research and studies in this thesis suggest 
that reactive management is not always rational. An example of irrational prescrib-
ing behaviour is that aggressive patients use more psychotropics in their regular 
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medication regimen, compared to non-aggressive patients (41, 42) despite the lack 
of evidence for pharma cological maintenance treatment of aggression. Further-
more, in chapter 2.3, oxaze pam was the most frequently used as needed medication. 
Considering that the Tmax of oxazepam is between two and four hours following 
administration, medication with a shorter Tmax like midazolam seems more ap-
propriate. As a recent review about as needed medication shows that the choice 
of drug differs between typical antipsychot ics, benzodiazepines and antihistamines 
(43), we hypothesize that administering as needed medication has to do with the 
need of clinicians to act when faced with ag gressive behaviour. In that case, the 
prescriber is likely to base his choice of drug upon local policies and/or the clini-
cians’ preference and experience, rather than evi dence-based medicine. Besides the 
need of clinicians, the administration of as needed medication seems to fulfil a need 
of the patient too as shown in chapter 3.4. If both patient and staff seem to be satis-
fied why change or criticise these practices? What we are concerned about, is that 
(long-term) evaluation of as needed medication practices is sparse, or even lacking, 
not just in our study population, but also in general (44). We assumed this lack of 
evaluation to be part of the reactive character of handling: both staff and patients are 
satisfied when after the administration the aggressive be haviour stops or does not 
further escalate, and the intervention is assumed effective. Whether the intervention 
really had an effect or whether the patient would also have calmed down without 
the medication does not seem important anymore. 
With regard to long-term management, the lack of evaluation is a bigger con-
cern as psychotropics used for the long-term management of aggression – mainly 
antipsy chotics, antidepressants and anticonvulsants- have more side effects com-
pared to ben zodiazepines used in the acute situation. A similar situation occurred 
years ago when hyoscine was used frequently to manage aggressive behaviour, de-
spite the well-known and apparently ignored side effects including hallucinations 
and depression. More recently, in 2005, the FDA warned that with an approximately 
1.6-1.7 fold in crease in mortality, the use of atypical antipsychotics for the elderly 
with dementia is a risk (45). In 2008, it became clear that this warning should be 
applied to all antipsy chotics(46). Prescription behaviour of antipsychotics for be-
haviour problems in eld erly with dementia, however, did not change (47). This is 
remarkable, taking into ac count the limited effect of antipsychotics on behavioural 
problems in elderly with de mentia. Recently, Kleijer et al, e.g. showed an improve-
ment of behavioural problems for only one on six elderly patients treated with 
antipyschotics, where withdrawal of antipsychotics was successful in 58% (48). 
The latter brings on another concern about the long-term treatment of be-
havioural problems with psychotropics: the continuation of psychotropics even if 
they are not effective. For this we also refer to the last study, chapter 3.5. In that 
study we showed that patients with both aggressive behaviour and using two or 
more psychotropics are at highest risk for having a negative treatment outcome. 
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As stated in that chapter it is unclear whether the behaviour would change when 
less medication would be given. However, we strongly have the impression that all 
too often tapering the use of medi cation is not taken into consideration, and if it 
is, clinicians are reluctant to do so, re membering previous aggressive incidents and 
fearing worsening of the situation. Fi nally, this implies that the need to act in case 
of aggressive behaviour and this fear to taper medication can result in patients using 
more and more medication.
 
R e c o m m e n d a t i o n s  f o r  i m p r o v e m e n t
To come to a more rational, evidence-based management of aggressive behaviour, 
more evidence about effective interventions is required. Here we will focus on 
what is needed to obtain evidence for the pharmacological management of aggres-
sion. Ran domized controlled trials are still considered the gold standard to obtain 
evidence. In the case of aggression there are several important subjects researchers 
should take into account. First, consensus about the concept of aggressive behaviour 
is needed. This is not only needed to select patients for study inclusion. As we stated 
previously, regu latory agencies, i.e. the FDA and the EMEA, are only likely to reg-
ister medication for the management of aggression if consensus about the concept 
exists among the clini cal and academic field. A possible first step to reach this might 
be to cluster different types of aggressive behaviour in the DSM as described previ-
ously. For study inclu sion, a certain level of baseline aggression is required. When 
baseline aggression is low –as was the case in some trials included in our review 
(chapter2.2) – a long study period is required to reliably detect a reduction of ag-
gressive behaviour. Subse quently, good measurement is important; the use of both 
an incident-based scale and period based observation scales will likely obtain the 
most valid results. In chapter 2.3, we showed that a large amount of patients would 
not be eligible in a typical trial due to the used in- and exclusion criteria. Therefore 
to obtain results that are gener alizable to daily clinical practice, it is important to 
pay special attention to the used in- and exclusion criteria. With previous research 
showing a strong link of substance abuse with aggressive behaviour, this should not 
be used as an exclusion criterion, as is quite common in RCTs. Furthermore, one 
should seriously consider whether the patient’s main DSM disorder should be stable 
or not for study inclusion. Reason for this is the association of acute mental illness 
with aggressive behaviour. If during the trial period remission of acute symptoms 
occurs, it would be difficult to assess if a possible reduction in aggressive behaviour 
is due to the drug under investigation or to the remission. In summary, conduct-
ing such randomized controlled trials may be fea sible, but certainly not simple. 
We, therefore assume that evidence for the manage ment of aggression based upon 
randomized controlled trials will not appear that soon. However, RCTs are not the 
sole source for evidence based medicine. Practice based-evidence can be found in 
pragmatic trials, i.e. trials measuring the benefit a treatment produces in routine 
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clinical practice. In such trials mostly two different treatments are compared(49). 
The treatment response is the total difference between two treatments, including 
both treatment and associated placebo effects, as this will best reflect the likely clini-
cal response in practice (50). Besides pragmatic trials, well-designed obser vational 
research can provide valuable practice-based evidence. One could think, e.g. of the 
current introduction in many health settings of routine measurement of treat ment 
outcome with instruments like the HoNOS, or aggression incidents with instru-
ments like the SOAS. Combining this information with hospital medication and 
ad ministration databases creates opportunities to conduct large-scale observational 
studies measuring effectiveness of treatment are provided. 
In these last paragraphs strategies for more preventive and rational acting in clini-
cal practice will be discussed. In general, to act more in a preventive and rational 
way, clinicians should be aware of the course of aggressive behaviour of individual 
pa tients. Defining patters can give clues about context of aggressive incidents and 
give clues for prevention. 
Besides the identification of potential triggering factors, monitoring is useful 
to evalu ate interventions used. From a practical point of view this could be achieved 
by meas uring aggressive behaviour. Not only the monitoring of aggressive behav-
iour is re quired, but also the monitoring of applied interventions, including coer-
cive measures, and maybe also interventions such as having a walk with the patient 
in case of agita tion. Considering the high pressure of work and the observation on 
psychiatric wards that a large percentage of aggressive incidents is caused by a small 
percentage of pa tients (51), such monitoring could be restricted to these repetitively 
aggressive pa tients. Risk factors like previous violence and substance abuse could be 
used to iden tify those patients. Additionally, the occurrence of frequent changes in 
regular medi cation, as shown in chapter 3.2, may be used for this purpose, especially 
on long-stay wards. Combining the monitoring of both aggressive behaviour and 
used interven tions can give insight into what is effective and what is not effective 
for the individual patient. If interventions like pharmacological maintenance treat-
ment are not effective they should be discontinuated.
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S u m m a r y 
Aggressive behaviour is an important problem in mental health care. Aggressive 
behaviour does not only affect staff and other patients, but also has a negative 
impact on the patient self. Studies have shown that aggressive patients have a 
longer stay on psychiatric wards compared to non-aggressive patients. In psy-
chiatric wards, several interventions are used to manage aggressive behaviour. 
In the Netherlands, seclusion has for decades been a highly common interven-
tion to manage (imminent) aggression. During recent years, however, the use 
of seclusion has been heavily criticized. Pharmacotherapy is another commonly 
used intervention, which is viewed by many as a potential alternative for the 
management of aggressive behaviour. 
In chapter 1 a historical overview of aggression management is provided. 
Overall, it appears that the interventions used in case of aggressive or disrup-
tive behaviour can be classified into three main categories: restricting free-
dom of movement (either by seclusion or mechanical restraints), the use of 
pharmacologically active substances, and a variety of more behavioural and 
interactional approaches. Furthermore, history shows that some therapies like 
prolonged bathing and insulin coma, initially deployed with the idea that they 
have healing properties, kept on being used even after they were shown to be 
ineffective. Reason for keeping on using these measures was to manage difficult 
behaviour like agitation and aggression through restriction. When the historical 
background is not taken into account, it is difficult to understand how caretak-
ers could be convinced of the efficacy and rationality of such interventions. 
Nowadays, the importance of evidence-based treatment is highly emphasized 
in medicine. The question is, however, whether current management of aggres-
sive behaviour is more evidence based given the lack of proper studies into the 
effects of interventions on aggressive behaviour.
The aim of this thesis is to examine the scientific rationale for the phar-
macological management of aggressive behaviour, and juxtapose that against 
clinical practice. We therefore conducted systematic reviews of existing litera-
ture and observational studies on psychiatric wards specialized in externalizing 
behaviour disorders. 
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In chapters 2.1 and 2.2, we systematically searched the literature for ran-
domized controlled trials (RCTs) investigating the pharmacological manage-
ment of aggression. In chapter 2.1 we focused on the treatment of aggressive 
behaviour in the acute situation, while in chapter 2.2 we investigated the main-
tenance treatment of aggressive behaviour. For the acute situation, both ben-
zodiazepines and antipsychotics appeared to be effective. However, the selected 
RCTs have important methodological limitations, including small study sam-
ples, short study durations and strict in-and exclusion criteria. The same meth-
odological limitations were observed in RCTs investigating the maintenance 
treatment of aggression. Only weak evidence for anti-aggressive effects of anti-
psychotics, antidepressants, anticonvulsants, and β-adrenergic–blocking drugs 
in maintenance treatment was found. Especially in chapter 2.2 we observed that 
patients enrolled in RCTs differ greatly from psychiatric patients that are seen 
in clinical practice for whom aggression is a severe problem. In chapter 2.3 we 
quantified this by applying inclusion and exclusion criteria used in the RCTs 
to the 106 aggressive psychiatric patients in our study sample. Results show that 
only 30% to 46% of aggressive psychiatric patients as seen in clinical practice 
would be eligible to participate in a typical randomized controlled trial based 
on the most frequently applied exclusion criteria. The comparability of RCTs 
to clinical practice, and probably also the generalizability, therefore is judged 
to be low. 
In chapter 3 medication patterns in relation to aggressive behaviour were 
investigated on psychiatric wards. To measure aggressive incidents, the Staff 
Observation Aggression Scale-Revised (SOAS-R) was used. Because previous 
literature suggests that the use of the SOAS-R may lead to underreporting 
of aggressive incidents, the underreporting phenomenon was investigated by 
comparing SOAS-R recorded incidents with incidents reported in the daily 
reports of the hospital (chapter 3.1). About 30% of the incidents documented 
in the staff reports were also documented in the SOAS-R. The other way 
around, however, we showed that a substantial proportion of incidents reported 
in the SOAS-R (40%) were not documented in the daily staff reports. The 
proportions of mild incidents (verbal aggression) and severe incidents (physical 
aggression) were the same for both methods. Thus, although underreporting 
does occur when using the SOAS-R, this underreporting appears to be non-
selective, at least for the severity of the aggressive incidents.
Despite limited evidence for effectiveness of pharmacological treatment 
of aggressive behaviour, observational studies in this thesis showed that aggres-
sive patients in daily clinical practice use more medication compared to non-
aggressive patients. In chapter 3.2 we found that, for aggressive patients, new 
psychotropics were started more frequently, and dosages were more likely to be 
increased, compared to non-aggressive patients (Incidence-density ratio [IDR] 
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1.8, 95% confidence interval [CI] 1.2-2.6 and 2.1; 95% CI 1.4-3.1, respective-
ly); IDs for other changes were non-significantly increased. Furthermore, with-
in the group of aggressive patients, more medication changes were observed 
in the period of one day before until one day following aggressive episodes, 
compared to the remaining aggression-free follow-up time (IDR= 2.5; 95% 
CI 2.0-3.1). We concluded that difficult behaviour such as aggression, triggers 
reactive prescribing behaviour. In chapter 3.3 we found that aggressive patients 
have an increased use of both psychotropic and somatic as-needed medication 
(IDR, 2.5; 95% CI, 2.2 – 2.7 and IDR, 2.1; 95% CI, 1.8 – 2.4, respectively). 
In the three hours following aggressive incidents, more as-needed medica-
tion was administered, compared to the period previous to aggressive inci-
dents. To gain more insight into the reasons for the observed increased use of 
as-needed medication by aggressive patients, semi-structured interviews with 
patients and nursing staff, were conducted within 24 hours after an as-needed 
medication administration (chapter 3.4). In this study, aggressive behaviour was 
measured through daily nursing reports. In the interviews with the patients, 
it was explored who took the initiative for the administration of as-needed 
medication (patient versus nurse), the reasons for administration, and the effects 
of medication. Identical questions were asked to nurses who had administrated 
the medication. For severely aggressive patients, compared to non-aggressive 
patients, medication was more frequently administered on the basis of the 
nurse’s initiative (instead of the patient’s initiative) (48 versus 19%, respectively, 
p=0.02). Interestingly, the perceived time of onset of effect of medication was 
significantly shorter in the perception of the patients compared to the nurses. 
We hypothesized that apart from pharmacological effects there also appears to 
be a placebo-effect. Overall, we concluded that the administration of as-needed 
medication seems to fulfill certain needs of both patients and staff. The ques-
tion remains whether use of as-needed medication is desirable. An advantage of 
use of as-needed medication could be that patients use less medication when 
it is administered on as-needed medication instead of on regular basis. On the 
other hand we wondered whether use of as-needed medication could possibly 
lead to a vicious circle in some patients: (physical) violence leads to the admin-
istration of more as-needed medication, in this study mainly benzodiazepines. 
Patients are satisfied with this practice, which thus may to a certain extent 
reinforce displaying aggressive behaviour. 
In chapter 3.5 we investigated the association between aggressive behav-
iour and psychotropic use on the one hand, and treatment outcome of hospi-
talized psychiatric patients on the other. Treatment outcome was defined as a 
transfer to a more open (positive outcome) or a (more) closed ward (negative 
outcome). Aggressive patients using psychotropic polypharmacy were at high-
est risk for a negative treatment outcome (Odds ratio 7.6; 95%CI 2.0-29.9; 
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reference = patients without aggression, without polypharmacy) Results were 
adjusted for age, sex and diagnosis. A study limitation was that we could not 
adjust for the severity of illness within diagnoses, which could also be a reason 
for negative treatment outcome. Overall, as psychotropic polypharmacy does 
not seem to positively influence treatment outcome and considering the lack 
of evidence for the pharmacological management of aggression, cautiousness 
is recommended for the pharmacological management of aggression, and with 
multiple psychotropic agents in particular.. 
In chapter 4 the results are discussed in a broader perspective. Although both 
in clinical and academical field people agree that aggression poses a pro-blem, 
there is far less consensus about the concept of aggressive behaviour and the 
way to measure it. More uniformity is required, both for clinical practice 
and for future research. A way to reach this is more (systematic) attention for 
aggressive behaviour, which may be reached by including aggressive behaviour 
in the DSM. 
Considering the lack of evidence for the (pharmacological) management 
of aggressive behaviour it is strongly recommended for daily practice to record 
aggressive behaviour during admission. Such registrations will facilitate the 
evaluation of the effects of (pharmacological) interventions aimed at reducing 
aggression. Furthermore analyses of patterns of aggression of individual patients 
may provide clues for the treatment and management of aggressive behaviour. 
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Samenva t t i ng
In de psychiatrie is agressie een belangrijk probleem. Naast de impact die het 
heeft op medewerkers en medepatiënten, heeft agressie ook negatieve gevolgen 
voor de patiënt zelf, bijvoorbeeld door de toepassing van drang en dwang. Bin-
nen de psychiatrie worden verschillende interventies toegepast ter behandeling 
of beheersing van agressie. Van deze interventies staat met name separatie de 
laatste jaren sterk ter discussie: in GGZ instellingen wordt alles in het werk 
gesteld om het gebruik van separatie tot een minimum te beperken of zelfs 
helemaal uit te bannen. Farmacotherapie is een van de andere veelgebruikte 
interventies voor de beheersing en behandeling van agressie. 
In hoofdstuk 1 wordt een overzicht gegeven van de interventies die ingezet 
worden bij agressie door de jaren heen. Grofweg kan daarbij een onderscheid 
gemaakt worden tussen maatregelen zoals separatie en fixatie die de bewegings-
vrijheid belemmeren, medicatie en gedragsmatige benaderingen. Een aantal in-
terventies, zoals bed- en badtherapie en insuline coma, die aanvankelijk gene-
zing dan wel behandeling van psychiatrisch ziektebeelden beoogden bleken al 
snel ineffectief. Ze werden echter wel jarenlang toegepast waarbij de focus van 
de deze interventies niet zelden verschoof van behandeling naar beheersing 
van gedragsproblemen en agressie. Met de komst van antipsychotica in de jaren 
50 in de vorige eeuw leek er aanvankelijk rust te komen op de afdelingen, zo 
wordt in de literatuur over de zogenaamde ‘Largactil-rust’ gesproken. Terugkij-
kend naar de geschiedenis van de psychiatrie lijken veel behandelmethoden uit 
het verleden nu irrationeel. De vraag is echter of in het huidige tijdperk waarin 
evidence-based medicine hoog in het vaandel staat, de behandeling van agres-
sie daadwerkelijk rationeler is geworden. Doel van dit proefschrift, is het on-
derzoeken van de wetenschappelijke onderbouwing voor de medicamenteuze 
behandeling van agressie, en het in kaart brengen van medicatiegebruik van 
opgenomen agressieve patiënten in de dagelijkse praktijk. Dit deden we aan de 
hand van systematische reviews van de bestaande literatuur en een aantal empi-
rische studies binnen afdelingen in een psychiatrische instelling gespecialiseerd 
in gedragsstoornissen. 
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In de hoofdstukken 2.1 en 2.2, hebben we in literatuurdatabases systema-
tisch gezocht naar gepubliceerde randomised controlled trials (RCTs) die de 
farmacotherapeutische behandeling van agressie bestuderen; in hoofdstuk 2.1 
betreft het de behandeling van agressie in de acute situatie, in hoofdstuk 2.2 de 
onderhoudsbehandeling van agressie. Voor de acute behandeling van agressie lij-
ken zowel benzodiazepines als antipsychotica effectief. Er valt, methodologisch 
gezien, echter veel aan te merken op de kwaliteit van de onderzoekingen naar 
acute behandeling van agressie: kleine groepsgroottes, korte onderzoeksduur en 
vaak strenge in- en exclusie criteria waardoor veel cliënten met wie we in de 
praktijk van alledag te maken hebben buiten de boot vallen. Deze beperkingen 
gelden ook voor de trials die de effectiviteit van de langdurende medicamen-
teuze behandeling van agressie onderzoeken. Veel verschillende middelen zijn 
onderzocht op werkzaamheid voor de langdurende medicamenteuze behan-
deling van agressie, waarbij de evidentie steeds matig blijkt te zijn. Met name 
op basis van hoofdstuk 2.2 concluderen wij dat de patiënten-populaties die in 
RCTs geïncludeerd worden, op een aantal wezenlijke punten niet overeenko-
men met de populatie van patiënten die in de praktijk behandeld worden en bij 
wie agressiviteit daadwerkelijk een groot probleem is. 
In hoofdstuk 2.3 hebben we dit verschil tussen de RCT populatie en de 
dagelijkse praktijk populatie gekwantificeerd door de gebruikte in- en exclu-
siecriteria van de RCTs toe te passen op de 106 agressieve patiënten uit onze 
psychiatrische praktijkpopulatie. De resultaten laten zien dat maximaal 50% van 
de onderzochte patiënten uit de dagelijkse praktijk in aanmerking komt voor 
deelname aan een RCT die de effectiviteit van psychofarmaca ter behandeling 
van agressie onderzoeken. Dit percentage ligt feitelijk waarschijnlijk nog lager, 
omdat er in de meeste RCTs gekeken wordt naar ambulante patiënten, terwijl 
veel patiënten in dit onderzoek vaak jarenlang zijn opgenomen. Onderzoeksre-
sultaten van RCTs waarin de medicamenteuze behandeling van agressie wordt 
onderzocht lijken dus slechts beperkt gegeneraliseerd te kunnen worden naar 
klinische patiënten in de dagelijkse praktijk. 
In hoofdstuk 3 hebben we het gebruik van medicatie in relatie tot agressie on-
derzocht. Om agressie te meten hebben we gebruik gemaakt van de Staff Ob-
servation Aggression Scale-Revised (SOAS-R). Omdat in de literatuur wordt 
gesuggereerd dat het gebruik van de SOAS-R kan leiden tot onderrapportage, 
hebben we dit onderzocht door de geregistreerde SOAS-R incidenten naast 
de dagrapportages te leggen (hoofdstuk 3.1). Uit de dagrapportages werden 
inderdaad meer agressieve incidenten gescoord; ruim 70% van de agressieve 
incidenten in de dagrapportages waren niet geregistreerd met de SOAS-R. Te-
gelijkertijd was ruim 40% van de SOAS-R incidenten niet terug te vinden in 
de dagrapportages. Daarnaast was de verhouding tussen milde agressieve inci-
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denten (verbaal) en zware agressieve incidenten (fysiek) wel dezelfde bij beide 
methodes. Hoewel er dus wel sprake is van een onderrapportage, is deze niet 
selectief voor de ernst van het incident.
Ondanks de geringe wetenschappelijke onderbouwing voor de farmaco-
therapeutische behandeling van agressie, bleek uit de observationele studies dat 
agressieve patiënten in de praktijk meer medicatie krijgen dan niet agressieve 
patiënten. Zo vonden wij in hoofdstuk 3.2 dat starten van nieuwe medica-
tie en dosisverhogingen significant vaker voorkomen bij agressieve patiënten 
(Incidentie-dichtheid ratio [IDR] respectievelijk 1,8; 95% betrouwbaarheids-
interval [BI] 1,2-2,6 en 2,1; 95%BI 1,4-3,1). De overige medicatiewisselingen 
bleken niet significant vaker voor te komen. Daarnaast vonden we dat meer 
medicatiewisselingen plaatsvinden rondom agressieve incidenten dan tijdens 
de agressie-vrije periodes van agressieve patiënten (IDR 2,5; 95%BI 2,0-3,1). 
Wij concludeerden dat moeilijk gedrag zoals agressie leidt tot veranderingen 
in het gebruik van medicatie. In hoofdstuk 3.3 vonden wij dat agressieve pa-
tiënten ook meer zonodig medicatie gebruiken -zowel sederende medicatie als 
pijnstillers- dan niet agressieve patiënten (IDR respectievelijk 2,5; 95%BI 2,2-
2,7 en 2,1; 95%BI 1,8-2,4). Daarnaast bleek dat er in de drie uur volgend op 
het agressieve incident, de meeste medicatie gegeven werd. Om meer inzicht 
te krijgen in de redenen van verhoogd gebruik hebben we, zoals beschreven 
in hoofdstuk 3.4, semi-gestructureerde interviews afgenomen bij patiënten die 
binnen de voorafgaande 24 uur zonodig medicatie hadden gekregen. Agressie 
werd in dit onderzoek gemeten door gebruik te maken van de dagrapportages. 
Er werd onder andere gevraagd op wiens initiatief de medicatie gegeven was, 
waarom de medicatie gegeven was en wat het effect van de medicatie was. De-
zelfde vragen werden ook aan de verpleging gesteld. Het initiatief tot gebruik 
van medicatie blijkt niet (alleen) vanuit de verstrekkers (verpleging) te komen 
maar juist vooral vanuit de patiënt zelf. In de groep van de fysiek agressieve 
patiënten kwam het initiatief voor het geven van zonodig medicatie wel vaker 
vanuit de verpleging in vergelijking met de groep van niet-agressieve patiënten 
(p=0,02). Opvallend was dat patiënten, vaker dan verpleging een snel effect 
van de medicatie bemerkten (binnen 15 minuten). Naast het farmacologisch 
effect lijkt zonodig medicatie ook een placebo-functie te hebben. Uit deze 
studie concludeerden we dat zonodig medicatie voorziet in een behoefte van 
zowel patiënten als verpleging. Het blijft de vraag of het gebruik van zonodig 
medicatie wenselijk is. Een voordeel zou kunnen zijn dat patiënten per saldo 
minder sederende medicatie gebruiken wanneer het zonodig gegeven wordt 
dan wanneer het op reguliere basis gegeven wordt. Anderzijds vragen we ons 
af of er ook een vicieuze cirkel kan ontstaan: patiënten vragen vaak zelf om 
zonodig medicatie en bij (ernstig) agressieve patiënten wordt het vaker op ini-
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tiatief van de verpleging gegeven, de vraag is of dit agressief gedrag zou kunnen 
bekrachtigen.
In hoofdstuk 3.5 hebben we de relatie tussen agressie en medicatie enerzijds 
en de uitkomst van behandeling anderzijds onderzocht. De behandeluitkomst 
werd gedefinieerd als overplaatsing naar een meer open (positieve uitkomst) of 
gesloten afdeling (negatieve uitkomst). Patiënten die tijdens de studie periode 
niet werden overgeplaatst en minimaal 6 maanden opgenomen waren hadden 
ook een negatieve behandeluitkomst. We toonden aan dat agressieve patiënten 
met veel medicatie het meest vaak een negatieve behandeluitkomst hadden ten 
opzichte van de patiënten zonder agressieve incidenten en met weinig medi-
catie (Odds Ratio 7,6; 95%BI 2,0-29,9). Deze uitkomst is gecorrigeerd voor 
diagnose, leeftijd en geslacht. Een beperking van deze studie was dat we niet 
konden aantonen of deze resultaten direct met agressief gedrag samenhangen 
of mogelijk (ook) verklaard kunnen worden door de ernst van de ziekte. We 
concludeerden dat het gebruik van veel medicatie niet leidt tot een betere be-
handeluitkomst, ook al weten we niet of het nog slechter met de “agressieve 
patiënten” zou gaan als ze minder medicatie gebruiken. Gezien deze resulta-
ten, alsmede de bijwerkingen die geneesmiddelen kunnen veroorzaken en de 
eerder gevonden beperkte wetenschappelijke onderbouwing voor de medica-
menteuze behandeling van agressie, stellen we daarom dat goede evaluatie van 
medicatie(additie) noodzakelijk is. 
In hoofdstuk 4 worden de resultaten in breder perspectief besproken.Hoewel 
agressie binnen de psychiatrie in het algemeen gezien wordt als een belang-
rijk probleem, is er onvoldoende consensus over de definitie en hoe agressie 
te meten. Dit gebrek aan consensus is een belemmering voor onderzoek naar, 
maar ook voor behandeling van agressie in de praktijk. Wij stellen daarom dat 
er meer consensus over het concept agressie en het meten daarvan bereikt moet 
worden. Een manier om dat te bereiken is meer (sytematische) aandacht voor 
agressie; gedacht kan worden aan het opnemen van agressie in de DSM.
Gezien de geringe wetenschappelijke onderbouwing van de medicamen-
teuze behandeling van agressie wordt ook geadviseerd agressief gedrag tijdens 
de behandeling te registreren om zo het effect van interventies te kunnen eva-
lueren. Daarnaast kan analyse van agressieregistratie aanknopingspunten geven 
voor behandeling. 
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Na 6 jaar is het dan zover, het boek is klaar. Onderzoek doen kan soms eenzaam 
zijn, zeker als je het vergelijkt met de drukte in de (poli)kliniek, maar je doet 
het niet alleen, integendeel! Graag wil ik een aantal mensen die -elk op hun 
eigen wijze- hebben bijgedragen aan dit proefschrift, bedanken:
Allereerst wil ik mijn promotoren Toine Egberts, Henk Nijman en co-promo-
toren Rob Heerdink en Joost Jan Stolker bedanken:
Beste Toine, ik heb je scherpheid zeer gewaardeerd; de manier waarop je 
paralellen legt tussen onze onderzoeksresultaten en andere “vakgebieden”. Ik 
denk daarbij ook aan de overleggen wanneer ik vastliep en niet meer wist hoe 
verder, waarop jij het structureerde, meestal door terug te gaan naar de basis: wat 
wil je nu precies onderzoeken…. En natuurlijk altijd fijn, die snelheid waarmee 
je commentaar gaf!
Beste Henk: Ondanks je vreselijk drukke schema en de lange reisafstanden 
die je moest afleggen voor de overleggen kwam je altijd vol enthousiasme bin-
nen en dat werkt aanstekelijk. Blij was ik ook met je uitgebreide kennis over 
agressie en onderzoeken daarnaar. Met plezier las ik je commentaren op manus-
cripten: prachtig hoe je slechtlopende zinnen, lekker leesbaar maakte.
Beste Rob, Altijd tijd. Het hele traject door kon ik laagdrempelig bij je 
terecht: voor rap tekstueel en inhoudelijk commentaar in de manuscripten met 
je rode pen, meedenken over studieopzetten, om data te programmeren, of 
gewoon even een praatje te maken over contrabassen of zo. En -met name de 
laatste weken voor de leescommissie- heel fijn: bij tegenslag lukte het je altijd 
weer de dingen in perspectief te plaatsen waarop ik weer vol goede moed je 
kamer verliet. “Baas”, bedankt voor alles!
Beste Joost Jan, jij wees me op de vacature voor AGIKO waarop ik dacht: 
“Ik? Kan en wil ik dat zo’n heel lang traject?”. En ja, ik ben blij dat ik die kans 
gekregen heb! Ik heb het zeer gewaardeerd hoe je duidelijk een visie had over 
wat wij tegenkwamen tijdens dit onderzoeksproject en tegelijkertijd ook veel 
ruimte en vrijheid gaf om daarbij mijn eigen weg te zoeken. Waardevol, de in-
put die ik van je kreeg vanuit je klinische ervaring. Bedankt ook voor de tijd 
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die je ondanks je drukke werkzaamheden de laatste periode wist vrij te maken 
voor overleg!
Furthermore, I gratefully thank Prof. dr. L Bowers, Prof. dr. GJM Hutschemae-
kers Prof. dr. HGM Leufkens, Prof dr. B Olivier and Prof dr. T Steinert -the 
members of the thesis committee- for their quick judgement of this thesis. 
Berend Olivier, hartelijk dank ook voor uw bijdrage aan twee van de arti-
kelen in dit proefschrift.
De patiëntenstudies in dit proefschrift zijn uitgevoerd in Altrecht.
Zonder de inzet van de 24uurszorg -van de afdelingen Wier, Barentsz, 
Roosenburg, SPB Zeist en Unit A van het WA huis- die agressie registreerde, 
was dit proefschrift nooit tot stand gekomen. Bedankt hiervoor!! 
Afdeling Wier wil ik bedanken voor het mogelijk maken van dit onder-
zoek. In het bijzonder denk ik aan Evert Geitenbeek, die drie extra maanden 
onderzoekstijd op het einde waren hard nodig!
Eline Veltkamp, ik heb het zeer gewaardeerd hoe jij nauwgezet bij de ge-
gevensverzameling en invoering daarvan in de computer ondersteund hebt, ik 
moet er niet aan denken dat ik dat allemaal alleen had moeten doen.
De andere “mede-bewoners” van Antonia, Tineke, Astrid, Nico en Gaby, 
dank voor de ontspannende thee-pauzes.
Gerard Hugenholtz en later Lennart Stoker, fijn dat jullie geholpen hebben 
met het verzamelen van de medicatie-gegevens.
Een enkele keer had ik tijdens de stages van de opleiding tot psychiater 
meer aaneengesloten onderzoekstijd nodig. Dr. R Kukpka, beste Ralph, be-
dankt dat jij dit faciliteerde en hiervoor in het opleidingsschema ruimte maakte.
Leny van Dijk, geweldig zo’n opleidingssecretaresse die als je krap in tijd 
zit altijd bereid is praktische zaken voor je uit te zoeken en regelen.
Wendy, dank voor je betrokkenheid en die ene dienst! 
Prof. dr. J. Vijselaar, uw boeiende onderwijs over de geschiedenis van de psy-
chiatrie heeft me geïnspireerd bij het schrijven van de introductie. Hartelijk 
dank voor uw literatuuradviezen. Prof. dr. T. Pieters, hartelijk dank voor uw 
suggesties.
En dan F&F. Het was leuk en leerzaam om als “ dagjesmens” bij jullie op de 
afdeling te werken. Een aantal mensen wil ik in het bijzonder noemen:
Het secretariaat, bestaande uit Addy, Ineke, Suzanne en later Marije wil ik 
bedanken voor de goede en prettige ondersteuning. 
Patrick Souverein, bij jou kon ik altijd op korte termijn een afspraak ma-
ken om lastige databases te programmeren. Optimistisch boekte ik een paar 
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uurtjes, dat liep meestal (heel erg) uit omdat we altijd weer “verrassingen” in 
de databases tegenkwamen. Ik werd er soms wanhopig van, maar jij program-
meerde gewoon rustig door, verzekerde me ervan dat je wel een oplossing zou 
vinden en die kwam er ook altijd, al moest je er in de avonduren aan doorwer-
ken. Patrick, dank daarvoor!
Svetlana Belitser, toen ik begon aan mijn onderzoek wist ik zeer weinig 
over statistiek. Dank je voor al die tijd die je nam om voor mijn eerste studie 
helemaal uit te zoeken wat nu de beste methode was om de gegevens te ana-
lyseren. 
Het contact met medeonderzoekers vond ik belangrijk en aangenaam: om 
het even te hebben over de pieken en dalen van het onderzoek, een snoepau-
tomaat leeghalen of een wedstrijd geografiekennis doen; daar heb je je kamer-
genoten voor! Speciaal wil ik noemen Karin, Bas, Pieter , Harald, Joelle, Thijs, 
Helga en Arlette.
Lieke Goumans en Didier Meulendijks, dank voor jullie bijdrage aan een 
artikel in dit proefschrift.
Ik wil alle vrienden en familie bedanken die ik afgelopen periode helaas wel 
eens verwaarloosd heb. Dank voor jullie steun in verschillende vormen waar-
onder gezonde maaltijden tussendoor, hulp bij lay-out en een weekendje weg.
Jamie, thanks a lot for commenting on one of my manuscripts as native speaker!
Les “Old Glories”; depuis plus que 20 ans, je pars avec vous: pour une balade le 
week-end ou pour une semaine de vacances. Toujours contente de vous voir et 
de plus les balades, cela change bien les idées et c’est une bonne façon pour se 
détendre après une semaine derrière le PC! 
Lieve Lisette en Liselijn, bedankt voor jullie steun en belangstelling; ik ben heel 
blij dat jullie mijn paranimf willen zijn.
Papa et maman, Geneviève, Joel et Marielle: Enfin, c’est fini ! Un très très grand 
merci pour votre support, d’être intéressé comment ça se passait les recherches, 
mais surtout d’avoir supporté mes mauvaises humeurs et ‘stresse’ quand ça 
n’avançait pas du tout comme moi je le voulais et dans c’est moment la ne 
surtout pas top en parler...! 
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